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HISTORY 
More than 2000 years have elapsed since the first description of cervical cancer by Hippocrates. 
Aretaeus, an ancient Greek physician practicing in the first century before Christ, described 
uterine cancer as superficial and deep ulcers, which later infiltrate the uterus1• In 1812 John 
Clarke described a peculiar degeneration of the cervix, which he called a cauliflower tumor 
because of it's appearance2• Charles Mansneld Clarke introduced the term carci noma uteri in 
1821 and Hooper identified the caul iflower as a carcinoma of the cervix in 18323. 
Initia lly there was no distinction between cervical and endometria l carcinoma. Adenoma 
malignum was used for highly differentiated glandular carcinomas, without distinction in origin. 
When it became clear that cervical cancer was a separate entity, different types of cervical cancer 
were described. In German literature Portiokarzinom (karzinom der ektocervix, squamous cell 
carcinoma origi nating from the portio vaginalis) and Zervixhohlenkarzinom (karzi nom der 
endocervix, adenocarcinoma arizing from the cervical channei)H were d ist inguished. 
Ruge and Veit 1881 and later the school of Schroeder different iated between a portio 
carcinoma, arising from the connect ive tissue oft he cervix or from columnar epithelia l erosions 
and cervica l carcinoma arising from de cervical glands or from the connective tissue. Treub in 
1892 proposed another classification, based on the extension of the different tumor types. He 
described t he carcinoma of the cervix, also called cancroid or epithelioma as a cancer which 
originated from the squamous epithelium of the portio vagina lis and the 'Zervixcarcinoma' 
Karzinome des Collum uteri crstcn Grades 
Dns Karzinom ist streng auf dns K ollum beschrlinkt 
Portiokarzinom 
Abb 198 from Lehrbuch der Gynakologie, prof Guggisberg 19465 
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(cervical cancer) which originated from the cervical glands8 . Today, we speak of cervical 
carcinoma, without differentiating between portio and cervical cancer. 
The prognosis of cervical cancer has improved due to improved therapeutic strategies; for 
many years surgical intervention fo r cervical cancer was obsolete [Hippocrates, Celsus]. A 
Morbus contra naturam as Galenus proclaimed. Although it is suspected that in the 15 and 16 
century hysterectomies were performed, CJM Langenbeck performed t he first deliberate and 
well-planned vaginal hysterectomy for malignancy in 18133• It was performed upon a pro lapsed 
uterus and afterwards the diagnosis of cancer was doubted. French authors stated that the 
Italian surgeon Paletta accidentally performed the first vaginal hysterectomy in 1812. Sauter did 
the second complete vag inal hysterectomy for cervica l cancer with an unprolapsed uterus in 
Konstanz, 28 januari 18223• The operation had no effect on survival, as mortality was almost 
100%. On the 30t h January of 1878 W.A. Freund performed the first abdominal hysterectomy 
for cervical cancer. Although conditions of asepsis and Trendelenburg position were available, 
primary mortality was still as high as 70%. Czerney in 1878 introd uced a new vaginal technique 
combined with narcosis, asepsis and anatomical hemostasis, which reduced mortality, 
after which surgical procedures developed rapidly. DDhrssen and Schuchhardt refined this 
procedure, with t heir modified incision, making hysterectomy possible in very narrow vaginas. 
Bleeding which was previously contro lled, by leaving clamps in situ for 48 hours, was replaced by 
carefully la id ligatures. By dissection of t he ureters, it was possible to remove the parametrium 
and with this refinement 5chauta has discovered the radica l vaginal hysterectomy in 190F. 
Rumpf performed the first abdominal radical hysterectomy in 1895, which enabled the removal 
of the regional lymph nodes. Short ly after that, in 1898, Wertheim perfected this technique in 
1898 and developed the Wertheim Operation which included removal of uterus, tubes, ovaries, 
parametria, much of the vag ina and paravaginal tissues as well as enlarged pelvic nodes9. This 
procedure had a primary mortality of15-20% and a 5 year survival of18.4%. Bonney modified the 
radical abdominal hysterectomy by removing al l pelvic lymph nodes10• 
The discovery of radium in 1898 offered a low-risk alternative to surgery, dominat ing the 
scene for three decades11• Margaret Cleaves is credited with having been the first to t reat 
cancer of the cervix with interstitial application of radium (brachytherapy) in 1903'2• Soon 
after sulfa became available, Meigs combined bilateral pelvic lymph node dissection with 
the standard Wert heim operation in 1944. This procedure had no primary mortality13• In 1957 
Sindram succeeded in developing a techniq ue, which rout inely combines vaginal hysterectomy 
accord ing to Schauta, with abdominal transperitoneal lymphadenectomy according to Taussig 
(AVRU EL)14•15• In 1982, Lammes int roduced the Japanese modification of the Wertheim radical 
hysterectomy, the Wertheim Okabayashi operation, which lead to an improved survival 
and decrease in morbidity16•17• 1994 Dargent introduced a conservative radical therapy with 
preservation offert il ity, the radica l vaginal trachelectomy18• 
Nowadays in the Netherlands, standard treatment for early stage cervical cancer consists 
of a radical hysterectomy with pelvic lymphadenectomy or primary radiotherapy. The choice 
is made on t he basis of co-morbidity and age. In patients without contraindication for an 
operation is usually chosen as primary surgery in view of the effect of radiotherapy on the 
ovaries and I or sexual function. For patients who wish to preserve fertility, with stage IBl 
cervical carcinoma sma ller t han 2 em tumor a radical t rachelectomy (vaginal or abdomina l) 
with pelvic lymph node dissection is preferable. Adenocarcinoma is treated as squamous 
ce ll carcinoma19 
AIS, A PRECURSOR OF ADENOCARCINOMA 
The word "dysplasia" is derived from the Greek word dys for "bad" and plasia for "molding" 
and has been used in many fields of medicine, usually to describe a nonmalignant process. 
Cervix, the Latin word for the neck, is a narrow cilindric segment ofthe uterus, positioned 
between t he uterus and vagina. In the average patient it measures 2-4 em in length. The 
uterine cervix consists of two parts; t he ectocervix (outer part), which is lined by strat ified non-
keratizing squamous epit helium and the endocervix (inner part) which is covered by a single 
layer of mucus-secreting columnar epithelium with foca lly underlying reservece lls. Squamous 
cell carc inoma (SCC) usua lly originates in the transitionzone between squamous and columnar 
epithelium. It is preceded by dysplastic precursor lesions characterized by a disturbed epithelial 
architecture and cellu lar atypia. In the late 1960s the concept cervica l intraepithelia l neoplasia 
(CI N) was introduced20• CIN is graded from 1 to 3 (CINl, CIN2 and CIN3). CINl, low grade, shows 
dysplasia in less than one third of the epithelium. CIN2, moderate dysplasia, in two third of 
the epithelium and CIN 3, severe dysplasia or carcinoma in situ in more than two t hird of the 
epithelium. Most CIN lesions wi ll regress even without t reatment, however t he higher the CIN 
grade, t he less often regressions occurs. Approximately two third of CI N 1 lesions wi ll regress, 
but only one thi rd of CIN 3 revert and untreated CIN Ill will result in more tha n SO% to an invasive 
cancer on long-term21·23• 
In analogy to premalig nant lesions of squamous type in t he cervix (CI N), the concept 
of premalignant lesions of endocervical t ype epithelium has also been developed. 
Adenocarcinoma in situ (AIS) was first described by Hepler24 in 1952. One year later Friedel I and 
McKay25 published 2 case reports on AIS proposing that AIS was the precursory premalignent 
lesion for adenocarcinoma of t he uterine cervix (AC). AIS has consistently been characterized 
by the fol lowing histological features; preservation of normal glandular architecture coupled 
with cellular alterations of part or all of the surface and /or g landular epithelium lining the 
endocervix. These cons ist of nuclear enlargement, coarse chromatin, smal l single or multiple 
nucleoli, increased mitotic activity and variable stratification of nuclei26_ Cytoplasmic mucin 
may be either reduced in quantity or be abundant. 
There is reasonable evidence that AIS is the precursor of adenocarcinoma of the uterine 
cervi£ 5•27'30• This based on the follow observations 1) AIS is frequently fou nd adjacent to invasive 
adenocarcinoma31, 2) the cytologic and histologic featu res of AIS resemble AC, only stroma-
invasion is absent, 3) the mean age of patients with AIS (35 yrs) is 10-20 years younger than of 
patients with AC (51 yr) underlying its precursory role32 and 4) the same type hrHPV is found in 
both AIS and invasive adenocarcinoma. 33 Furthermore there are published case reports which 
describe AIS progressing into an AC and the recurrence of AIS as an AC34' 40• 
Glandular lesions of lesser severity t han AIS represent a heterogeneous gro up of poorly 
defined lesions with uncertain biological behavior. The ability to recognize t hese lesions in a 
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reproducible fashion is also questionable. Therefore, it has been argued that, irrespective of 
the number of glands involved, lesions containing columnar cells with enlarged nuclei, coarse 
chromatin, increased nuclear cytoplasmic ratio and mitotic activity are best classified and 
treated as AIS4 1• Therefore as opposed to sec, the precursor lesion of AC, AIS is not further 
subdivided into conditions with less severe changes. The d iagnosis of AIS is a challenge, as AIS 
has no pathognomonic clinica l or colposcopic features. 
EPIDEMIOLOGY AND PREVALENCE OF CERVICAL 
CANCER AND AIS 
Cervical cancer is the fourth most common cancer in women worldwide, and the seventh 
overal l, with an estimated 528,000 new cases in 2012 42-44• More than 85% of these cases and 88% 
of the cervica l cancer related deaths occur in developing count ries. Over t he last decades the 
incidence of cervical carcinoma in indust rialized countries has decreased. This disproportional 
incidence and mortality of cervical cancer is due to the lack of screening in developing count ries. 
The Netherlands has a low incidence of cervical cancer, 8.0/100.000, compared to a mean 
of 11.3/100.000 in Europe43 and one of the lowest morta lity rates in Europe for cervical cancer 
(2.1/100.000). The screening programs for cervica l cancer by cytology started in the mid 
1960's. However a nationwide populat ion-based screening prog ram was not int roduced until 
1988. This program was restructured in 1996 and has remained so unti l the present day: Women 
aged 30-60 are invited every five years for cytological testing of the cervix45• The incidence and 
mortality of cervical cancer decreased during the seventies and from 2000 on it has remained 
stable, with 605-722 new patients a year46. The decrease in cervica l cancer is however restricted 
to cervical squamous cell carcinoma, while the incidence of other types of cervica l cancer 
like adenocarcinoma (AC) and its precursor AIS has remained stable or has increased47-55• The 
registration for the mortality of cervical cancer in the Netherlands is not divided for histological 
subtypes as sec and AC separately, in cont rast to the regist ration for incidence of cervica l cancer. 
In 1952 4.5% of all cervical ca ncers were adenocarcinomas24, t his percentage has risen to 
20% today46•53• Reasons for this phenomenon are the use of oral contraceptives, an increasing 
prevalence of HPV-i nfect ion and the relative inefficiency of screening programs in detect ing 
glandular abnormalities, part ially explai n the striking increase in cervica l adenocarcinoma 
in women who were in their 20s and 30s during the early 1960s in developed count ries 47. 
Furthermore, improved performance of pathologists with regard to the subclassification of 
cervical carcinoma is also thought to play a ro le56 
Like adenocarcinoma, t he incidence of AIS has also increased significantly since the 
seventies in the USA, from 0.2 per 100,000 to 1.8 per 100,000 women per yea r57.59. In Korea, 
t he incidence of AC remained stable but the incidence of AIS increased, by 13,2% per year 54• 
In contrast to incidence in other countries, in the Nether lands, a decrease was found in the 
incidence of AIS between 1989-2003 althoug h the incidence of AC remained stable in the sa me 
period60• The authors explained this decrease by pointing out that many lesions being detected 
were combined and harbored an AIS and squamous component, the latter of which was being 
detected during routine screening. 
.<t----lAncl&lijk.6 UllfOI, WIIIIJn& geleldlelljke 
el'nalnt tcreenl I van ClUb 
J;nr v~n dl:agnose 
Fig . Mortalit y of cervical cancer in the Netherlands in relation to screeningsprogram" 
DIAGNOSIS AND THERAPY 
Adenocarcinoma in situ 
AIS is generally asymptomat ic. In SO% of cases, AIS and CIN are both present and identifying 
and treating the CIN lesion facil itates the diagnosis61 . AIS is usually diagnosed in a conization 
specimen. Only 38 - 69% AIS cases will be discovered in cervixcytology, wit h or without 
kolposcopic biopsies•Hs. The combinat ion of cytology, biopsy and endocervix curretage (ECC) 
has increased the sensitivity of detecting a glandular abnormality before a conization up to 
85%64, There is no consensus on the diagnostic colposcopic features of AIS63•66• The presence 
of white fused villi after application of acetic acid has been described and also large gland 
duct openings, papillary abnormalities, epithelial budding, abnormal vasculair pattern61 • These 
changes have also been noted in benign diseases. 
Treatment is complicated on the one hand by the location of t he disease high in the 
endocervical canal and its possible multifocality and on the other hand by t he fact that the 
patient populat ion often wishes to undergo fertility-preserving t herapy. 
Microinvasive adenocarcinoma 
The optimal treatment fo r microinvasive cervical AC is controversia l. Although curative therapy 
is pivotal, preservation of fert ility is an important issue and therefore influences the choice of 
the therapeutic strategy. The different strategies vary between radical hysterectomy(RH) with 
pelvic lymph node dissection (PLND) to conization ofthe cervix. 
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Early stage Adenocarcinoma 
The outcome in early squamous cell carcinoma of the uter ine cervix is similar after either 
primary surgery or primary radiotherapy. There are reports that this is not t he case for early 
adenocarcinoma (AC) of the uterine cervix: some studies have reported that the outcome is 
better after primary surgery. It remains controversial whether or not patients with AC have a 
worse prognosis. 
HPV AND CERVICAL CANCER 
The Human Papil lomavirus (H PV) is a non-enveloped, double-stranded DNA virus t hat 
belongs to t he Papil lomaviridae family67• The HPV virion contains an 8-kb ci rcular genome 
that is enclosed in a capsid shell compromised of major (L1) and minor capsid protein (L2). 
The genome not only encodes for late structura l genes (L1 and L2), but also for several early 
genes (E1, E2, E4, ES, E6 and E7) that enable viral t ranscription and replication and interact with 
the host genome68. Papil lomavirus genomes can be subdivided into three main regions. HPV 
strains can be practically classified by their risk of causing cervica l cancer into low-risk (e.g. 
HPV-6 and -11) and high-risk (e.g. HPV-16 and -18) types. Since t he nineteenth century it was 
known t hat cervica l cancer was associated with sexual activity. Harald zur Hausen identified HPV 
as the ca usal factor in cervical cancer in 1970. Cervical carc inomas are associated wit h specific 
high-risk human papilloma vi rus (HPV) types, mainly HPV-16 and HPV-1869-71 • All squamous cell 
cervical carcinomas are HPV positive however, HPV prevalence in cervica l adenocarcinomas 
is variable and generally lower t han reported for sq uamous cell carcinoma72• The difference in 
prevalence may reflect technical factors re lated to sampling and DNA detection or histologic 
misclassification i.e. endometrial adenocarcinomas previously being classified as cervical 
adenocarcinomas. The addition of hrHPV testing in cervical screening programs wi ll lead to a 
reduction in the incidence of cervical cancer and precursor lesions73.74• 
With t he int roduct ion of prophylactic HPV vaccines a new path in t he field of primary 
prevent ion of cervix cancer has started . The current prophylact ic vaccines provide protection 
against persistent infection with HPV types 16 and 18. These two HPV types together account 
for over 85% of all adenocarcinomas and for 90% of t he adenocarcinoma in situ of the cervix 
uteri" . In cervical squamous cell carcinoma t hese figures are 75% and fo r t he premalignent 
disease (CI N) 50%. If the assumed potentia l of t hese vaccines can be met, a put big step in the 
fight against t his insidious disease. 
AIM AND OUTLINE OF THIS THESIS 
A great deal is known about the etiology and t reatment of squamous ce ll carcinoma of the 
cervix, however a lot less about adenocarcinoma of t he cervix. Essent ial quest ions such as 
et iology, relat ion with HPV, diagnosis, t reatment and survival have not been extensively studied. 
The central theme of t his invest igation was to investigate t he opinion t hat adenocarcinoma 
of t he uterine cervix (AC) carries a worse prognosis t han squa mous cell carcino ma (SCC). 
Although t he incidence of AC and its precursor lesion adenocarcinoma in situ (AIS) is a fraction 
of mammacarcinoma, and the incidence is declining, it is a disease particularly found in younger 
women and it can be fatal. Radica l t herapy in these young women, when fertility preservation is 
an issue, is not appropriate anymore but the question is: is conservative therapy justified in early 
AC and AIS? This is outlined in chapter 2 in a systematic review on AIS, in a retrospective study 
in 132 patients with AIS and in chapter 5.2 in a retrospective study in 59 cases of microinvasive 
adenocarci noma. 
Chapter 3 is a retrospective investigation in prognostic factors for survival in adenocarc i-
noma. 
To reduce the incidence of cervical cancer and its precursory conditions, HPV vaccination 
has been introduced. In chapter 4 in we investigated whether AC and Clear cell carcinoma are 
HPV related and if HPV-type is of prognostic significance. 
In Chapter 5 we investigated whether early stage and microinvasive AC should be treated as 
early stage and microinvasive SCC; for early stage cancer by a systematic review according to 
Cochrane guidelines and for microinvasive cancer by a retrospective study in 59 cases. 
The general discussion, in chapter 6, provides an overview of our main results. We final ly 
conclude t hat AIS and early stage AC, rare but increasingly existing, especially in young women, 
harbor the same prognosis as CIN and early sec and t herefor should be treated as such. 
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ABSTRACT 
Objective 
This study aimed to review literature if therapeutic strategies in AIS could lead to more 
conservative approach. 
Methods 
A review of the literature was conducted using a Medline search for articles published between 
1966-2013. 
Results 
35 studies showed that after a radical cone 16,5% residual disease in t he re -cone or uterus was 
found. After cone with positive margins res idual abnormalities were found in 49,3%. 37 studies 
showed after conservat ive therapy (LLETZ-CKC) 5% recurrence rate. After con ization with 
negative margins the risk of recurrence was 3%. 
Conclusions 
AIS is a relatively ra re premalignant but increasingly frequent lesion of the cervix. Although t here 
is a risk of relapse (3%) with chance of malignancy ( <1%), th is risk is so small that conservative 
treatment with negative margins by LLETZ or CKC is justified and just ifiable not only for women 
to have chi ldren. 
INTRODUCTION 
Adenocarcinoma in situ of the cervix (AIS), first described by Hepler' in 19S2, is the 
precursory condition for adenocarcinoma. Over the last decades t he incidence of cervical 
ca rcinoma in industrialized countries has decreased. This is due to t he success of organized 
cyto logy-based cervica l screening programmes. This decrease is, however, restricted t o 
cervical squamous cell carcinoma, while t he incidence of adenocarcinoma (AC) and its 
precursor AIS has remained stable or increased2·•. In 19S2 4.S% of all cervica l cancers were 
adenocarc inomas', nowadays this percentage has risen to 20%5. The proper management 
of AIS is complicated by on one side t he location of the disease high endocervical and the 
potential for multifocal disease and on the other side the patient population who wish to 
undergo fert ility-preserving therapy. 
The aim of this study was to review literature if therapeutic strategies in AIS could lead to 
more conservat ive approach . 
MATERIALS AND METHODS 
A review of the literature was conducted using a Medline search for art icles published 
between 1966 - 2013. Search strategies have been carried out with a combination of the 
following MeSH headings: adenocarcinoma in situ of t he cervix, adenocarcinoma, AIS and 
glandular dysplasia of the cervix. In addition, t he refe rences of the selected studies were 
checked. Studies were excluded if information was missing about t reatment. We therefore 
enrolled patients wit h an adenocarc inoma in situ of t he cervix, which were t reated wit h 
a Cold Kni fe Conization (CKC) or Large Loop Excision Transformat ion Zone (LLETZ) or 
Loop Electrocautery Excision Biopsy (LEEP) or hysterectomy. The study parameters were 
res idual lesions, cutting edges and d isease recurrence. Stud ies describing resid ual disease 
in subsequent surgica l specimen in relation to margin status in initial cone were evaluated. 
Studies describing patients t reated conservat ively w ith cervical conization (CKC or LLETZ) 
alone were evaluated fo r recurrent disease. 
Case reports were evaluated for the study but not included in the analysis. 
Studies were excluded if more recent reports of the same series of patients were published. 
RESULTS 
The MEDLI NE search using the described search st rategy identified 740 hits. The reference 
lists were checked and the hand searching of congress abstracts did not add any studies (only 
abstracts). 
Going through all the abstracts of the studies/hits has produced 104 possible eligible 
studies, which were retrieved for more detai led informat ion. We have found no RCT. Of the 
remaining abstracts obtained, 63 studies were excluded for the following reasons: invasive 
carcinoma, case reports, review article, about cytology, no abstract, russian-chinese language, 
not about therapy and if more recent reports of the same series of patients were published. 
41 studies were left for analysis; 3 prospective studies• 7'10, all other studies were ret rospective. 
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Residual disease 
A total of 35 studies showed that after a radical cone 75/454=16,5% residual disease in t he re-cone 
or uterus was found (table 1). A radica l cone is a conization by cold knife, LLETZ or Laser in which 
the margins are without AIS, also ca lled negative margins. After cone with positive margins 
(AIS in margins) residual abnormalities were fou nd in 252/511=49,3%. Furthermore 3 invasive 
carcinomas were found after a radical cone (0,6%) and after a cone with positive margins, 31 
carcinomas were found (5,9%). 
Recurrence 
37 studies showed after conservative therapy (LLETZ-CKC) 64/1277=5% recurrence rate with 17 
carcinomas (table II). In most studies, a subdivision of recurrence after positive and negative 
margin was indicated. This shows t hat after conization with negative margins the risk of 
recurrence was 26/870=3% whi le in positive margins, the recurrence rate rises to 17% (23/135). 
Mean/median follow up varied between 12 and 120 months. 
The manner and duration of fol low up was different in the various studies, as it was already 
ment ioned, t he precise histo logy of t he recur rence was also not described in every study. 
Conization vs. Large Loop Excision Transformation Zone (LLETZ) 
Several studies compared t he conization (with a surgical knife, in the English literature as co ld 
knife cone) with the LLETZ and found a clinically significantly higher rate (average 51%) of 
incomplete excision at the LLETZ in comparison with the conization (average 30%). However, 
there are no prospect ive studies between the different treat ments. Recurrence rate after LLETZ 
is 9-29% compared to 6-11% after CKC20222957(table Ill). 
DISCUSSION 
Nowadays AIS is a well-described entity in pathology. Argument supporting the hypothesis that 
AIS is t he precursor of invasive adenocarcinoma of the uterine cervix2347"50 are, 1) the presence 
of AIS next to AC, 2) the cytologic and histologic resembles of AIS to AC, except for the missing 
stroma- invasion, 3) the mean age of patients with AIS (37 yr) is 6-13 years younger than of 
patients with AC (51 yr) and 4) the same type hrHPV. Fu rthermore there are case reports, which 
showed how AIS progressed into an AC and the fact of recurrences of AIS as an AC51"55. 
Therapy 
The treatment of AIS is controversial. In the past, a hysterectomy, even radica l hysterectomy 
was recommended as treat ment because AIS was considered as a multifocal disease, because 
negative margins had a limited predictive value for t he presence of residual lesions and because 
of the risk of occult carcinoma. Since women in who AIS is established, usually are in t he fertile 
phase of life are, this is not accept able t reatment. Contrary to what was adopted, AIS is less 
t han 15% multifocal'6 19. In the last few years t here is a t rend to more conservative treatment. 
The main reason to abject conservat ive treatment is the high incidence of resid ual disease after 
various forms of conization. 
Ta ble I. Residual AIS lesions in re -conus or uterus in relation to marg in of the cone 
proportion with residual disease 
year n age positive margin negat ive marg in 
Qizilbash" 1975 7 38,4 0/7 
Lues ley" 1987 19 35,0 4/8 1/2 
Andersen" 1989 28 33,6 2/4 0/4 )> 0 
m 
Hopkins14 1988 18 37,0 4/5 1/7 z 0 
Nickl in" 1991 37 36,4 5/11 2/11 n )> 
;o 
Cullimore• 1992 51 35.7 1/8 0/7 n z 
Muntz'• 1992 40 7/10 (2ca) 1/12 0 s: 
lm" 1995 18 35,0 4/6 4/9 
)> 
z 
Poynor" 1995 28 37,0 4/8 (lea) 4/10 Vl ~ 
De nehy19 1997 42 37,0 8/10 4/7 c 0 
"T1 
Ho ug hton'• 1997 19 31,0 0/3 0/2 
""" I 
Goldstein" 1998 61 43,0 8/18 13/43 m c 
""" Maini" 1998 50 37,1 8/16 (1 ca) 1/2 m ~ 
Azodi" 1999 40 37,0 9/16 (2ca) 5/16 z m 
n 
Tay" 1999 21 44,2 3/6 0/5 m ;o 
< 
Kuohung" 2000 48 35,8 6/18 (3ca) 0/3 x 
o stor• 2000 100 35,0 9/12 2/8 )> 
Vl 
Shin' 13/21 1/16 -< 2000 132 29,0 Vl 
""" m 
McHale" 2001 42 36,7 10/14 1/6 s: 
So utter'1 2001 84 37,3 11/27 (2ca) 0/4 ~ n 
Kennedy" 2002 98 37,0 14/21 (3 ca) 0/6 ;o m ~ 
Bryson'• 2004 22 0/6 0/2 m ::;;: 
Hwang" 2004 95 35,8 10/24 1/11 
Bull" 2007 101 29,0 3/24 
Young" 2007 74 34,3 11/18 (3ca) 1/13 
Dalrymple 34 2008 82 34,0 4/11(lca) 2/13 
De decker" 2008 115 37,5 12/26 2/11 
Kim'• 2009 78 42,0 14/29(5ca) 5/30 (lea) 
Kim 201137 2011 99 40,0 3/10 2/45 
Desimone" 2011 43 34,0 13/19 5/11 
Kietpeerakool39 2012 60 45,1 17/26 0/26 
Hanegem•• 2012 112 25,0 6/25 0/15 
Costales" 2013 180 33,8 3/13 (lea) 7/52 (lea) 
Hiramatsu" 2013 10 44,0 3/4 (2ca) 0/5 
Tierney" 2013 78 40,0 23/34(4ca) 10/44(lca) 
TOTAL 2125 252/511=49,3% 75/454=16,5% 
30 ca=5,9% 3ca=0,6% 
29 
Table II . AIS recurrence after conservative t reatme nt 
n conservative 
year recurrence(%} positive margin negative margin 
Lues ley" 1987 1/6 nm nm 
Andersen" 1989 0/23 0/1 0/22 
)> 
0 
Hopkins" 1988 0/3 nm 0/3 
m Nicklin" 1991 0/12 0/1 0/11 z 
0 Cullimore• 1992 n 
)> 
0/35 na 0/35 
"" Muntz'• 1992 0/18 na 0/18 n 
z lm1' 1995 0/3 0/1 0/2 0 
s: Poynor" 1995 7/15 (2 ca) 4/8 (lea) 3/7(lca) )> 
z Denehy" 1997 1/19 (1 ca) 1/3 (lea) 0/14 V> 
=i Houghton' • 1997 0/15 0/6 0/9 c 
0 Maini" 1998 3/32 (l ea) 3/18 (l ea) 0/14 .,., 
.., 
I Azodi" 1999 2/13 (1 ca) na 2/13(lca) m 
c Tay" 1999 0/10 0/1 0/7 .., 
m 
~ Kuohung" 2000 1/12 na 1/12 z 
m 
Ostor• 0/53 0/6 0/47 n 2000 
m 
"" Shin' 2000 0/95 0/3 0/92 <
x 
McHale" 2001 3/20 (1 ca) 3/5 (lea) 0/15 
)> 
V> Sautter" 2001 4/59 2/26 2/33 
-< 
V> 
.., Kennedy" 2002 9/61 (lea) 5/17 (lea) 4/42 m 
s: Andersen' 2002 4/60 1/15 3/43 ~ 
n Schorge• 
"" 
2003 0/7 0/7 
m Omnes44 2003 0/9 0/9 ~ 
m 
:;! Bryson'• 2004 0/17 0/2 0/15 
Hwang" 2004 3/67 3/9 0/35 
Akiba•• 2005 0/15 0/15 
Bull" 2007 0/101 
Young" 2007 6/40(lca) 1/4 5/27 (lea) 
Dedecker" 2008 3/61 (1 ca) 0 3/61 (1 ca) 
Kim'• 2009 0/19 0/2 0/17 
Costa•• 2012 15/119 (8ca) 
Desimone" 2011 0/11 0/1 0/10 
kim 201137 2011 0/28 0/5 1/23 
Hanegem•• 2012 0/109 0/103 
Kietpeerakool" 2012 0/6 0/1 0/5 
Hiramatsu42 2013 0/3 0 0/3 
Costales41 2013 2/101 0 2/101 
TOTAL 64/1277=S% 23/13S=l7% 26/870=3% 
17 ca (1,3%) 5 ca (3,7%) 4ca (<1%) 
30 
Our review of 35 studies showed that after a radica l cone 16,5% residual disease in the 
re-cone or uterus was found (table 1). After cone with positive margins residual abnormalities 
were found in 49%. Furthermore 3 invasive carcinomas were found after a radica l cone (0,6%) 
and after a cone with positive margins, 30 carcinomas were found (5,9%). 
Explanations for the percentage of residual lesions after cone with negative margins: 
Multifocal disease, but research shows that this occurs in about 15%, which is lower than 
the percentage of residua l lesions after radical cone, namely 23%. 
AIS is located beyond t he proximal end of the endocervica l cutti ng edge of the cone. 
This is missed by the long and tortuous elongated invaginations and turns of the 
endocervical mucosa. Goldstein et al found in a margin of more than 10 mm no residual 
lesions in uterus21• 
Inadequate histo-pathological examination of the cone specimen. 
The discrepancies found in the literature can be explained by d ifferent pathological 
interpretation of AIS. There is also a difference between a patient with a small focus AIS in a 
superficial g land and a patient with multifocal disease extending into deeper layers, both types 
are defeated as "AIS cone wit h negative margins". Young patients often have smaller lesions 
and less frequently positive margins, therefore they are a candidate for a more conservative 
treat ment with conization t han older women. If st rict fol low up is not possible due to for example 
cervical stenosis or if t here are other complains like dysmenorrhoea this justifies a hysterectomy. 
Recurrence 
In literature, the risk of recurrence is between 0-47% after conservative t reatment. Several 
authors have attempted to determine (prognost ic) factors which predict residual lesions 
or recurrence after conservative t reatment , as the depth and length of the cone56, volume 
deviation, number of quadrants in which AIS existeds7, age, endocervix curettage. None of 
these factors, however, has a significant meaning. 
36 studies showed after conservative therapy (LLETZ-CKC) 64/1277=5% recurrence rate with 
17 carcinomas. After conization with negative margins the risk of recurrence was 26/870=3% 
while in positive margins, the recurrence rate rises to 17% (23/135). The margin of the cone 
appears to be a predictor for the risk of recurrence. The manner and duration of follow up 
was different in the various studies, as it was already mentioned, the precise histo logy of the 
recurrence was also not described in every study. 
The discrepancy between t he high residual disease (17-49%) and t he low change of 
recurrence (3-17%) is explained by the fact that residual AIS in conservatively treated 
patients following conization is often eradicated, possibly from postsurgical inflammation 
and granulation t issue reaction, tissue devascularization, necrosis and reepithelialization by 
benign columnar mucosa. This might be similar to processes in breast that showed that 50% 
of breast reexcision specimens are devoid of invasive carcinoma despite positive margins on 
initia l excision58 
Conization vs. Large Loop Excision Transformation Zone (LLETZ) 
Recurrence rate after LLETZ is 9-29% compared to 6-11% after CKC20 22 29 57. The safety of 
conservative t reatment with LLETZ is comparable to CKC when negative margins are achieved30. 
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Table Ill . Marg ins in cold knife conizat ion versus LLETZ versus Laser-conization 
conus pos margin LLETZ pos margin Laser pos margin 
Wolf49 43 18 7 5 
Denehy19 24 8 13 9 
Kuohung" 39 11 9 6 
Azodi" 25 6 8 6 7 4 
Soutter21 10 4 43 25 24 14 
Houghton•• 19 8 
Maini22 so 34 
Kennedy" 37 10 49 28 4 0 
Wid rich" 18 6 14 7 
Bryson30 22 8 
Hwang" 20 9 23 9 41 11 
Akiba45 15 0 
Bull326' 69 13 32 11 
Young" 52 15 9 4 
Dalrymple34 38 8 44 6 
Dedecker" 38 6 64 31 11 2 
Costa•• 74 31 60 33 21 11 
Desimone" 26 12 17 8 
Hanegem•• 58 11 54 14 
Kietpeerakool39 23 6 37 21 
Costales41 110 35 54 30 
Hiramatsu42 10 4 
TOTAL 704 209 (30%) 594 301 (51%) 167 48 (28%) 
LLETZ as t reatment will lead to better obstetric outcome (preterme partus OR CKC 2.8; 
LLETZ 1.759 • Every additional excised mm wil l increase risk preterm partus with 6%60• 
Conclusion 
AIS is a relatively rare premalignant but increasingly frequent lesion of the cervix. lt is considered 
a pre-invasive disease of invasive adenocarcinoma. Although there is a risk of relapse (3%) 
with chance of malignancy ( <1%), this risk is so small that this review encourage to consider 
conservative treatment if AIS is completely resected by LLETZ or CKC and the patient is well 
informed about the follow-up. Nowadays patients should chose whether they want a strict 
follow up with the smal l change of recurrence of definite therapy with hysterectomy. 
Follow up after conservat ive treatment should preferably be done by endocervixcytologie 
and HPV and deviations hereby further histo logical examination should be performed. 
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ABSTRACT 
Objective 
We studied diagnostic and therapeutic strategies and follow-up in a large population of women 
with adenocarcinoma (AIS) in situ ofthe uterine cervix. We fu rther investigated whether Human 
Papilloma Vi rus (HPV) typ ing in previous cytology, classified as normal, would have helped with 
early AIS detect ion. 
Materials and Methods 
Records of 132 AIS cases diagnosed between 1989 and 2012 were retrieved. Clinical and 
pathological data were reviewed and analyzed. 
Results 
Mean age at diagnosiswas37.2 years (95% Cl37.2 ± 1.4). Seventy-two percent (n=95) of all patients 
were asymptomatic, so diagnosis was established by cyto logy and biopsy. Primary treatment 
for 124 patents was Cold Knife Cone (CKC) or Loop Electrosurgical Excision Procedure (LEEP). 
Positive margins were found in 18% of those women treated with CKC versus 40% in those 
treated w ith LEEP. The median fo llow-up time was 55.5 months (range 2-217 months). Three 
recurrences were found after conservat ive t reatment in 86 patients. High Risk HPV (HrHPV) 
positivity was detected in 96%, with HPV-18 being the most commonly occurring type (51%). 
Negative cytology taken 5 years prior to the diagnosis turned out to be positive for hrHPV in 
71% of cases, with 88% exhibiting the same type of HPV. 
Conclusions 
There is a small risk of re lapse after conservative therapy with CKC or LEEP when resect ion 
margins are negative in women with AIS. Patients should be given the options of hysterectomy 
or conservative therapy with strict follow up. HPV typing of normal smears could enable early 
detection of AIS. 
INTRODUCTION 
Adenocarcinoma in situ of the cervix (AIS), first described by Hepler' in 1952, is known to be the 
precursory condition to most adenocarcinoma of t he cervix (AC). In contrast to the precursory 
condit ions of squamous cell carcinoma (SCC), cervica l intraepithelial neoplasia (CIN), t here is 
no gradation of the adenocarcinoma precursors. 
Over the last few decades, the incidence of cervica l carc inoma in industrialized countries 
has decreased. This decrease is, however, restricted to cervical squamous ce ll carcinoma, 
while the incidence of AC and its precursor AIS has increased2·• f rom 4.5% in 19S2 ' to 20% in 
the nineties5. In the Netherlands, the incidence rate (European Standardized Rates - ESR) of 
cervical cancer in the period 1989-2012 decreased from 9.16 to 7.91 per 100.000. This is due 
primarily to the decreasing incidence of SCC (ESR 7.07 to 5.86), whereas the incidence of AC has 
actually increased from 1.22 to 1.50 6 In 2012,140 of735 new patients with cervica l cancers were 
AC (19%). The incidence of AIS has also grown significantly in the USA f rom 0.2 per 100,000 in 
t he seventies7 to 1.8 per 100,000 women per year in the late nineties8 . In the Netherlands, the 
incidence of AIS compared to AC is 1,1: 1 9. 
Early detection of AIS can prevent the occurrence of AC. Diagnosis and treatment of 
Al5, however, remains a challenge. This is because AIS has no pathognomonic clinical or 
colposcopic features and treatment is complicated, on one hand, by the location of the disease 
high in the endocervical canal and the fact that it maybe multifocal and, on the other hand, by 
the patient population who wish to undergo ferti lity-preserving therapy. Preferred t herapy for 
women diagnosed with AIS who have completed having a family is hysterectomy. Conservative 
management is generally more acceptable if future fertility is desired10 • 
The aim of this study was t o analyze d iagnostic and therapeut ic strategies fo r AIS through 
cli nical evaluation and pathologic review including HPV typing, in order to investigate whether 
conservative therapy is justified and if HPV typing in previous cytology, previously classified as 
normal, would have helped detect AIS earlier. 
MATERIALS AND METHODS 
Patient material 
One hundred ad seventy cases of women diagnosed with AIS between 1989 and 2012 in Erasmus 
Medical Center in Rotterdam and t he Reinier de Graaf Hospital in Delft were retrieved from the 
Dutch National Pathology Archive (PALGA), a centra l computer, in which coded in formation 
f rom all reports regarding cervical smears and histologic specimens from all pat hology and 
cytology laboratories in the Netherlands are registered. Case notes were retrieved f rom the 
Erasmus MC University Hospital Rotterdam and the Reinier de Graaf Hospital. Formalin-fixed, 
paraffin - embedded samples were available for HPV typing from all patients. Hematoxylin and 
eosin (H&E) stained sl ides, supplemented with mucin-stained slides, were used for review. A 
pathologist (FS) reviewed the histology of all cases. Thirty-eight cases were excluded when 
there was clinica l or pathologic doubt with regard to the diagnosis of cervical AIS were excluded 
f rom the study, as were patients in whom cl inical follow-up was inadequate or unavailable. 
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The project was approved by t he Medical Ethics Committee of the Erasm us MC University 
Hospital Rotterdam (nr.211.651/2002/48) and t he Reinier de Graaf Hospital. 
HrHPV testing 
Samples with a confirmed histopathological diagnosis of AIS underwent HPV DNA typing usi ng 
SPF10PCR-DEIA-LiPA25 Version 1 System (Labo Biomedical Prod ucts, The Netherlands). Total DNA 
was isolated and extracted usi ng a protei nase-K lysis procedure. DNA was am plified by S-phase 
promoting Factor (5PF)10 and generic amplificat ion products were detected by DNA probe 
hybrid ization and DNA enzyme immune assay (DEIA). HPV-positive specimens were typed 
by reverse hybrid ization line probe assay using 25 type-specific hybridization probes (LiPA25), 
which detected 14 high-risk (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68/73) and 11 
low-risk (HPV6, 11, 34, 40, 42, 43, 44, 53, 54, 70, 74) types, as previously described". Samples 
t hat were DEIA-posit ive and LiPA25 negat ive were class ifi ed as HPV non-typeable. Positive 
and negative cont rols were used to monitor DNA isolat ion, polymerase chain reaction (PCR) 
ampl ifi cat ion, HPV detect ion and typing proced ures. 
Statistics 
Baseline characteristics of the pat ients were evaluated using a commercia lly avai lable package 
(I BM Statistical package of the Social Science/Predict ive Analytic Software version 22). Mann-
Whitney- U test en ch i square test were performed to compare baseline characterist ics of the 
pat ient s. A p-va lue < 0.05 was considered st atistical ly significant . 
RESULTS 
Patient characteristics 
We were able to analyze 132 patients with cervical AIS between 1989-2012 fo r t his study. The 
mean age at diagnosis of this group was 37.2 years (range 22-60 years; 95% Cl 37.2 ± 1.4). Nine 
percent were younger than 30 years (the age at which screening for cervica l cancer starts in 
The Net herlands) and were noticed due to external symptoms (post-coital bleeding, spotting, 
vaginal discharge) or to abnormal cytology done for non-screening reasons. Seventy-five 
percent of patients were younger than 41 years and 35% of were nullipara. The majority of 
patient s (72%) were asymptomat ic at t ime of diagnosis (Table 1). 
55 of t he 132 (42%) cases were diagnosed with cytological as atypical g land ular cells (AGC) 
favoring neoplasia or endocervica l AIS, and 39 (30%) were diagnosed with biopsy. In 130 
patient s, previo us cyto logy was available (F igure 1), where 7 (5%) were normal, 36 (28%) showed 
no abnormality of glandular cells or showed AGC-NOS (atypical g lanudular cel ls not ot herwise 
specified) and in 78 (60%) AGC- favoring neoplasia or AIS was d iagnosed. Ninety-three 
percent (n=l 23) of patients had colposcopy, which was adequate in 71% of t he cases (95/123). 
Colposcopic impression was normal in 15 (11%) patients, was characteristic for CI N in 52 (39%), 
and showed signs of gland ular pat hology in 44 patients (33%). In 12 cases (9%), the colposcopic 
impression was not mentioned in the fi le. 
Table I. Pat ient characteristics 
Major presenting symptoms 
None 
Postcoital bleeding/spotting 
Vaginal d ischarge 
Other 
Diagnosis made by 
Cytology 
Biopsy 
Endocervix curettage 
Loop Electrosurgical Excision Procedure 
Conization 
Hysterectomy 
Colposcopic impression 
Cervical lntraepithelial Neoplasia 
Signs of g landular pathology 
Normal 
Not mentioned 
No colposcopy 
Primary therapy 
LEEP-Iaser conization 
Cold Knife Conization 
Hysterectomy 
Definite therapy 
Loop Electrosurgical Excision Procedure 
Cold Knife Conization 
Hysterectomy 
Treatment 
No of patients 
95 
27 
2 
8 
55 
39 
6 
19 
10 
52 
44 
15 
12 
9 
55 
69 
8 
26 
60 
46 
percentage 
72 
21 
6 
42 
30 
4 
14 
8 
2 
39 
33 
11 
9 
7 
42 
52 
6 
20 
45 
35 
Primary treat ment included Cold Knife Cone (CKC) (n=69, 52%), Loop Electrosurgical Excision 
Procedure (LEEP) (n= 52, 39%), laser conizat ion (n=3, 2%) and hysterectomy (n=8, 6%) (Table 1). 
Margin status was available in 65 of the 69 patients who underwent CKC as primary 
treatment. Twelve (18%) had positive and 53 (82%) had negative margins. Margin status was 
also avai lable in 45 of the 52 pat ients who had LEEP as primary treatment . Eighteen (40%) had 
positive and 27 (60%) had negative margi ns. The 3 patients treated by laser conization had 
negative margins. 
A co-existing squa mous lesion was present in 57 of the 132 patient s (43%). Of the 129 
patients for w hom information regardi ng focallity of the lesion was available, Al5 was noted 
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No38 
No AIS, no 
follow up 
hrHPV test not 
performed N=t 2 
No previous 
cytology 
1 Bethesda System 2001 glandular cell abnormalities iWright, 
2007 #2177) 
~AGC-NOS: atypical glandular cells not otherwise specified 
-AGC-favor neoplasia: atypical glandular cells favor 
neoplastia 
• AIS: endocervical adenocarcinoma in situ 
- AC : adenocarcinoma 
Figure 1. Flowchart cytology and hrHPV testing in the study group 
HPV- t8 N=40 (St%) 
HPV-16 N=31 (40%) 
HPV-45 N- 6 (9%) 
HPV-18 N=22 
HPV-16 N=11 
HPV-45 N=1 
Other type of HPV N= 17 
to be multifoca l in 9 patients (7%). Multifocal disease was not associated with higher rates of 
positive cone margins (11%) versus 24% in unifocal disease. 
Fifty-three of the 124 patients initially treated with CKC, LEEP or laser conization underwent 
further therapy within 9 months after diagnosis of AIS (Figure 2), with 1 patient having a re-LEEP, 
1 patient having a CKC with positive margins fo llowed by hysterectomy, 14 pat ients having a 
CKC and 37 pat ients having a hysterectomy of whom 5 were radical. These 5 patients had radical 
hysterectomies because of microinvasive AC. Th ree had no residual disease and 2 had AIS in the 
hysterectomy specimen. No lymph node metastases were found. 
Final specimens showed residua l disease in 33 patients. In 45 of the 53 pat ients, marg in 
status was avai lable. In 12 of the 24 (SO%) patients with positive margins in CKC or LEEP, residual 
disease (AIS, carcinoma) was found. In patients with negative margins this result was lower (5/21 
- 24%). 
Because t here is a tendency towards more conservative t reatment , we compared therapy 
choices f rom 1990-2000 and 2001-2012. These 2 groups were comparable for number of 
cases (71 versus 61) and mean age (37.0 (range 31.0-42.0) versus 37.4 (range 32.0-40.5) years) 
(Table II). Diagnosis of AIS was mostly cytologica l, being 40.8 and 42.6% for the two groups, 
respectively. LEEP was performed as defin ite t herapy in 19.7% for bot h groups. Hysterectomy, 
as definite therapy, was done in 38.0% of cases in t he first period versus 31.1% in the most recent 
period. No significant difference was observed. 
PRIMARY THERAPY 
N=55 
LEEP(n• 52)-Laser(n• 3) 
N=69 
CKC 
Hysterectomy 
further THERAPY 
N=1 CKC-hysterectomy 
N=37 Hysterectomy 
N= 79 
No further therapy 
LEEP Loop Electrosu rgical Excision Procedu re 
CKC Cold Kn ife Conization 
Figure 2. Flowchart primary therapy and definite therapy in t he st udy group 
Follow-up 
DEFINITE THERAPY 
N=26 
Q) 
.e: LEEP-laser iii >. a. 
> Cll Q; Q; 
"' :5 N=60 c 
0 
0 CKC 
N=46 
Hysterectomy 
In 116 patients (88%), follow-up was available, with a mean time frame of 59.8 months (range 1.5-217 
months; median 46.3 months). Follow-up was performed by cytology, only, in 57% of cases, by 
cytology plus endocervical curettage (ECC) in 2%, by cytology plus HPV testing in 24% and by 
cytology plus ECC-HPV in 3%. No follow-up procedure was reported in 14% of cases. Of the 86 
conservatively treated patients, those with a median fol low up of 55.5 months (range 2-217 months), 
3 had recurrences, with 2 cases of AIS after CKC, 1 with negative margins and 1 where margin status 
could not be evaluated. One patient treated with a LEEP, in which margins were negative, had 
recurrence of AIS detected by biopsy, which was treated by hysterectomy. Histology of the uterus 
showed AIS with early invasion. All recur rences occurred within 24 month after therapy. 
Of the 86 conservatively t reated pat ients of reproduct ive age, 24 (27.9%) became pregnant, 
of which 18 cases had incomplete follow- up was. Of the 46 patients treated by hysterectomy, 31 
had follow-up, with a median of21 months (range 2-180 months) and no recurrences were found. 
HPV status 
In 120 patients, hrHPV at t ime of diagnosis was determined by cytology or histology. One 
hundred and fifteen patients (95.8%) were positive and 5 (4.2%) tested negative. In 102 of the 
115, HPV-typing could be performed (88.7%- Figure 2). Seventy- five percent (n=77) of patients 
had a single HPV type and 25% (n=25) had mult iple types of HPV, t he majority of which had co-
infection with HPV type 18 and 16. The prevalent HPV types were HPV-18 (51%), HPV-16 (40%) 
and HPV-45 (9%). 
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Table II . Diagnosis and t herapy 1990 -200 0 versus 2000-2010 
1990-2000 
N=71 
Age (years) 37.0 (31 .0-42.0) 
Diagnosis n (%) 
Cyt o logy 29 (40.8) 
Biopsy 28 (39.4} 
LEEP/CKC 11 (15.5) 
Uterus 3 (4.2) 
Definite Therapy n (%) 
LEEP 14(19.7} 
CKC 30 (42.3) 
Hysterectomy 27 (38.0) 
2001-2012 
N=61 
37.4 (32.0-40.5) 
26 (42.6) 
17 (27.9} 
18 (29.5) 
0 
12 (19.7} 
30 (49.2) 
19 (31.1} 
p-value 
0.58 
0.08 
0.67 
Baseline characteristics are presented in means and interquartile range (IQR) for continuous variables and numbers and 
percentages(%} for categorical variables. A p-value' 0.05 was considered stat ist ically significant. 
LEEP Loop Electrosurgical Excision Procedure; CKC Cold Knife Conization 
In 24 patients, cervical smears diagnosed within normal limits taken 5 years before the 
diagnosis of AIS, were available and could be tested for hrHPV. In 17 (71%) of the cases, hrHPV 
was present. In 15 (88%), the same type of HPV was present in the smear at t ime of diagnosis 
indicating a persistent HPV infection. 
DISCUSSION 
Diagnosis 
AIS is general ly asymptomatic. This was the case with 72% of our patients, who had no 
symptoms. AIS in these patients was eventually detected by Pap smear screening. Cytology 
showed a glandular abnormality (AGC-FN, AIS, AC) in 60%. AIS in 42% of our cases was 
detected by cytology alone, which is the same as reported in the literature'l.13. Although the 
previous diagnosis of AIS was often made based on a conization14, in our study, 76% of cases 
were diagnosed before CKC or LEEP. In 19 of 132 (14%), patients were diagnosed with AIS based 
on a CKC or LEEP, which was performed for high grade squamous dysplasia. 
HPV in AIS detection 
The most important cause of cervica l cancer is a persistent hrHPV infection of the cervical 
epithelium's Analogous to CIN and SCC, different studies have proved the connection 
between hrHPV and the presence of AIS and AC8•16•17• In part icular HPV type 16, 18 and 45 are 
important in AIS and AC'8•19• Generally, type 18 is more commonly found8•20•21 • Our findings 
support this conclusion. 
In our study, negative cytology taken 5 years before the diagnosis of AIS was posit ive for 
hrHPV in 74% of cases and in 88% the same type of HPV was found at t he t ime of diagnosis, 
implying a persistent HPV infect ion. In the Dutch nat ionwide cervical cancer-screening 
program, women between 30 and 60 years are tested by cyto logy every 5 years. If HPV test ing 
had added to the Pap smear, patients testing positive for hrHPV would be rescheduled sooner 
than the normal 5 years. This supports the theory that HPV test ing might be superior to 
cytology in screening for AIS and AC22 
Therapy 
The treat ment of AIS is still controversial. In the pase3, a hysterectomy, even radical 
hysterectomy, was recommended as a t reatment . This aggressive approach was advocated 
because, fi rstly, AIS was considered to be a multifocal disease, secondly because negative 
margins were t hought to have limited predictive value for the presence of residual disease and 
t hirdly because of the risk of occult carc inoma. Research has however shown t hat al l these 
arg uments are incorrect17·24 Because AIS is usual ly diagnosed in women in the fert ile phase of 
their lives, radica l t herapy is not acceptable and should be reevaluated. Cont ra ry to what was 
initia lly thought, AIS is mult ifocal in less than 15% of patients25•26• In our series, this number was 
even lower (7%). 
With regards to the incidence of residual disease after various forms of conizat ion in women 
with AIS, a meta-analysis of 33 studies24 with 1278 patients was published in 2009. Since then 
anot her 10 studies have been published. A total of 44 studies (including o ur own study) showed 
that after a radical cone (negative margins - 90/556=16%) residual disease in the re-cone or 
uterus was found (Table Ill). After cone with positive margins, residual abnormalities were 
found in 303/586 (52%). Furt hermore, 7 invasive carcinomas were found after a radical cone 
(1.3%) and after a cone with positive margins, 30 carcinomas were fou nd (5.4%). 
CKC versus LEEP 
The goal of theses procedure is to remove not only the lesion with a 3- 4 mm margin, but also, 
whenever possible, the total transformation zone, in a single pass. In our study, 80% of the 
patient s t reated with CKC had negative surg ical margins versus only 60% in the group treated 
by LEEP. Fortunately, the safety of LEEP is comparable to CKC when AIS is unexpectedly found 
in a loop excision and margins can be judged and negative margins are achieved27. Achieving 
negative margins is important because positive margins are associated with a 3-fold increase 
in risk of residual disease and a 7-fold increase in risk of recurrence (2.3% versus 16,5% positive 
versus negat ive margins, respectively- Table IV). 
Recurrence 
In t he literature, recurrence is reported between 028 - 4729% after conservative treat ment 
(Table IV). Several authors have attempted to determine (prognostic) factors which predict 
residual lesions or recurrence after conservat ive treatment, such as t he dept h and length of 
t he cone30, volume deviation, number of quadrants in which AIS is present31 , patient age and 
endocervix curettage. None of these factors are however, significant. 
We found 3% (3/86) recurrence rate after conservative t herapy. We added our and 10 
recent studies to the meta-analysis of Salani in 200924• Thirty-six studies showed 4.6% (59/1285) 
recurrence rate, with 20 carcinomas after conservative therapy (CKC or LEEP). Furthermore, 
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Table Ill . Residual lesions after conization for AIS 
proportion with residual disease 
N Mean age positive margin negative margin 
Sa lani-metaanalysis24 1278 180/341 (17ca) 54/266 (4ca) 
Dedecker" 115 37,5 12/26 2/11 
Kim" 78 42 14/29 (Sea) 5/30 (lea) 
Desimone" 43 34 13/19 5/11 
Kim 201135 99 40 3/10 2/45 
Hanegem" 112 25 6/25 0/15 
Kietpeerakool16 60 45,1 17/26 0/26 
Costales" 180 33,8 3/13 (lea) 7/52 (lea) 
Hiramatsu" 10 44 3/4 (2ca) 0/5 
Tierney" 78 40 23/34 (4ca) 10/44 (lea) 
u•o 136 35 17/35 0/30 
Baalbergen (present study) 132 37,2 12/24 (lea) 5/21 
TOTAL 2321 303/586=52% 90/556=16% 
30ca (5,4%) 7 ca (1,3%) 
ca carcinoma 
in most stud ies, a subdivision of recurrence after positive and negative margins was reported. 
These result s show that after con ization with negative marg ins the risk of recurrence was 2.3% 
(24/1030), while with positive margins, the recurrence rate rose to 16.5% (20/121). The resection 
margin oft he cone, t herefore, appears to be a predictor fo r the risk of recurrence. These results 
support the feasibility of a conservative approach in women with AIS. 
CONCLUSION 
In our study, most patients with AIS (72%) were asymptomatic and diagnosed only after 
cytology or histologic biopsy at colposcopy. We are convinced that the etiologic agent in AIS 
is hrHPV, and that the majority of lesions are positive for HPV-18 (51%) and HPV-16 (40%). The 
high percentage hrHPV posit ive cases in normal cytology 5 years before t he diagnosis of AIS, 
with a continuing HPV persistence of 88%, supports t he hypothesis t hat HPV testing may be 
superior t o cyto logical screen ing for t he detection of AIS and AC. Although there is a risk of 
relapse and residual disease, with a chance of malignancy, t his risk is very low (2.3%) and fortifies 
the concept that conservat ive t reat ment by a CKC or LEEP with negative surgical margins is a 
feasible approach for all women and not only in those who wish to bear children in t he future. 
Patients should have a choice whether they want a strict fol low-up, with the smal l chance of 
recurrence or definite therapy with hysterectomy. 
Table IV. AIS/AC recurrence after conservative therapy only 
Recurrence AIS{%) 
Median follow up Conservative positive negative 
n (month) therapy margin margin 
Salani-metaanalysis24 671 34/671 (Sea) 19/9S (6ca) 15/573 (2ca) 
Dedecker" 61 37,5 3/61 (lea) 0 3/61 (lea) 
Kim" 19 42 0/19 0/2 0/17 
kim2011" 99 23,5 0/2S 0/5 1/23 
Costa 41 119 42 15/119 (Sea) nm nm 
Desimone" 11 40 0/11 0/1 0/10 
Hanegem" 109 37. 0/109 0/103 
Kietpeerakool,. 6 60 0/6 0/1 0/5 
Costales" 101 43,7 2/101 0 2/101 
Hiramatsu" 12 0/3 0 0/3 
u•o 71 40 2/71 (2ca) 1/1 (lea) 1/70 (lea) 
Baalbergen {present study) S6 55,5 3/86 (lea) 0/13 2/64 (lea) 
TOTAL 1356 59/1285=4,6% 20/121=16,5% 24/1030=2,3% 
20 ca {1,6%) 7 ca {S,S%) 5 ca (<1%) 
ca carcinoma 
nm not mentioned 
• mean follow up 
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SUMMARY 
Introduction 
To determine the behaviour of adenocarcinomas of the uterine cervix, during the last 10 years 
in the South-West region of the Netherlands, and to determine prognostic factors. 
Methods 
Three hundred and five cases of primary cervical adenocarcinomas diagnosed between 
1989-1999 in the region of Rotterdam, The Netherlands, were retrieved. Clinical and pathological 
data were reviewed and analysed. 
Results 
Mean age at presentat ion was 52 years. The mean follow-up time for surviving pat ients was 
61 months. The overall survival was 60% at 5 years. The 5-year survival rates for stage I and 
II were respectively 79 and 37%. The 5-yr survival rates for stage Il l and IV were less than 9%. 
Using univariate analysis stage, grade, age <35 years and histo logical type were significant 
prognostic factors. In the group of patients who underwent surgery (n=200), stage l-IlA, 
lymph node metastases, lymph-vascular-space-invasion and depth of st romal invasion were 
significant for survival. For patients with stage I and II-A disease survival was significant ly better 
where the primary treatment was surg ical as opposed to primary radiotherapy, p=0.002. 
Using multivariate analysis only stage, grade and lymph node metastases remained significant 
independent predictors for surviva l. 
Conclusions 
This report about cervical adenocarcinoma in the South-West region ofThe Netherlands shows 
similar results for survival to previous reports. Longest survival was for patients with early stage 
disease, younger patients and after primary surgery. We found FICO-stage, grade and lymph 
node metastases of significant prognostic value for survival in cervical adenocarcinoma. 
INTRODUCTION 
Carcinoma of the uterine cervix is one of the most common malignancies in women worldwide. 
Although the incidence of cervical cancer has decreased over the past 40 years, the relative 
proportion and absolute incidence of cervica l adenocarcinoma (AC) compared with squamous 
cell carcinoma (SCC) has increased. In the 1950s and 1960s 5% of all cervical carcinomas were 
adenocarcinoma. This proportion increased t o 25% in t he 1990s1•2•3• The overall incidence of 
invasive cervical cancer has decreased in countries with a national screening program. This 
declining incidence is accounted for by a decrease in cervical squamous cell carcinoma, 
whereas the incidence of adenocarcinoma has raised or remained stable•.s·6•7. 
It remains controversia l whether or not patients with adenocarcinoma have a worse 
prognosis. The literature is inconsistent. Questions remain about whet her cervical 
adenocarcinoma metastasizes earlier or is detected later, or whether a poorer response to 
radiotherapy, or the inclusion of special subtypes such as clear cell carcinoma could account 
for an apparent poorer prognosis3. 
This retrospective study was undertaken to determine t he clinical outcome for patients 
with cervical adenocarcinoma in the Rotterdam region over a ten year period, and to attempt 
to determine prognostic factors. 
PATIENTS AND METHODS 
Patient material 
All primary cervica l adenocarcinomas diagnosed between 1989 and 1999 in the Rotterdam area 
were retrieved f rom local cancer registries: IKRcancer reg istration, Palga pathology registration 
and oncology registration Daniel den Hoed Cancer Clinic. Case notes were retrieved from 
the Erasmus MC University Hospital Rotterdam, the Daniel den Hoed Cancer Clinic and the 
affiliated hospitals in the region. The patients were staged according to the FICO system. 
One pathologist (P.C. E.-G.) reviewed the available haematoxylin and eosin slides (n = 98 
cases). The tu mours were graded as well (grade 1), moderately (grade II) or poorly (grade Ill) 
differentiated using architectural and nuclear features. The proportion of the tumour showing 
glandular and tubular architecture was assessed (>90% well, 50 - 90% moderately and <SO% 
poorly differentiated). Where nuclear atypia was marked this led to the tumour being allocated 
to a less differentiated category. Those tumours categorised as adenosquamous showed both 
invasive adenocarcinomatous and squamous elements. Clear cel l carcinomas were not graded. 
Any cases in which there was clinical or pathological doubt concerning the primary site 
were excluded f rom t he study, as were patients fo r whom clinica l fo llow-up was inadequate 
or unavai lable. 
Treatment methods 
Patients with early disease underwent radica l hysterectomy and pelvic lymph node dissection, 
unless their cl inical condition did not permit this. The criteria for postoperative radiotherapy 
were positive lymph node involvement, compromised surgical margin or extension of 
tumour into the parametrium. Patients wit h stage 11 -B disease or higher were t reated with 
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external irradiation and brachytherapy. In 1999 hyperthermia was added to this reg imen to 
improve survival8 . 
Pat ients were followed-up every three-months during t he first 2 years, then every 6 months 
until the fifth year. 
Statistical analysis 
Patient disease-specific survival distribution was calcu lated using the Kaplan-Meier method. 
Patients who died of intercurrent disease or who were lost to fol low-up, were censored at the 
time of last known fo llow-up. The significance of the survival was tested by log-rank test. A 
value of P < 0.05 was considered statistically significant. Multivariate analysis was performed 
using t he Cox proport ional hazard regression analysis in a forward stepwise manner with a 
p-value of 0.05 as inclusion. 
RESULTS 
Bet ween 1989 - 19991424 women w ith cervical carcinoma (of all types) were registered by the 
IKR cancer reg ist ration system. Histological sl ides from 98 pat ients were available for review. 
Twenty-three patients were excluded for t he following reasons: clinical doubt concerni ng 
the primary site (n=10), pathologica l doubt concern ing primary site (n=3) and inadequate 
or unavailable cl inical fol low up (n=lO). We analysed the clinical and pathological data of 305 
patients with an invasive adenocarcinoma of the cervix. The clinicopat hologic characteristics 
of the patients are summarized in table 1. 
Almost half of t he pat ients (45%) had stage 181 disease at t he time of diagnosis while only 
25% were found to have stage liB or more. Age at presentation ranged from 19 to 92, mean 51.6 
years, with bimodal distribution; one peak in t he mid-t hirties and another at 70 years. 19% of 
the patients were nullipara. 
The most predominant presenting symptom was recorded as: vaginal discharge, 
dysfunctional bleeding/post menopausal bleeding, postcoital bleeding, asymptomatic or 
otherw ise. 20% of t he patients were asymptomatic at t ime of presentation, predominant ly 
patients in FICO stage I. The most frequent symptoms were dysfunctional or postmenopausal 
bleeding. Over 70% of the patients with Stage II, Ill o r IV disease reported this as the main 
symptom. 28% of the patients with stage I and 16% with stage II complained of postcoital 
bleeding as t he main symptom . Vaginal discharge or pelvic pain were not important 
presenting symptoms. 
In 74% of cases diagnosis was made on a biopsy whereas in 11 %diagnosis was made after 
surgery for non-malignant reasons. 
67% of the woman had a Papanicolaou (Pap) smear before diagnosis. However most 
smears were taken just before diagnosis (mean interval 6 months) and only 32 pat ient s had 
an interval between last Pap-smear and diagnosis of more t han 6 months. 40% of the smears 
showed abnormalities categorized as not more than mi ld or moderate, with a mean interval 
of14 months while 60% showed severe dysplasia or more with a mean interval of1.8 months. 
39% of the patients at some time used oral contraceptives (OC), 39 % had never used OC 
and for 22% the data were missing. 
Table 1. The clinicopatholog ic characterist ics of the 305 patient s w it h adenocarcinoma of t he uterine cervix 
Stage 
Ill 
IV 
Age (years) 
<35 
35-64 
>65 
Histological Subtype 
Adenocarcinoma 
Adenosquamous 
Adenoma Malignum 
Clear cell 
Tumor grade 
Ill 
unknown 
Primary treatment 
Surgery 
Radiotherapy 
Palliat ive 
Major presenting symptoms 
None 
Dysfunctional/postmenopausal 
Post coi t al 
Vaginal discharge 
Other 
Oral Contraception Use 
Never 
Past / now 
Unknown 
Other Oncology 
None 
Yes 
- breast 
-intest inal 
-other 
No of patients 
204 
56 
22 
23 
60 
160 
85 
230 
56 
2 
16 
80 
103 
84 
38 
201 
77 
27 
58 
156 
65 
13 
13 
119 
120 
66 
279 
24 
10 
4 
10 
percentage 
67 
18 
7 
8 
20 
52 
28 
75 
18 
26 
34 
28 
12 
66 
25 
9 
19 
51 
21 
4 
39 
39 
22 
92 
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24 pat ients (8 %) had another malignancy; 10 breast carcinoma, 4 colon carcinoma. 
The follow- up time for surviving patients ranged from 3-180 months (mean 61 months). 
The overal l survival was 60% at 5 years. The 5-year survival rates for stage I and II were 
respectively 79 and 37%. The 5-year survival rates for stage Il l and IV were less than 9%. 
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Figure 1. Kaplan-Meier plot for disease specific survival for305 patients with adenocarcinoma of the cervix uteri 
according to stage. 
The 5-year disease-specific survival related to several clinocopat hological variables is 
presented in table II. For t his analysis only treated patients in Stage 1-111 were used (patients 
who had no or only pall iative t herapy were excluded). 
Using univariate analysis stage and grade were significant prognostic factors. Younger 
pat ients (age <35 years) had a significantly better surviva l than older patients(> 65 years) (p<O.OOl). 
Histo logical type (adenocarcinoma versus adenosquamous versus clear cell carcinoma) showed 
significant d ifference in survival (p=O.OOS). 
In the group of patients t reated surgical ly, stage l-IlA (n=200), 17% had lymph node metastases. 
The patients without lymph node metastases had a 5-year survival of 91% compared to 34% when 
positive lymph nodes were found. 75% of patients who had lymph node metastases developed 
recurrent disease while only 13% in the group without lymph node metastases had a recurrence. 
Table 2. The 5-year disease-specific survival of treated pat ients with adenocarcinoma of t he uterine cervix 
related to clinicopathological variables 
p value p value 
Factor No. 5-yr Survival univariate multivariate 
Stage <0.001 <0.001 
200 80 
55 37 
Ill 17 <11 
Grade <0.001 <0.001 
79 92 
94 66 
Ill 68 53 
Age <0.001 ns 
< 35 year 60 83 
35-65 year 152 69 
, 65 year 60 46 
Histological type 0,005 ns 
adenocarcinoma 202 73 
adenosquamous 48 56 
clear cell 16 53 
Lymph node metastases <0.001 <0.003 
no 119 91 
yes 23 34 
Lymphvascular space invasion <0.001 ns 
no 134 89 
yes 46 so 
Depth invasion <0.001 ns 
<lOmm 81 85 
>lOmm 22 53 
After recurrent disease only 24% surv ived 5 years or more. 40% of the patients w ith grade Ill 
tumour had lymph node metastases, while on ly 15% of g rade II and 2% of grade I t umours were 
associated w it h lymph node metastases. Lymph-vascular-space- invasion (LVSI) was a significant 
factor for survival. The 5-year survival in the group without LVSI was 89%, whereas in patients w ith 
LVSI survival was 50% (p<O.OOl). When LVSI was found, the chance o f positive lymph nodes was 
32% whereas, when LVSI was negative, t he chance of lymph node metastases was on ly 5%. The 
depth o f stromal invasion influenced survival significantly; when depth o f stromal invasion was< 
10 mm the 5-year survival was 85% versus 53% when invasion was> 10 mm (p<0.001). 
The survival was significantly better in pat ients undergoing primary su rgical t reatment in 
st age I and IIA when compared to primary rad iation t herapy, p=0.002. When corrected for 
stage and grade this significance disappeared (p=0.12) . 
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In t he final step, all t he significant variables tested in the univariate model were entered 
in the Cox regression model. Using this approach, only stage and grade remained significant 
independent predictors for survival. Multivariate analysis of lymph node metastases, depth 
of infi lt ration and LVSI showed that t he presence of lymph node metastases was the most 
important prognost ic factor. Although depth of invasion and LVSI were significantly related to 
disease free survival in univariate analysis, adjusted for lymph node metastases bot h factors lost 
their significance. This could be explained by the significant (p<0.003) relationship between 
both paramet ers (depth of invasion and LVSI) and lymph node metastases. 
DISCUSSION 
This report represents a review of 305 patients with adenocarcinoma of the uterine cervix, 
presenting between 1989 and 1999 in the reg ion of Rotterdam. The overall survival after 5 years 
was 60%. The 5-year survival rates for stage I, II, Ill and IV were 79, 37, <9 and <9 %, respectively. 
This is consistent with the literature. The reported 5-year survival for stage I varies from 60-99%, 
for stage 11 14-100%, stage Il l 0-39% and stage IV 0 -11%2•9•18• 
The incidence of cervica l carcinoma in The Netherlands has decreased during the last 
decade, this decline representing a fall in squamous cell carcinoma since the incidence of 
adenocarcinoma has remained stable, approximately 150 new patients a year19• 
The use of oral contraceptives has been repeatedly (albeit inconsistent ly) associated 
with the risk of cervica l cancer20, especially adenocarcinoma21 . Should such an association 
be confirmed t his coupled with an increasing prevalence of HPV-infect ion and the relative 
inefficiency of screening programs in detecting glandular abnormalities22, could offer a part ial 
explanation for the lack of decrease in cervical adenocarcinoma in women who were in t heir 
20s and 30s during t he early 1960s in developed count ri es4 
Adenocarcinoma is reported 4 t imes more commonly t han sq uamous carcinoma in cervical 
st umps. There may be a relat ionship between ablat ive t reat ments and adenocarcinoma . Such 
a relationship could partly explain t he observed increase in t he incidence of adenocarcinoma 
since the 1960s, as this period has coincided with the introduction of screening for cervica l 
cancer and a consequent increase in the number of surgical and ablative procedures performed 
on the cervix15. In o ur group there were four stump carcinomas. Two were treated with radical 
surgery and one had a stump resection plus adjuvant radiotherapy. These three patients are 
without recurrent d isease. The fourt h pat ient was t reated with rad iotherapy (stage I-B2) but 
died two years later because of recurrent disease. 
40% of our patients had no abnormality or abnormal ities graded as mild to moderate on 
cervical smear before diagnosis of cervical adenocarcinoma. Recently several reports have 
shown t hat an AGUS smear (atypical glandular cells of uncertain significance) has clinical 
sig nificance23• Hammoud eta/ studied a gro up of 114 patients with AGUS smears and histological 
fol low up and found 55 significant abnormalit ies24• Ursin et a/ found a protective effect from 
having had previous cervical smears, which suggests t hat cervical smears can detect early 
endocervical lesions25. In postmenopausal women, one possible explanation fo r a lack of 
screening efficiency is that t he transformation zone moves up the cervical ca nal with age22. 
The mean age of our patients was 51.6 years. Some authors10•26 have observed a significant 
decrease in the of age of t he patients during the period of their studies. We d id not observe 
this in our study group. In the period 1989-1994, 169 new patients had a mean age of 52.8 years 
whereas between 1995 and 2000 the mean age for the 139 new patients was 49.9 years. 
The significantly better survival for patients younger than 35 years as compared to those 
over 65 years is the result of different t herapy. Radica l surgery with or without adjuvant 
radiotherapy was carried out in 90% of the young patients whereas in t he group> 65 years only 
41% underwent radical surgery. 20% of women over 65 had primary radiotherapy, 20% received 
adjuvant radiotherapy after simple hysterectomy and 6% had palliative t hera py only. 
In early stage disease we found stage, grade and lymph node metastases to be of prognostic 
significance. The literature is consistent about stage and lymph node metastases as prognostic 
facto rs for survival in cervical adenocarcinoma, but inconsistent about the importance of 
grade, histological type, LVSI or age. All these studies2·3·"·'s.ms are retrospective studies. They 
include different types of patients and some studies exc luded adenosquamous carcinomas. 
Histology was not always reviewed and statistics were used in different ways. If preoperative 
facto rs are of prognostic va lue, t hey could be used for decisions about therapy. For example we 
found LVSI to be predictive of lymph nodes metastases: if LVSI was present 32% had lymph node 
metastases and thus had an indication for adjuvant radiotherapy. Furthermore, when LVSI was 
negative the chance of lymph node metastases was only 5%. 
Lymph node metastases in early cervical adenocarcinoma is a poor prognostic facto r. We 
found a significantly decreased survival despite adjuvant radiot herapy. The 5-year survival 
decreased f rom 90 to 33% where there were positive lymph nodes. Sam/a/eta/ and Nakanishi 
et a/ both found that in the absence of lymph node metastases there was no significant 
difference in 5-year disease-free interval (94% resp. 90%) o r survival (97.9% resp. 93.9%) 
between squamous carcinoma and adenocarcinoma. However, survival and disease-free 
interval (DFI) were significantly decreased in pat ients with adenocarcinoma (5-year survival 
58%, DFI 59%) compared to squamous carcinoma (5-year survival 84%, DFI 87%), when lymph 
node metastases were present34•36• 
Standard therapy for cervical carcinoma stage I & I lA is radical surgery, but patients were 
irradiated w hen their clin ical condition was poor because of o ld age (mean age 65 years in the 
radiation group versus 41 years in the surgery group) o r coexistent medical problems (obesity, 
cardiovascu lar disease). In keeping with a num ber of earlier reports1u6·37'40 we found a better 
survival after primary surgery than after primary radiation therapy, despite the opinion of, for 
example, Cuccia eta/ w ho wrote in 1967 " it is w idely accepted that t he t reatment of choice 
of primary adenocarcinoma of the cervix is radiation therapy"41 . In our study patients with 
stage I lA (n=26) had a 5-year disease-specific survival after primary surgery of 77%, whereas 
after primary radiat ion t herapy this was approximately 15%. When comparing t hese groups, 
the mean age was significantly higher in the radiation group and the significant difference in 
survival disappeared after correcting for age. In stage I we found no d ifference in survival after 
primary surgery or radiation therapy. 
Like others12, we found a worse survival in the 27 patients where diagnosis was made after 
surgery for other conditions. Despite adjuvant radiation therapy survival was worse compared 
"0 
"' 0 
C'l 
z 
0 
Vl 
-i 
n 
~ 
-i 
0 
"' Vl 
z 
)> 
0 
m 
z 
0 
() 
)> 
"' () 
z 
0 
s: 
)> 
0 
-n 
-i 
I 
m 
c 
-i 
m 
"' z 
m 
() 
m 
~ 
X 
61 
" 
"' 0 
C'> 
z 
0 
V> 
..; 
() 
~ 
..; 
0 
"' V> 
z 
)> 
0 
rn 
z 
0 
(") 
)> 
"' (") 
z 
0 
s: 
)> 
0 
.., 
..; 
I 
rn 
c 
..; 
rn 
"' z 
rn 
(") 
rn 
~ 
X 
62 
to the group who received adequate treatment. In stage I the 5-year survival was 60%, in stage 
1114%. In patients with cervical squamous cell carcinomas this difference was not found42• 
Despite adjuvant radiotherapy after radical surgery in Stage I and I lAthe 5 yr-survival was 
significant decreased from 92 to 49% in our group. In squamous carcinoma survival is also 
decreased where adjuvant radiotherapy is req uired, but not so dramatical ly3"- Peters et a/ 
showed a 4-year progression-free survival of43% for adenocarcinoma versus 69% for squamous 
carcinoma in patients initially treated with radical hysterectomy and pelvic lymphadenectomy 
with adjuvant radiotherapy. This difference in 4-year progression-free survival almost equalised 
when chemotherapy was added to the adjuvant radiotherapy (80 respectively 85%)43• 
All t hese studies suggest that cervical adenocarcinoma is less radiosensitive than squamous 
carcinoma, but hard evidence such as a randomised cont rolled t rial of surgery versus radiation 
therapy for adenocarcinoma is lacking. In their randomised controlled t r ia l of stage IB-IIA 
cervical cancer however Landoni eta/showed in a subgroup of 46 patients with adenocarcinoma 
that radiotherapy was less effective than surgery for adenocarcinoma of the cervix39 
CONCLUSION 
This report about cervica l adenocarcinoma in South-West region of The Netherlands shows 
a similar pattern of survival to that found in previous reports. The best survival rate was for 
patients with early-stage disease, younger patients and after primary surgery. We found FIGO-
stage, grade and lymph node metastases to be of significant prognostic va lue for survival in 
cervical adenocarcinoma. 
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ABSTRACT 
Introduction 
We investigated the significance of prognostic markers-est rogen receptor, progesterone 
receptor, p53, MIB-1 and bcl-2- in adenocarcinoma ofthe uterine cervix. 
Methods 
In 101 patients with primary cervical adenocarcinoma, t reated from 1989 to 2000, we evaluated 
clinical parameters in relation to these prognostic markers. Est rogen receptor, progesterone 
receptor, p53 and bcl-2 immunoreactivity was scored as 0 (up to 5% positive cel ls), 11 (5- 25% 
of cel ls positive), 21 (26- 50% of cells positive), 31 (51 - 75% of cells posit ive) or 41 (>76% of ce lls 
positive). MIB-1 was scored in 10 categories: 0 - 10, 11- 20, 21 - 30, 31 - 40, 41 - 50, 51- 60, 61 - 70, 
71- 80, 81- 90, 91- 100. 
Results 
Mean age of patients was 45 years. Seventy eight percent of the patients were in FICO stage I, 
16% stage II, 7% stage Ill and IV. The overall survival rate was 67%. Survival was not influenced by 
estrogen receptor, progesterone receptor, MIB-1, o r bcl -2 strongly positive staining. Only p53 
showed significant influence on survival, even when adjusted for stage or tumor grade. 
Conclusions 
It does not seems useful to determine estrogen receptor, progesterone receptor, MIB-1 or 
bcl-2 in cervical adenocarcinomas as an indication of prognosis: survival is not influenced by 
presence or absence. However, if p53 staining is strongly positive survival is significantly worse 
than in tumors scored as negative or weak positive. 
INTRODUCTION 
The prevalence of cervica l adenocarcinoma has risen worldwide, in recent studies 
accounting for 25% of all cervical carcinomas.' In The Netherlands there are =700 new cases 
of cervical cancer per year, of which 19% are adenocarcinomas.2 The overall survival rate 
for cervica l adenocarcinoma is worse than for the more common squamous ce ll carcinoma 
of the uterine cervix. 3-s However, for early stage adenocarcinoma survival is equivalent to 
squamous cell carcinoma.6•7 Stage is one of the most important factors for survival in cervical 
adenocarcinoma.8- 10 In breast and uterine corpus carcinoma expression of estrogen receptor 
and progesterone receptor are associated with better prognosis."·'2 The prognostic significance 
of hormone receptor status in adenocarcinoma of the uterine cervix is still unclear. The p53 
tumor suppressor gene plays a major role in cel l cycle cont ro l and growth arrest following DNA 
damage. Mut ations ofthe p53 tumor suppressor gene are t he most common genetic alterations 
in human cancers. PS3 protein overexpression has been found to be a associated with poor 
prognosis in several malignancies13- 15; however results of studies in cervical cancer mostly 
show no association.16 It has been shown t hat the aberrant expression of cel l cycle regulatory 
proteins is a potentia l prognost ic indicator within different tumor groups. Ki-67 nuclear antigen 
is found in proliferating cells. It ident ifies the growth fraction of normal and neoplastic cells, 
and is expressed solely in cells in the G1, S, G2 and mitotic phases. It has been reported t hat the 
percentage Ki-67 index correlates inversely with the prognosis of various tumors. The MIB-1 
murine monoclonal antibody, which reacts with the Ki-67 nuclear antigen, 
is a marker for proliferating cells and in breast and ovarian cancer it is a good prognostic 
marker.17•18 Bcl -2 is t he protein product of a proto -oncogene that inhibits apoptosis, and it has 
been shown to prevent apoptosis instead of promoting cell proliferation. Together with the 
proapoptotic protein Bax it forms a dimeer to control progression to apoptosis. Expression 
of bcl-2 is associated with better survival in patients with solid tumors.19 The present study 
evaluates the prognostic significance of estrogen and progesterone receptor, p53, MIB-1 , and 
bcl-2 in adenocarcinoma of the uterine cervix. 
MATERIAL AND METHODS 
Patient material 
All primary invas ive cervica l adenocarcinomas diagnosed between 1989 and 2000 in the 
Rotterdam area were ret r ieved from local cancer registries: IKR regional cancer registration 
body, Pa lga pathology registration and oncology registration at the Daniel den Hoed Cancer 
Clinic. Case notes were ret rieved from t he Erasmus MC University Hospital Rotterdam, the 
Daniel den Hoed Cancer Clinic and the affi liated hospitals in t he region. The patients were 
staged according to t he FICO system. From 103 patients formalin-fixed and paraffin-embedded 
tissue was available for immunohistochemical test ing. The haematoxylin and eosin slides 
(n = 103 cases) were reviewed by an experienced gynaecopathologist (P.C.E-G). Any cases 
in which there was clinical or pathological doubt concerning t he primary site were excluded 
f rom the study, as were patients for whom clinica l follow-up was inadequate or unavailable. All 
cases of usual/mucinous type cervix adenocarcinoma were included, along with the variants 
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of mucinous carcinoma.20 Where there was a suggestion of endometrioid morphology the 
case was not included unless clearly located in the cervix only. If a squamous component was 
present the case was classified separately as adenosquamous. A number of rare tumors were 
excluded: serous, clearcell and adenoid basal. 
The t umors were graded architecturally into well, moderately or poorly differentiated 
depending on the proportion of solid growth .21 The project was approved by the Medical 
Et hical Committee ofthe ErasmusMC University Hospital Rotterdam (nr.211 .651/2002/48). 
Marker analysis immunohistochemistry 
All immunohistochemical analyzes were carried out by applying the avidin-biotin complex 
(ABC) method, on 4 lm sections cut from formalin-fixed, paraffin embedded tissues using 
commercia lly available mouse- monoclonal antibodies and DAB as co lor technique. Sect ions 
were deparaffinized and then manually incubated in the primary antibodies for 30 min at 20oc 
Before incubation the sections were placed in a microwave oven with citric acid buffer solution 
(pH 6.0, 0.1 M) for 15 min to ret rieve the antigens. In all cases a microwave pretreatment of the 
slides was used. 
For estrogen and progesterone receptors t he antibodies and dilut ions used were as 
fo llows: oestrogen receptor DAKO M7047, IDS, 1:160, progesterone receptor DAO M3569 
PgR 636, 1:40. PS3 was analyzed with the mouse monoclonal antibody pS3, clone D0-7, 
isotype lgG2b, which recogn izes wildtype and mutant forms o f t he pS3 protein (1:50; 
DAKO, Glostrup, Denmark) . For pS3 only cells with a distinct brown stain confined to the 
nucleus were regarded as immunoreactive . In slides stained for MIB-1 the antibody used 
was lmmunotech OSOS M IB-1, 1:100. Immunohistochemical staining for bcl-2 was with DAKO 
M0887 124, 1:80 and a semi-quantitative assessment was made of the percentage of cells 
showing cytoplasmat ic stai ni ng. 
Scoring of immunostaining 
lmmunostaining was scored semiquantitat ively. For estrogen receptor, progesterone receptor, 
pS3 and bcl-2 the percentage of positive cel ls was graded as follows: 0 (up to 5% positive cells), 
11 (S-2S% of cells positive), 21 (26- SO% of cells positive), 31 (S1-7S% of ce lls positive) or 41 (>76% 
of cells positive). MIB-1 was scored in 10 categories: 0- 10, 11- 20, 21 - 30, 31 - 40, 41 - SO, S1 - 60, 
61 - 70, 71 - 80, 81 - 90, 91 - 100. Estrogen receptor, progesterone receptor, pS3 and MIB-1 were 
scored for nuclear staining, whereas bcl-2 was scored for cytoplasmic staining. In the analysis, a 
cut-off value at <SO% versus >SO% was used as it gave the best survival curve separation. 
Treatment methods 
Patients with early disease underwent radica l hysterectomy andpelvic lymph node dissection, 
unless their clinical condition d id not permit this procedure. The crit eria for postoperative 
radiotherapy were: posit ive lymph node involvement compromised surgical margi n or 
extension of tumor into t he parametrium. Patients with stage 11-B disease or higher were 
treated with external irradiation and brachytherapy. In 1999 hyperthermia was added to this 
regimen to improve surviva l.22 Patients were followed-up every t hree months during the fi rst 
2 years, and thereafter every 6 months until the fifth year. 
Statistical analysis 
Pat ient disease-specific survival distribut ion was calculated using t he Kaplan-Meier method. 
Patients who died of intercurrent disease or who were lost to follow-up, were censored at 
the time of last known fo llow- up. The significance of t he survival was tested by log-rank test . 
To obtain independent prognostic significance of the var iables, Cox's proport ional hazards 
regression analysis was used in mult ivariate analyzes. A value of p < 0.05 was considered 
statistical ly significant in all analyzes. 
RESULTS 
Tumor characteristics such as FIGO stage and tumor grade are presented in Table I. The mean 
age of t he patients (n 5 101) was 45 years (26-81 years). Seventy nine percent of the patient s 
were in FIGO stage I, 14% stage II, 7% stage Ill and IV. Eight percent had primary surgery, 
Table I. The cl inicopathologic characteristics of t he 101 patients with adenocarcinoma of the uterine cervix 
Stage 
Ill 
IV 
Age (years) 
< 35 
35-64 
>65 
Histological subtype 
Adenocarcinoma 
Adenosquameus 
Tumor grade 
Well 
Moderate 
Poor 
Unknown 
Primary treatment 
Surgery 
Radiotherapy 
Palliat ive 
Recurrence 
No 
Yes 
Number of Patients Percentage 
80 79 
14 14 
2 2 
5 5 
28 28 
60 59 
13 13 
80 79 
21 21 
37 37 
37 37 
23 23 
4 3 
85 84 
13 13 
3 3 
71 70 
30 30 
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Table II . Immunohistochemical staining results for estrogen receptor, progesterone receptor, p53 and 
Bcl-2 markers in 101 patients w ith invasive adenocarcinoma of uterine cervix 
No. of tumors w ith positive staining by 
extent of distribution 
No. of tumors with 1+ 2+ 3+ 4+ No. of positive tumors with 
Marker negative staining (<SO%) (S-2S%) {26-30%) {S1-7S%) {>76%) strong positive staining (>SO%) 
ER 84 4 3 2 8 10 
PR 89 3 2 6 8 
PS3 58 21 4 3 8 12 
Bcl-2 77 9 5 0 5 5 
whereas 13% had primary radiotherapy and 3 patients received pall iative t herapy. The overall 
disease-specific survival was 67%. 
The results of immunohistochemical staining are shown in Table II. In 7 patients there 
was insufficient material for all immunohistochemical analyzes. The est rogen receptor was 
analyzed in 101 patients. In 83% of the patients less t han 5% of the tumor cells stained positively 
for estrogen receptor, leading to a classification as 'negative' for the receptor. In 88% of the 101 
patients we found a negative staining for progesterone receptor. 
p53 was analyzed in 94 patients. In 62% oft he patients less than 5% of t he t umor cells stained 
positively for p53, leading to a classification as 'negative'. 80% of the 96 patients had less than 
5% stain ing for the apoptosis control gene, bcl-2. 
The proliferat ion marker MIB-1 was analyzed in 100 patients. See Figure 1. The mean MIB-1 index 
was 60%. In univariate analysis using the Kaplan-Meier method only marker P53 was significant 
MIB·1 index (%) 
Figure 1. Immunohistochemica l results for MIB-1 (n=lOO) 
Table Ill. Immunoh istochemical results and the 5-year disease specific su rvival based on log rank t est in 
pat ients with adenocarcinoma of the uterine cervix 
5-yr 5-yr 
Weak-negative su rv ival Strong positive survival p 
ER 91/101 (90%) 68% 10/101 (10%) 64% 0.32 
PR 93/101 {92%} 68% 8/101 {8%) 67% 0.26 
p53 83/94 (88%) 71% 11/94 (12%) 26% 0.0004 
Bcl-2 91/96 (95%) 67% 5/96 (5%) 60% 0.71 
MIB-1 41/100 (41%) 61% 59/100 (59%} 72% 0.32 
for survival; patients with a higher p53 sta ining had a worse surviva l; in the p53 negative group 
(staining less than 5%) the 5-year survival was 68%, which declined to 40% when stain ing was 41 
(p < 0.05). Accordingly, patients were grouped into those with strongly positive tumors (>SO% 
sta ining) and those with negative or weak immunostaining (sSO%). Ten percent of our patients 
had a strongly positive staining for ER and 8% of the patients for PR. Only 5% of our patients had 
a strongly positive staining for bcl-2. Fifty nine percent of patients had a strongly positive sta ining 
for MIB-1. Survival was not significantly influenced by strongly positive staining for ER, PR, bcl-2 or 
MIB-1. Patients with strongly p53 immunoreactive tumors had a significantly worse outcome than 
patients whose tumors were p53-negative or weakly posit ive (p < 0.05). See Table Ill and Figure 2. 
Strongly posit ive staining for p53 also was significant in multivariate analysis using the Cox's 
proportional regression mode, when survival was adjusted for stage and grade (p < 0.05). These 
results are shown in Table IV. 
1 .0 
.9 . . . .. : 
.8 
.7 
p53 V\eak-neg (n=83) 
.6 
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Survival (month) 
Figure 2. Kaplan-Meier curve for disease specific survival stratified according to p53 status in 94 patients with 
cervical adenocarcinoma, p= 0.0004 
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Table IV. Results of COX's mult ivariate ana lysis for disease free surviva l in patients with adenocarcinoma 
of uterine cervix 
Variables 
PS3 expression 
Stage 
Grade 
Beta (SE) 
1.55 
1.30 
0.54 
DISCUSSION 
(0.49} 
(0.31) 
(0.29) 
Relative risk (95% Cl) 
4.7 
3.66 
1.7 
(1.81-12.34) 
(1.98·6.76) 
(0.96-3.06) 
p-value 
0.002 
0.000 
0.068 
Compar ison of d ifferent studies in this area is difficult owing to lack of standardized fixation 
procedures, protocols, heterogeneous tumor stage, differing antibodies and fixation 
procedures, determination of tumor cel l positivity qual itat ively or quantitatively, and differing 
st atistical analyses. Anot her reason for t he difference between the immunohistochemical 
studies are the misclassified cases, for example endometrial cancers t hat could have been 
misclassified as being of endocervical orig in. There are a number of immunohistochemical 
reports about adenocarcinoma of the uterine cervix, but there is no consistency among t hese 
studies in t he definition of positive and negative staining. Used cut-off values are 1%/3- 25 5%/6 
10% or 0%.16•27•28 We showed sta ining results semi-quantitat ively from 0- 41 and for analysis 
used cutoff value off st rong positive, which is more that SO% staining. Unl ike breast cancer and 
cancer of t he uterine corpus where hormone receptor status is of prognostic significance12•29•30 
and can determine response to endocrine therapy, the significance of hormone receptor 
st atus in adenocarcinoma of the uterine cervix still remains unclear. The expression of est rogen 
receptor in adenocarcinoma of the uterine cervix has been found to vary between 4%31 and 
81%.32 Ten percent of our patients were classified as having tumors strongly positive for the 
estrogen receptor. This is lower than in many studies, possibly because of d ifferences in tumor 
stage distribut ion or different cut-off values for determining hormone receptor positivity 
like others32- 34 we found no significant difference in survival between those with positive or 
negative estrogen receptor status. Some groups have reported bett er disease free survival 
where estrogen receptor is positive35•36 although in some studies t his was marginal.33 
The preva lence of progesterone receptor in adenocarcinomas of the uterine cervix varies 
between 4%31 and 54%.32 In ou r study 8% of cases were strongly positive for progesterone 
receptor. As in other studies32•33•36 we found that survival was not influenced by presence or 
absence of the progesterone receptor, although Masood et al.35 and Suzuki et al. 34 found a better 
survival in patients with positive progesterone receptor. In endometrial cancer high estrogen/ 
progesterone receptor levels are more freq uent in well-differentiated adenocarcinomasY 
We did not detect any re lation between tumor grade and immunohistochemical staining for 
hormone receptors . 
When DNA damage occurs, the cell cyc le is stopped in G1 and DNA repair is carried out 
prior to cell division. If DNA damage is irreversible, apoptosis is induced. PS3 is involved in 
t he regulat ion of cel l proliferation by stimulating the t ranscription of other specific cell cycle 
control genes. Cells with inactivated or mutant p53 cannot delay progression from t he G1 to 
the S phase of the cell cycle and thereby cannot prevent the replicat ion of abnormal DNA. 
Mutations result in a conformational change of the protein, which becomes stabilized, thus 
allowing for immunohistochemical detection.38 Usually when p53 mutation is present, there is 
a diffuse intense nuclear positivity. However, lower levels of p53 positivity may occur without 
mutation, as a result of stabilization of wild -type p53 by non mutational events.39 It has been 
suggested that over-expression of wi ld type p53 gene products may indicate a poorer prognosis. 
There are confl ict ing reports about p53 as a prognostic factor in cervical cancer. Some found 
no relationship between p53 and survival in cervical adenocarcinoma.19•40- 44 However, in 
accordance with some other groups,<5- 48 we found a significantly worse 5-year d isease specific 
survival if p53 staining was strongly positive. Multivariate analysis showed, adjusted for FIGO 
stage and grade, a significantly worse survival in patients with strong positive p53 staining. 
Ki-67 antibody is found in proliferative cells and is observed during the late G1, S, G2 and M 
phases oft he cell cycle; cells in GO and earlyG1 consistently lack reactivity.'7 MIB-1 is a monoclonal 
antibody, which reacts with the Ki-67 antigen. MIB-1 is a prognostic factor in breast cancer,'9 
ovarian cancer,18 squamous cell cervica l carcinomas50 and endocervical adenocarcinomas_~' 
In general a high MIB-1 index reflects a poorer prognosis. Higher proliferative act ivity of 
cancer ce lls is associated with a more aggressive behavior and results in a higher frequency 
of recurrence or metastases. However, we found no d ifference in survival with higher MIB-1 
index. Suzuki et al.34 and Nakano et a I. 52 showed a better survival in patients with squamous cell 
carcinoma of the uterine cervix with higher levels of MIB-1. This study group studied a large 
homogeneous group of patients with long follow up. The primary treatment was radiotherapy, 
and the authors suggest that this treatment may explain t heir results. Tumors containing 
a large numbers of proliferating cells, as indicated by a high Ki-67 growth fraction or MIB-1 
index, may be more sensitive to radiation therapy, possibly conferring a better prognosis. In 
our group most patients (84%) were treated by primary surgery. It may be that growth fract ion 
of t he tumor does not correlate directly with its biological behavior. Van der Putte et al. found 
in a large group of early SCC, no differences in survival, but an inverse relation between Ki -67 
and both tumor size and stromal invasion.28 lt is our interpretation that MIB-1 seems not to be 
of clinica l significance for survival in adenocarcinomas of the cervix. The prevalence of bcl-2 
positivity in cervical adenocarcinomas varies between 27%53 and 61%.42 Using a cutoff va lue of 
SO% we found a much lower level of bcl-2 positivity : only 5% of cases. Even when the cutoff was 
lowered to 1%, the level used by other groups,15•23 the percentage of bcl-2 positivity remained 
low, 23%. Unlike other studies where a better19•44•45 or worse16•41·54 survival was demonstrated for 
bcl-2 positive tumors, we found no sig nificant difference in survival. 
In summary, our study suggests that it is not of clinica l significance to determine estrogen 
receptor, progesterone receptor, MIB-1 or bcl-2 in cervica l adenocarcinomas as an adjunct to 
determine surviva l. However, determination of p53 seems useful since p53 staining is a marker 
for surviva l. p53 positivity appears to be linked to poorer survival in cervica l adenocarcinoma, 
and adjuvant therapy may need to be adjusted. 
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ABSTRACT 
Objective 
To review and characterise by clinical evaluation, immunohistochemistry and HPV typing 
a group of adenocarcinomas initially diagnosed with primary localisation in the cervix. 
Furthermore, to assess t he prevalence and prognost ic significance of HPV genotypes in a large 
series of HPV positive cervical adenocarcinomas (AC). 
Methods 
One hundred and seventy-one cases of adenocarcinomas (AC) with a primary localisation in 
the cervix and diagnosed between 1989 and 2008 in the region of Rotterdam, the Netherlands 
were retrieved. Slides and blocks were reviewed and immunohistochemically stained for CEA 
and Vimentin. HPV testing for high-risk HPV (hrHPV) by PCR (GP5+/6+) and genotyping by 
reversed line blot were performed. 
Results 
In 113 of171 patients HPVevaluation was possib le.101 were HPV-positive (89%) and 11 were HPV-
negative (11%). The 5-year disease free survival was 80% in the HPV-positive group versus 74% 
in the HPV-negative group (ns) . The distribut ion of HPV types was type 18 in 55 patients (54%), 
t ype 16 in 37 (37%), type 45 in 7 (7%), t ypes 53 and 39 were found in 2 respective pat ients . 5-yr 
overal l-surviva l in patients wit h HPV-18 was not significant ly worse t han in pat ients with HPV-16 
(81 versus 87%). Patients with HPV-45 had a worse 5-yr survival, 57%. 
Conclusions 
AC is hrHPV related in most cases (89%) and HPV-18 is the most freq uent type (54%) . With the 
exception of HPV-45, HPV-positivity or type in endocervica l AC has no significant influence 
on survival. 
INTRODUCTION 
Cervical carcinoma is the third most common type of malignancy in women worldwide'. Over 
the last decades the incidence of cervical carcinoma in industrial ized countries has decreased. 
This is due to the success of organized cytology-based cervical screening programmes. This 
decrease is, however, restricted to cervical squamous ce ll carcinoma, while the incidence of 
adenocarcinoma (AC) has remained stable or increased2· 3• In t he Netherlands this phenomenon 
has also been observed•. The use of oral contraceptives, an increasing prevalence of 
HPV-infection and the relative inefficiency of screening programs in detecting glandular 
abnormalities, part ial ly explain the st riking increase in cervica l adenocarcinoma in women who 
were in their 20s and 30s during the early1960s in developed countries2• Furthermore, improved 
performance of pathologists with regard to t he subclassification of cervical carcinoma is also 
t hought to play a roles 
Invasive AC and adenosquamous carc inoma of the cervix detected by screening are found 
at an earlier stage and associated with lower disease-specific mortality t han carcinomas 
not detected by screening6• Therefore, initiatives directed toward improving the efficacy of 
screening fo r AC are worthwhile. 
Cervical carcinomas are associated with specific high-risk human papil lomavirus (hrHPV) 
types, mainly HPV-16 and HPV-187•9• Almost all cervical squamous cell carcinomas are HPV 
positive. However, HPV prevalence in cervical adenocarcinomas is var iable and generally 
lower than reported for squamous cell carcinoma10 The difference in prevalence may reflect 
technical factors related to DNA detection or misclassification, i.e. endometria l AC erroneously 
being classified as cervical AC. The addition of hrHPV testing in cervical screening programs 
will lead to a reduction in the incidence of cervical cancer and precursor lesions11•12• 
The aim of this study was to characterise by clinical evaluation, pathologic review including 
immunohistochemistry and HPV typing a group of AC with primary localisat ion in t he cervix and 
formerly classified as of cervical origin. Moreover, we assessed the H PV type-specific prevalence 
in undisputable cervica l AC compared the survival of respective patients by HPV status. 
MATERIALS AND METHODS 
Patient material 
All primary cervical AC diagnosed between 1989 and 2008 in the Rotterdam area were ret rieved 
f rom local cancer registries: IKR cancer registrat ion, Palga pathology regist ration and oncology 
registration Daniel den Hoed Cancer Cl inic. Case notes were retrieved from the Erasmus 
MC University Hospital Rotterdam, the Daniel den Hoed Cancer Clinic and the affiliated 
hospitals in t he region. Patients had been staged according to the FIGO system. Of 171 patients 
formalin -fixed paraffin embedded blocks were available for HPV typing. H&E stai ned slides 
supplemented with mucin-stained slides were used for review. Any cases in which there was 
clinical or pat hologic doubt with regard to the diagnosis, cervical AC were excluded from the 
study, as were patients for whom clinical follow-up was inadequate or unavailable. 
The project was approved by the Medica l Ethics Committee of the Erasmus MC University 
Hospital Rotterdam (nr.211.651/2002/48). 
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Revision of histology and additional use of immunohistochemistry 
An expert pathologist first reviewed the histology of all cases. Review of the adenocarcinomas 
included additional immunohistochemistry for carcinoembryonic antigen (CEA) and viment in 
to differentiate between cervica l and endometrial AC when the origin of the tumour was 
disputable. AC that stained diffusely or focally positive for CEA but completely negative for 
vimentin were classified as cervical AC. On the other hand, AC that stained negative for CEA but 
diffusely or foca lly positive for vimentin were typed as endometrial AC. Non-mucinous (clear-
cell), minimal deviation AC and adenosquamous carc inomas were excluded, from the study. 
HrHPV testing 
To ensure adequate DNA preparation, all samples were subjected to !?>-globin PCR. We used the 
primer combination PC03 and PC05 to generate a 209 bp product13. Detection of hrHPV was 
performed by a home-brew PCR-based assay; GP5+/6+-PCR. The clinica lly val idated GP5+/6+-
PCR with enzyme-immunoassay read-out uses a cocktail probe for 14 HPV types (16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), according to established protocols14• The PCR products of 
hrHPV-positive women were subsequently genotyped by reverse line blot hybridizat ion. 
Treatment methods 
Patients with early disease underwent radica l hysterectomy and pelvic lymph node dissection, 
unless their clinical condition did not permit th is. The criteria for postoperative radiotherapy 
were positive lymph node involvement, compromised surgical margins or extension oftumour 
into the parametrium. Pat ients with stage 11-B disease or higher were t reated with external 
irradiation and brachytherapy. In 1999 chemot herapy or hyperthermia was added to this 
regimen to improve surviva l. Patients were fol lowed-up every three-months during t he first 2 
years, then every 6 months unti l the fifth year . 
Statistical analysis 
Statistical comparison was carried out using a Mann-Whitney U Test or the Pearson Chi-Square 
test to determine significant differences between HPV-positive and HPV-negative AC. Patient 
disease-specific survival distribution was ca lcu lated using the Kaplan-Meier met hod. Patients 
who died from intercurrent disease or who were lost to follow-up, were censored at the time of 
last known fo llow-up. The significance of survival was tested by log-rank test. A value of P < 0.05 
was considered statistically significant. 
RESULTS 
Characterization of the study group, Review and Reclassification 
We retrieved 171 patients with primary cervica l AC diagnosed between 1989 and 2008 in the 
Rotterdam area. In all cases tissue was available for review and HPV typing. 
The results are shown in Figure 1. After clinical evaluation 58 cases were excluded from the 
study. The reasons for exclusion were: in 23 patients furt her analysis could not be performed 
because insufficient pre-t reatment tissue was available for the assays . In eleven carcinomas were 
reclassified as endomet rial carcinomas and in twenty-four cases carcinomas were classified as 
171 
Patients with Adenocarcinoma 
Figure 1. Flowchart of patients 
CC clear cell carci noma 
MDA minimal deviation adenocarcinoma 
AQ adenosquamous carcinoma 
23 
Insufficient amount of 
pre-treatment tissue 
11 
t----t Reciassified endometrial 
24 
CC/MDNAO 
non-mucinous (clear cell, n=5), minimal deviat ion adenocarcinoma (n=2) and adenosquamous 
types (n=17). 
Characteristics such as FIGO stage and tumour grade of the remain ing 113 patients are 
presented in Table 1. The mean age was 42.8 years (26-74 years) . Sixty-nine percent was 
between 35-65 years old and six percent younger t han 30 years (the age when the National 
screening program in the Netherlands starts). Eighty-eight percent of t he pat ients had FIGO 
stage I, 11% stage II and 1% stage Il l and IV. 19% were nullipara. A quarter of the patients had no 
sympto ms at the t ime of diagnosis. In 82% of patients cervica l cyto logy was avai lable, of which 
only 24% had revealed a glandular abnormality in the cytology slides. Eighty-n ine percent of 
women were primarily surgically treated and 11% had primary radiotherapy. The mean follow 
up was 63 months (1-168) . The overall disease-specific survival was 80%. 
hrHPV detection and survival by hrHPV status 
Ofthe 113 pat ients with undisputable cervical AC 101 (89%) were HPV positive and 12 (11%) were 
HPV negative. Figure 1. The 5-year d isease free survival tended to be better in HPV-positive 
patients than in HPV-negative patients; 80% in HPV-positive group versus 74% in HPV-negative 
group, but did not reach statistical significance. Figure 2. 
There was no significant difference in stage, grade, lymph node metastases, primary 
therapy or recurrence rate between the two groups. Table 2. 
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Table 1. Patient characteristics, n=113 
Stage 
III&IV 
Age (years) 
<35 
35-64 
>65 
Tumor grade 
Ill 
LNM 
no 
yes 
not done 
LVSI 
no 
yes 
unknown 
Primary treatment 
Surgery 
Radiotherapy 
Major presenting symptoms 
None 
Dysfunctional/postmenopausal 
Postcoital 
Vaginal discharge 
Other 
Recurrence 
No 
Yes 
No of patients 
99 
12 
2 
30 
78 
5 
47 
39 
26 
77 
12 
24 
80 
24 
9 
100 
13 
33 
38 
31 
7 
4 
87 
26 
percentage 
88 
11 
27 
69 
4 
42 
39 
26 
87 
13 
77 
23 
89 
11 
29 
34 
27 
6 
4 
77 
23 
The dist ribution of viral types amongst t he 101 HPV-positive patients was as fol lows: type 
18 in 55 pat ients (54%), type 16 in 37 (37%), type 45 in 7 (7%), types 53 and 39 were found in 
2 respective patients. Ta ble 3. 
1,0 
0,8 
iii 
> ~ 0 ,6 
:I 
II) 
"' >~ 
3 0,4 E 
:I 
u 
0,2 
0 ,0 
HPV-positive 
HPV-negative 
u ~ ~ ~ ~ n M ~ ~ m 
Time Survival (month) 
Figure 2. Survival in patients with adenocarcinoma in relation to HPV 
5-yr survival of patients with H PV type 18 was not significantly worse than survival of patients 
with HPV type 16, 81 versus 87%. Patients with HPV type 45 had the worse 5-yr survival, i .e. 57%. 
Figure 3. 
HPV-16 
HPV-18 
12 24 36 ~ ~ 72 M ~ 108 120 
Time Survival (month) 
Figure 3. Survival related to t ype specific HPV 
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Table 2. HPV-posit ive versus HPV-negative, n=ll3 
HPV pos, n=lOl HPV neg, n=12 
n % n % 
Age (mean, yrs) 42,8 42,2 ns' 
Stage 
89 88 10 84 ns' 
11 11 8 
III/IV 8 
Grade 
42 42 5 42 ns' 
35 35 4 33 
Ill 23 23 3 25 
LNM 
I 
no 68 67 9 75 ns' 
" 9 9 3 25 < yes ~ 
-< not done 24 24 0 0 
" m 
I 
):> LVSI ns' 
Vl 
z negative 74 73 6 50 
0 
~ positive 19 19 5 42 
" ):> (') unknown 8 8 8 
"" Prim therapy 0 
z 
Vl surgery 89 88 11 92 ns2 
c 
;o 
radiation 12 12 8 < 
< ):> Recurrence 
.-
0 
., no 77 76 10 83 ns2 
" ):> 
:::! yes 24 24 2 17 
m 
z Survival 
"" Vl 
:;:;: 5 yr disease free 80 74 ns3 
~ 
I 
):> 1. Mann-Whitney Test 
0 2. Chi-Square Test m 
z 3. Kaplan Meier 0 
(') LNM Lymph Node Metastases ):> 
;o LVSI Lymph Vascular Space Invasion (') 
z 
0 
s 
):> 
0 DISCUSSION ., 
"" I This study confirms the hypothes is that alm ost all early stage AC o f t he cervix are H PV m 
c 
positive and therefo re H PV-testing seems to be a m o re powerful tool in d e tection o f AC than 
"" m ~ 
routine cytologic screening, in wh ich only 24% of t he cases w ere detected. The reported z 
m 
(') prevalence of HPV DNA in AC varies sig nificantly, f rom 4815 - 95%16. Poss ib le reasons for 
m 
;o 
::=:; this ext reme var iatio n are d iffe ren ces between the H PV test used either or not combined 
X 
w it h lower viral load in glan dular lesions as compa red to squamous lesion s. Recent ly, it has 
90 
Table 3. Literature review (since 2008) of HPV types in adenocarcinoma of the uterine cervix 
Author 
Dabic et a/.23 
lnsinga eta/. 24 
Clifford and Franceschi'0 
Quintet a/.'6 
San jose eta/. 31 
Tornesello et al." 
Li et a/9 
Duet a/" 
Coutlee eta/. 33 
Tjalma et a/.27 
Present study 
Clinic 
Zagreb, Croatia 
Meta analysis 22 USA 
studies 
Meta analysis worldwide 
New York, USA. 
RIS & HPV TTS study 
Milan, Naples. Italy 
Meta analysis 243 studies 
Stockholm, Sweden 
Canada 
Heracles/scale study 
R'dam NL 
HPV 
positive percentage percentage Percentage 
N (AC) (%) HPV-18 HPV-16 HPV-45 
51 
413 
2521 
55 
760 
39 
3S38 
3S 
70 
321 
113 
84 
84 
80 
95 
62 
72 
82 
91 
89 
92 
89 
42 
38 
38 
42 
32 
18 
37 
48 
40 
40 
54 
74 
39 
35 
44 
so 
57 
36 
40 
4S 
54 
37 
7 
6 
11 
12 
7 
8 
7 
been suggested that new HPV detection methods are more sensitive than those used in our 
studyn Other reasons for variation could be variability in sample size, geographical variation 
in HPV distribution, and/or incl usion of tu mours of endometrial o rigin in some studies. It is 
well accepted t hat AC is H PV associated, with t he exception of the rare non-m ucinous types 
such as serous, mesonephrenic and c lear ce ll carcinomas and adeno ma malignum (minimal 
deviation AC)18• 19• In DES-related c lear cell carcinoma (CC), HPV has recently suggested to be 
a co-carcinogen20 
HPV type 
In SCC, t he freq uency of HPV 16 is much greater than of HPV 18 o r HPV 45 (HPV 16: 49-70%; 
HPV18: 6-13%; HPV 45: 2-5%)9• 21• 22• Published studies have shown t hat HPV type 16, 18 and 
45 are found in up to approximately 90% of all ACn HPV 16 accounts for 35-74%, H PV 18 for 
18-57% and HPV45 for 3-12%10· 21· 23' 25 .. HPV-18 is t he type most strongly associated with AC. The 
majority of AC in this study harboured HPV type 18 (n=55; 54%); 37 (37%) were type 16, 7 (7%) 
were type 4S, and type 53 and 39 were found in 1 patient. This compares well with t he literature. 
Table 3. 
Age 
The prevalence of HPV in AC is age-dependent 26 . We found a similar mean age in HPV-positive 
tu mours (42.2 years) and HPV-negative tumours (42.8 years), suggesting that t he pat ients in 
the latter g ro up tested fa lse negative. In our group mean age in HPV-type 18 and 16 was the 
sa me (42.1 and 43.2 years). However, a younger mean age o f patients with H PV type-45 positive 
carcinomas (40.7 years) was noted in this study. This has also been reported by Seoud et all22 
and Tjalma eta IF'. 
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Prognosis 
The prognosis of HPV-18 positive pat ients was worse than of HPV-16 associated AC. However, 
this was not statistically significant; 5-year disease free survival was 81% for HPV-18 positives 
compared to 87% for HPV-16 positives. A worse survival was noted in cases with HPV t ype 
45, 5-year survival 57%. Because this study comprised only 7 patients with this vi ral type, the 
reliability of this conclusion is limited. Prev ious studies have shown that compared t o HPV-16, 
HPV-18 has been associated with a poo rer prognosis28'30. However, respective studies have 
included AC, adenosquamous carcinoma and SCC and t he aut hors were not able to obtain 
significant results for HPV-18 in pure AC due t o smal l numbers of patients w ith this cancer t ype 
in these studies. Studies invest igating survival in solely AC23 have also not shown a worse survival 
in HPV-18 positive adenocarcinomas, which is in line with our observations. 
CONCLUSIONS 
Despite the limitations of analyzing ret rospective data, the current large study shows that 
the large majorit y of AC of the cervix are hrHPV associated . Except for HPV 45 presence, HPV 
genotyping does not seem to have prognostic impact o n patient survival. However, this should 
be co nfirmed in a larger study. 
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ABSTRACT 
Introduction 
Over 90% of all cervica l adenocarcinoma are caused by a transforming infection with a high-risk 
type human papillomavirus (hrHPV). Previous studies demonstrated that the association 
between hrHPV positivity and cervica l clear-cell adenocarcinoma (CCAC) varies between 0% 
and 100%. As approximately 60% of all CCAC are associated with intra-uterine diethylstilbestrol 
(DES) exposure, we determined in a cohort of both DES-exposed and DES-unexposed women 
the prevalence of hrHPV infections, and t he potential et iological ro le of hrHPV by additional 
analysis of pl 61NK4a and pS3 expression. 
Methods 
Representative slides of 28 women diagnosed with CCAC were tested for hrH PV by two PCR 
methods (t he clinica lly validated GPS+/6+ PCR and the very sensitive SPFlOPCR/LiPA25). Fifteen 
women were DES-exposed, 10 unexposed and of 3 women DES-exposure was unknown. 
Twenty-one cases with sufficient material were immune-histochemica lly stained for pl61NK4a 
and p53. 
Results 
Seven tumors, of which fou r DES-exposed and two unexposed tested positive for hrHPV 
withGPS+/6+ PCR. Thirteen tumors, of which five DES-exposed and seven unexposed, tested 
positive with SPF10PCR/LiPA25. In one women with unknown exposure, a CCAC tested positive 
in both assays. Only three cases, none in DES-exposed women, and all posit ive with both hrH PV 
assays, revea led diffuse pl61NK4a immune-staining and weak p53 sta ining as wel l, support ing 
indisputable hrHPV involvement. 
Conclusions 
Although t he prevalence of hrHPV was high, only two DES-unrelated CCAC (25%) and one 
tumor in a woman with unknown exposure could be attributed to hrH PV. 
INTRODUCTION 
Clear cel l adenocarcinomas of t he cervix (CCAC) are relatively rare t umors of the lower genital 
tract and are characterized by abundant clear cytoplasm and hobnail cells1•2• CCAC have a 
bimodal age d istribution, with one peak in the early twenties and another after menopause3 .. . In 
1971, intrauterine exposure to the non-steroid estrogen diethylst ilbestrol (DES), used between 
1938 and 1978 to prevent miscarriage and other pregnancy-related problems' , was found to be 
associated with CCAC6 • DES-exposed women have a 40-fold increased risk of developing 
CCAC, resu lting in a cumulative incidence of 0.1 - 0.2%7.6 . As this tumor is still very rare 
in DES-exposed women, DES is suggested to be an incomplete carcinogen'. Most CCAC are 
found at a re latively low stage and therefore have a good prognosis with a five-year survival 
rate of 90%3 .. ·9 Although 60% of CCAC are detected in DES-exposed women, 40% develop in 
unexposed women, indicat ing t he involvement of alternat ive etiological factors2·4·7•10 
A factor of interest might be a t ransforming infection with a high-risk human 
papillomavirus (hrH PV) type, the key causat ive factor in almost al l cervica l squamous cell - and 
adenocarcinomas 11 ·13 . Transformation is provoked by inactivation oftumor-suppressor proteins 
by viral oncoproteins E6 and E714•15• The E6-oncoprotein degrades pS3 and thereby can block 
p53-mediated apoptosis. The E7-oncoprotein interferes with cell cyc le control by blocking 
retinoblastoma (Rb) (Fig . 1), ultimately leading to immortalization and invasive growth14•15 
As a consequence, hrHPV-induced cancers are generally characterized by absence of p53 
whereas cancers without hrHPV often display an increase in p53 protein reflecting stabilization 
caused by mutations in this gene13•16• In addition, hrHPVinduced cancers are characterized 
by over-expression of p16'NK<an·15•17 most likely reflect ing an oncogenes senescence- like 
response triggered by E716, but functionally ineffective because Rb is blocked downstream in 
the pathway (Fig. 1). HrHPV-positive tumors without these characteristics reflect t ransient, 
somet imes productive, infections which are commonly found in t he general population. Only 
few studies have explored the association between hrHPV and CCAC (Table 1). In these small 
studies hrHPV positivity varied between 0% and 100%, t hereby hampering any conc lusion to 
be made about its potential causal role1·16·19.26 • Only two studies provided information about 
immuno-histochemical staining . In one study the inverse relation between hrHPV presence 
and p53 presence was displayed in 11 CCAC6, t he other showed that extensive p16'NK<a st aining 
was absent in 3 CCAC24 The aim of this study was to determine in both DES-exposed and DES-
unexposed women whether hrHPV infections present in CCAC could be etiologically involved, 
or rather represent non-transforming infections. Therefore, we studied t issue specimens for 
the presence of hrH PV DNA and for the expression of p161NK<a and p53. 
MATERIALS AND METHODS 
Tumor specimens 
Twenty-eight paraffin-embedded CCAC samples reg istered in the Central Netherlands Registry 
(CNR) for CCAC were collected from four university medical centers and reviewed by an expert 
in gynecologic pathology (JB). Of these samples, diagnosed between 1975 and 2005, fifteen 
were FICO stage 1, 12 stage 2, and one stage 3. Follow-up varied between 14 and 405 months 
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Figure 1. Simpli fied scheme of hrHPV-mediated carcinogenesis effecting Rb and p53 activity 
Abbreviations: hrHPV, high-risk human papillomavirus; Rb, retinoblastoma 
HrHPV-E7 degrades Rb, wh ich results in inhibiting the cell cycle arrest, and triggers over-expression 
of p16'N'".14•15• 18 HrHPV E6 degrades p531eading to a block of p53-mediated apoptosis and cell cycle arrest. 14•15 
and depended on date of diagnosis and date of death, or last known visit to the outpatient 
clinic. The total number of women years in our study was 350. During follow-up, five women 
developed recurrent disease, four of them died of progression within 32 mont hs. None of 
these women had a history of DES-exposure. Another two women died of unrelated disease, 
respectively 81 and 220 months after diagnosis. Considering the similarities between the total 
CNR-cohort and our sample, we believe t he latter was representative (Table 11)29. Series of 4-J-lm 
sections were cut using a new blade for each t issue sample to prevent contamination. Outer 
sections were used for histological confi rmation and immuno-histochemical assays, whi le inner 
sections were collected for DNA extraction and hrHPV analyses. Ethical approval was waived, 
since study material was anonymized according to Dutch reg ulation30 
DES exposure 
Previously, DES exposure was not specified uniformly and varied between a statement 
concerning exposure by mother, daughter, or physic ian, and confirmation of exposure by 
hospita l bi rt h records3·8 -10·29 We collected information regarding intra-uterine DES exposure 
f rom CNR patient files29 Three categories were distinguished: (1) exposed (confirmation: (a) in 
medical record; or (b) by mother/daughter and clinical signs), (2) unknown (no data available), 
and (3) unexposed ((a) stated in medical record; or (b) DES denial by mother/daughter). 
HrHPV testing 
To ensure adequate DNA preparation, all samples were subjected to ~-g lobin PCR. We used 
the primer combination PC03 and PCOS to generate a 209 bp product3'. Detection of hrHPV 
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was performed by two PCR-based assays; GPS+/6+-PCR and t he ultrasensitive SPF10 -PCR/LiPA2/
2
. 
The clinica lly val idated GPS+/6+-PCR with enzymeimmuno assay read out uses a cocktail probe 
for 14 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), according to established 
protocols33•34 The PCR products of hrHPV-positive women were subseq uently genotyped by 
reverse line blot hybrid ization. The SPF'0 PCR/LiPA
25 
(version 1) was performed according to 
specifications of the manufacturer (Labo Bio-Medical Products, Rijswijk, Netherlands) to detect 
and genotype 25 HPV genotypes35• For both HPV detection assays, samples that were positive 
in the enzyme-immunoassay format, but negat ive for any specific probe in the genotypi ng 
format were considered positive for uncharacterized HPV (sub) types or variants (HPVX). 
Immuno-histochemistry (IHC) 
Immuno-histochemical staining was performed according to manufacturer's instructions: 
p16'NK•• (E6H4, MTM-Laboratories, Heidelberg, Germany) and p53 (BP53-12, BioGenex-
Laboratories, San Ramon, USA) . 
Sections were deparaffinised and incubated with t he primary mouse monoclonal antibodies 
against p16'NK••or p53 after which they were incubated with a secondary biot inylated rabbitant i-
mouse bridging antibody followed by incubation with streptavidin-biot inylated peroxidase 
coupled with horse radish peroxidase conjugate. The peroxidase activity was detected with 
DAB (diaminobenzidine; Fluka, Sigma Aldrich, Buchs SG, Switzerland). They were then were 
counterstained, washed, dehydrated and coverslipped. For positive controls sections from a 
breast carcinoma were used for p53 and sect ions from a CIN3+ lesion for p16'NK•a The negative 
controls were provided by performing the standard procedure rep lacing the primary antibody 
with BSA (1% bovine serum albumen). 
The immuno-reactivity of p16'NK•• and p53 was scored according to the percentage of tumor 
cells t hat stained positive as follows: no (~10% cel ls), weak (>10% but ~2S% cells), moderate 
(>25% but ~so% cells) and extensive (>50% cells) staining. Intensity of sta ining was not taken 
into account. Al l light-microscopic evaluations were scored blinded by two pathologists (CM/ 
FS). In cases of discrepancy, slides were reviewed unt il consensus was reached. 
Statistics 
The main outcome of this retrospective cohort study was the number of hrHPV-positive 
CCAC and t he number oftumors stai ning positive for p161 NK4a, and/or p53. The relationships 
between various parameters and the outcomes in women with and without intrauterine DES-
exposure were evaluated with 2x2 tables, Fisher-Exact, 
Cox-regression and Mann-Whitney analysis. All calculations were performed using SPSS 
Version 17.0 (SPSS Inc, Chicago Illinois, USA) . For al l tests, the level of significance was set at 
0.05. 
RESULTS 
DES-exposure 
Fifteen women were DES-exposed in utero, 10 were unexposed and of three women DES-
exposition was unknown (Table Ill). Exposed women developed CCAC at a younger median age 
Table Ill. Cha racterist ics of study population: age at diagnosis and status of human papillomav irus, p16'NK4A 
and p53. 
hrHPV Immuno-histochemistry 
.. 
Age GPS+/ 6+ SPF,0 Putative 
Nr (years) Year DES (type) (type) p161NI(4a pS3 aetiology 
20 1975 + + (16) + (16) n.m. n.m. DES 
2 21 1981 + n.m. n.m . DES 
21 1982 + + (18) n.m. n.m . DES 
4 19 1983 + + (16) + (16) n.m. n.m . DES 
19 1983 + 25 10 DES 
6 17 1984 + + (16) + (16) n.m. n.m. DES 
7 20 1989 + + (16) + (16) <5 <l DES 
8 21 1989 + 25 0 DES 
9 19 1990 + 50 0 DES 
10 27 1990 + 10 <5 DES 
11 24 1991 + 0 <5 DES 
I 
12 37 1993 + so 0 DES () 
=f= 
13 27 1993 + 45 60 DES ~ 
V1 
'"' 14 38 1995 + 60 35 DES I 
c 
15 29 2001 + 20 40 DES s: )> 
16 33 1985 u + (4S) + (45) hrHPV z 100 10 
" )> 
17 44 1997 u 90 5 unknown ~ r 
r 
18 41 1997 u 90 5 unknown 0 s: 
19 29 1982 +(51) 30 0 unknown ~ 
"' 
+(X) unknown c 20 41 1997 10 10 V1 
V1 
+ (16) unknown 
m 
21 36 2000 n.m. n.m . m s: 
+ (31) unknown V1 22 54 2002 so 60 z 
0 
23 28 2003 + (16) 30 60 unknown ~ z 
24 34 2004 + (16) + (16) 100 5 hrHPV < 0 
25 30 2005 + (18) + (18) 100 5 hrHPV < m 
0 
26 33 2000 50 so unknown z 
0 
27 44 2000 n.m. n.m . unknown m V1 
28 48 2001 5 60 unknown "' m r 
~ 
Abbreviations: DES, diethylstilbestrol exposure; hrHPV, high-risk type of the human papillomavirus; m 0 
SPF,O' SPF10PCR/LiPA25_, n.m, no material available; U, DES-exposition unknown; 
X, HPV infection, unable to type. 
at diagnosis 
.. indicated are t he percentages of immuno ·posit ive tumour cells 
103 
I 
Ci 
:;: 
~ 
Vl 
"' I 
c 
s: 
):> 
z 
., 
):> 
:::? 
r 
r 
0 
s: 
~ 
"" c 
Vl 
Vl 
m 
m 
s: 
Vl 
z 
0 
__, 
z 
< 
0 
< m 
0 
z 
0 
m 
'{' 
"" m r 
~ 
m 
9 
104 
than unexposed women (21 versus 35 years, p<O.OOl). Although no difference in tumor stage 
(p=0.23), growth pattern (p=0.09), nuclear atypia (p=0.83), o r lymph-vascular invasion (p=0.67) 
cou ld be demonstrated, DES-unexposed women had a worse overall survival (p=0.04, Hazard 
Ratio 0.10, 95%CI 0.01-0.86). 
H rH PV presence 
DNA quality was sufficient for all samples. With GP5+/6+ PCR testing seven specimens tested 
hrHPV-positive. Six more tested positive by SPF,iCR/LiPA2, , resulting in 13 (46.4%) positive 
tumors for either or both assays. Among hrHPV-positives, HPV16 was the most prevalent 
type (7/13, 53.8%), fol lowed by HPV18 (2/13, 15.4%). The remaining four tumors all contained a 
different hrHPV type: 
HPV31, HPV45, HPV51 and HPVX (Table Il l). Multiple infections were not found . 
Immuno-histochemistry (IHC) 
Of 21 tumors sufficient material remained for additional IHC. These included specimens of 
10/15 DES-exposed women, of 8/10 unexposed women, and of 3/3 women with unknown DES-
exposure (Fig. 2). 
A B 
c 
Figure 2. Expression of pl6'""'' and p53 in cervical clear-cell adenocarcinoma 
A) shows the typical features of a clear cell adenocarcinoma, composed of polygonal cells with distinct cell 
membranes and clear cytoplasm (H-E staining) 
B) clear-cell adenocarcinoma after staining with pl6'"' " . note both nuclear and cytoplasmatic staining 
C) p53 staining showing d ist inct nuclear staining in approximately 60% of the nuclei 
Two CCAC of DES-unexposed women (Table Ill, nr 24, 25) and one CCAC of a woman 
with unknown exposure (Table Ill, nr 16) displayed characteristics supporting a causal hrHPV 
involvement, i.e. extensive diffuse pl6'N"4' immuno-staining in al l tumor cells, and only weak, 
foca l p53 staining. All these cases were posit ive by GPS+/6+ PCR and SPF10PCR/LiP~5• These 
three tumors all had a high nuclear mitotic activity and a mainly solid growth pattern (data not 
shown). All other hrHPV-positive cases (Table Ill, nr 7, 19, 20, 22, 23) displayed a wide variation 
in p53 expression (0%-60% of tumor cells) and at maximum moderate p16'N••• staining (<SO% 
of tumor cells). None of the tumors found in DES-exposed women that were analyzed with all 
parameters, showed both hrHPV presence and extensive, diffuse p16'N••• immuno-staining in 
combination with no, or weak, focal pS3 stain ing. 
In three other tumors, one of a DES-exposed woman (Table Il l, nr 14) and 2 of women with 
unknown exposure (Table Ill, nr 17,18) extensive p16'N"4 ' staining in more than 50% of all tumor 
cells was found. However, none of these CCAC tested positive for hrHPV. None of the hrHPV 
assays or immuno-histochemical profiles was significantly associated with tumor stage, age at 
diagnosis, or survival rate. Table Il l lists the putative etiology for each tumor. 
DISCUSSION 
In a relatively large group of CCACwe showed t hat hrH PV has a limited role in the carcinogenesis 
ofCCAC. Taking into account that in hrHPV-positivewomen d iffuse p16'N••• staining and absence 
or weak p53 immuno-staining can be seen as a cellular correlate to E6/E7 mRNA expression 
of hrHPV and thus as functional involvement of hrHPV13·14•16, only three of 28 tumors could 
be attr ibuted to a t ransforming hrHPV infection. None of these were found in DES-exposed 
women . Interestingly, all these three tumors tested positive in both hrHPV assays (Table Il l). 
The fact that 3 out of 4 fully analyzable GPS+/6+ PCR positive tumors versus 3 out of 8 fully 
analyzable SPF,lCR/LiPA25 positives fulfilled the criterion of a clinically 
meaningful infection is in line with t he higher specificity of a clinically va lidated PCR (i .e. 
GPS+/6+ PCR) for relevant disease caused by hrHPV32•36• Hence, hrHPV positivity detected solely 
by SPF,lCR/LiPA25 most likely reflects non-transforming, t ransient hrHPV infections, which are 
also characterized by the presence of more diverse hrHPV types. 
Overall, 60% (15/25) of all analyzed CCAC developed in DES-exposed women4-'·16• The 
estrogenic effects of DES interfere with fetal development resulting in adenosis. This t issue is 
thought to be more susceptible to malignant transformation4 In DES-exposed women CCAC 
were diagnosed at a younger age than in unexposed women3 ... Furthermore, these women had 
a better five-year survival4•10• 
In our study hrHPV was detected in 46.4% (13/28) of all CCAC, similar to the overall 
percentage of 43% (15/35) found in literature (Table 1). When limited to DES-unexposed women 
the prevalence increased to 70% (7/10). Although similar to other reported frequencies in 
CCAC26·28, this is lower than the prevalence found in common cervical adenocarcinoma1.12. It 
is unlikely that this reflects deletion of sequences targeted by our PCR assays because of viral 
integration in the host DNA, since in most tumors no sign of viral activity reflected by diffuse 
p16'N"4 ' immunostaining was found. P16'N"4' immuno-staining is now widely considered a cellular 
correlate ofthe oncogenic expression of E6/E7 mRNA14·17•24•37 Extensive p16'N"4' immuno-staining 
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was only found in three hrHPV-negative tumors. This may also reflect undetectable hrHPV 
with L1-based PCR assays applied37, however, it is more likely to reflect an hrHPV independent 
mechanism triggering p161NK4• 24 
As can be seen from Table I, most previously described CCAC were positive for HPV1819·" ·'3•28, 
followed by HPV31 16 In contrast, HPV16 was most commonly found (7/13) in our cohort. HPV18 
was only found in two CCAC, which was surprising as in most cervica l adenocarcinoma HPV18 is 
more13 or equally1•11 often found as HPV16. However, 14/ 28 women in our cohort were younger 
than 30 years at t ime of d iagnosis. Because HPV DNA testing is not very specific under the 
age of 3038, the frequency of hrHPV-types might have been distorted due to the detection 
of transient hrHPV infections. Indeed, when we considered only the t hree CCAC with a likely 
hrHPV etiology, HPV16 and HPV18 both occurred in one tumor. 
A limitation of our study is that only 21/28 samples enclosed enough material to perform 
immuno-histochemical assays, hampering to draw conclusions about 7 tumors remaining. Five 
of these t umors were positive for hrHPV of which three in both assays (Table Il l, nr 1, 4, 6). As 
IHC could not be performed in these t hree DES-exposed CCAC, a causal role of hrHPV in DES-
exposed tumors might have been missed. 
A second limitation is the young median age in our cohort . Although consistent with 
previously publ ished data3•8•29 we can only comment on hrH PV-related carcinogenesis 
concerning t he first peak in the bimodal age distribut ion3•4 • 
CONCLUSIONS 
In summary, we limited our conclusions to the 21 of 28 fully analyzed CCAC. In none of the 10 
DES-related tumors a causal role of hrHPV could be identified. Overall, t hree tumors were likely 
caused by a transforming hrHPV infection. Two were found in DES-unexposed women (2/8) 
and one in a women of whom the DES-exposition was unknown (1/3). In the remai ning 8 tumors 
(6 in DES-unexposed women and 2 in women with an unknown exposure) t he etiology remains 
unclear, leaving room for other, unexplored factors in its carcinogenesis. 
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ABSTRACT 
Background 
For early squamous cell carcinoma of the uterine cervix, t he outcome is similar after either 
primary surgery or primary radiotherapy. There are reports that this is not t he case for early 
adenocarci noma (AC) of t he uteri ne cervix: some studies have reported that the outcome 
is better after primary surgery. There are no syst ematic reviews about surgery versus 
chemoradiat ion in the treatment of cervica l cancer. This is an updated version of t he original 
Cochrane review published in Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: 
CD006248. DOI:10.1002/14651858.CD006248. 
Objectives 
The objectives of this review were to compare the effectiveness and safety of primary surgery 
for early stage AC of the uterine cervix with primary radiotherapy or chemoradiation. 
Search methods 
We searched Cochrane Central Register of Controlled Trials (CENTRAL) Issue 3, 2009, MEDLINE 
(1950 to July week 5, 2009), EM BASE (1980 to week 32, 2009) and we also searched the related 
art ic les feature of PubMed and the Web of Science. We also checked t he reference lists 
of art icles. For this update, the searches were re-run in June 2012: MEDLIN E 2009 to June 
week 2, 2012, EM BASE 2009 to 2012 week 24, CENTRAL Issue 6, 2012, Cochrane Gynaecological 
Special ised Register June 2012. 
Selection criteria 
Studies of treatment of patients with early AC of the uterine cervix were included. Treatment 
included surgery, surgery followed by radiotherapy, radiotherapy and chemoradiation. 
Data collection and analysis 
Forty-three studies were selected by the search strategy and 30 studies were excluded. Twelve 
studies were considered for inclusion. Except for one randomised controlled t rial (RCT), all 
other studies were ret rospective cohort studies with variable methodological quality and had 
limitations of a ret rospect ive study. Comparing the resu lts f rom these retrospective studies was 
not possible due to diverging t reatment strategies. 
Main results 
Analysis of a subgroup of one RCT showed t hat surgery for early cervical AC was better than 
radiotherapy. However, the majority of operated patients required adjuvant radiot herapy, 
which is associated with greater morbidity. Furthermore, the radiotherapy in this study was not 
optimal, and surgery was not compared to chemoradiation, wh ich is currently recommended 
in most centres. Finally, modern imaging techniques (i.e.magnetic resonance imaging (MRI) 
and positive emission tomography - computed tomography (PETCT) scanning) allow better 
select ion of patients and node-negative patients can now be more easily identified for surgery, 
thereby reducing the risk of 'double t rouble' caused by surgery and adjuvant radiotherapy. 
Authors' conclusions 
We recommend surgery for early-stage AC of the uterine cervix in carefully staged pat ients. 
Primary chemoradiat ion remains a second best alternative for patients unfit for surgery; 
chemoradiation is probably first choice in patients with (MRI or PET-CT-suspected) positive 
lymph nodes. Since t he last version of this review no new studies were found. 
PLAIN LANGUAGE SUMMARY 
Surgery or radiotherapy for early cervical cancer of the adenocarcinoma 
type 
Early-stage cervical cancer of t he common type, squamous cell carcinoma, has the same 
prognosis after primary surgery or radiotherapy. For cervical cancer of the glandular ce ll 
type (adenocarcinoma) we recommend surgery. Second best alternative for patients unfit for 
surgery is chemoradiation. For patients with suspected positive lymph nodes, chemoradiation 
is probably the first choice. 
THE COCHRANE 
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BACKGROUND 
Description of the condition 
This review is an update of a previously published review in the Cochrane Database of Systematic 
Reviews 2006, Issue 4. Art.No.:CD006248. DOI:10.1002 /14651858.CD006248. 
Cervical cancer is the second most common cancer among women worldwide (Ferlay 
2004). The prognosis of pat ients with cervical cancer depends on FIGO (International 
Federation of Gynecologists and Obstetr icians) (Benedet 2001) stage at time of diagnosis, 
presence of lymph node metastases, tumour size and histo logical type (Baalbergen 2004; 
Chen 1998; Kasamatsu 2009). The t hree major histological types of invasive cervical cancer 
are sq uamous cell carcinomas (SCC), adenocarcinomas (AC) and adenosq uamous carcinoma 
(ASC). sec comprises 80% of cases, and AC and ASC comprise approximately 15% (ACOG 2002). 
Over the past 40 years the relative proport ion and absolute incidence of AC compared to sec 
has increased, especially in women younger than 35 years (Aifsen 2000; Chan 2003; Krane 
2001; Li u 2001;Schoolland 2002; Vizca ino 1998). Screening for SCC has effectively reduced 
both incidence and mortality of invasive squamous cancer by early detection and treatment 
of pre-invasive lesions (Smit h 2000). Althoug h screening reduces mortality f rom cervical AC, 
the incidence remains unaltered (Nieminen 1995). It remains controversia l whether or not 
patients with AC have a worse prognosis. The literature is inconsistent; some studies report 
a similar prognosis for ACof the uterine cervix and SCC (Grisaru 2001; Ishikawa 1999; Kilgore 
1988) whereas others report a poorer prognosis for AC (Bulk 2003; Eifei 1995;Hopkins 1991). 
Questions remain about what factors account for this apparent poorer prognosis. Cervica l AC 
may metastasize earlier (Lea 2002) or may be detected later (Drescher 1989; Hurt 1977). It may 
respond less well to radiotherapy (Hong 2000;Hurt1977), have a higher incidence of relapse 
and the treatment of recurrent disease less successful (Kasamatsu 2002; Lai 1999) or possibly 
the inclusion of special subtypes such as clear cell carcinoma could account for t his difference 
in prognosis (Look 1996). 
Description of the intervention 
Treatment protocols used for sec and AC are similar and therapy is based on clinical staging 
accord ing to FIGO (Benedet 2001). Due to recent developments in imaging such as magnetic 
resonance imaging (MRI) and developments of surg ical techniques such as endoscopy, 
the current FI GO classification for cervical cancer has been revised (Pecorelli 2009). Micro-
invasive disease managed by cone biopsy or hysterectomy. Radical hysterectomy (removal 
of the uterus with adjacent t issue and draining pelvic lymph nodes) has become standard 
management for the majority of early cervical cancers, but external beam-irradiation along 
with a vaginal application of brachytherapy to the cervix has been increasingly employed for 
bulky stage I and II disease (tumour diameter of more t han four centimetres). Both external 
beam irrad iation and brachyt herapy have undergone rapid developments, of which the 
therapeutic consequences are not yet clear. Intensity-modulated radiotherapy ( IMRT) allows 
more conformal external beam dose delivery to the clinical target (uterine cervix and regional 
pelvic lymph nodes) t hereby sparing critica l organs (bladder and intest ines). IMRT requires 
an accurate definition and delineation of clinical target (Small2008; Taylor 2005; Taylor 2007; 
Vizcaino 1998). Paradoxically, in clinical practice, compared to 'old fashioned' four-field box-
technique defined by osseous anatomical structures (Fletcher 1973), image-guided target 
definition has increased rather than decreased the irradiated volumes for radiotherapy of 
pelvic tumours. The historical low dose rate (LDR) brachytherapy techniques using radium 
and caes ium have largely been replaced by iridium as the radioactive source. Iridium allows 
high dose rate (HDR) and pulsed dose rate (PDR), which both have decreased irradiation time 
and patient burden. These techniques, particularly if combined with intraoperative MRI, have 
reduced the risk of misplacement of the brachytherapy applicato r, and allow image-guided 
brachytherapy, t hereby increasing local control whilst reducing toxicity (Georg 2009). After 
primary surgery, it may be useful to add radiotherapy (in up to 50% of operated patients 
depending on the select ion criteria of the series). In primary radiothera py in selected cases, 
adjuvant surgery (salvage hysterectomy) may be performed if the tumour recurs local ly 
(Weiner 1975). The use of both surgery and radiotherapy leads to more severe morbidity (Barter 
1989; Landoni 1997) than either used alone. Complications of radical hysterectomy are chronic 
bladder dysfunction (3% to 13%), ureterovaginal or vesicovaginal fistula (1%to 2%), pulmonary 
embolism (1% to 2%), small bowel obstruction (1%), lymphocoele formation (5% to 8%) and 
hydroureter nephrosis (3%). Complications of radiotherapy arise later but are ohen permanent: 
proctitis (7.6%), radiation col iti s, early menopause, sexual dysfunction, shortening and fibrosis 
of t he vagina, oedema of the legs (0.6%), hydroureter nephrosis (5%) and vesicovaginal fistu la 
(1.4%). The combination of radical surgery followed by radiot herapy carries t he worst morbidity: 
hydroureter nephrosis (10%), severe oedema of the legs (9%), lymphocoele formation (15%), 
ureterovaginal or vesicovagina l fistula (7.4%) and vesical complications and bowel morbidity 
(Boronow 1971; Kucera 1998 Landoni 1997; Waggoner 2003). 
Why it is important to do this review 
In 1999, a her the publication offour randomised contro lled trials (RCTs) on this issue (Keys 1999; 
Morris 1999; Rose 1999; Whitney 1999) t he US National Cancer Institute (NCI) issued an alert 
indicating that combined chemoradiation should be considered fo r all patients with cervical 
cancer who previously would be treated with radiot herapy. In 2001, a Cochrane review showed 
concomitant chemotherapy and radiotherapy improved overall survival (OS) and progression-
f ree survival (PFS) in locally advanced cancer (Green 2001; Green 2005). For early SCC, the 
outcome is simi lar aher eit her primary surgery or primary radiotherapy (Hopkins 1991; Landoni 
1997). There are reports that this is not the case for early AC of t he uterine cervix and some 
studies have reported that the outcome is better aher primary surgery (Chen 1999; Kucera 
1998). Currently there are no systematic reviews comparing surgery versus chemoradiation in 
the treatment of cervica l cancer. 
OBJECTIVES 
To compare the effectiveness and safety of primary surgery for early-stage AC of the uterine 
cervix with primary radiotherapy or chemoradiation. 
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METHODS 
Criteria for considering studies for this review 
Types of studies 
It was anticipated that only a very small number of RCTs, the preferred type of study, would 
have been conducted on cervical cancer treatment. Therefore, observational studies, non-
randomised studies with concurrent controls and studies with historical controls were also 
considered for incorporation in this review. The methodologica l quality of non-RCTs was 
assessed on the basis of comparabi lity of t reatment groups at baseline, adjustment for potential 
confounders and allocation of the treatment. 
Types of participants 
Patients with histological confi rmed early-stage AC ofthe uterine cervix were included. For the 
purpose of this review early-stage AC was defined as cancer in which the primary tumour was 
confined to the cervix and upper two-thi rds ofthe vagina or the parametrium (FICO stage lA to 
liB). For FICO staging see Appendix 1. 
Types of interventions 
The following surgical interventions were studied: 
extrafascial hysterectomy or Rutledge class I hysterectomy, which is defined as removal 
of all cervical tissue by incision of the pubocervical ligament allowing reflection and 
retraction of the ureters laterally without actual dissection from the ureteral bed; 
Rutledge class II extended hysterectomy, which is defined as the removal of the medial 
half of the cardina l and uterosacral ligaments and upper t hird of the vag ina. It is usually 
combined with a pelvic lymphadenect omy; 
radical hysterectomy or Rut ledge class Ill extended hysterectomy, which can be defined 
as the remova l of t he entire card inal and uterosacral ligaments and removal of the upper 
third of the vagina and a pelvic lymphadenectomy (Piver 1974). 
The following radiotherapy interventions were studied: 
whole pelvis radiotherapy, defined as external beam radiation in which the clinical target 
volume (CTV) encompasses the cervix, the uterus, t he upper two-thi rds of the 
vagina, the parametria and the draining lymph nodes at risk, up to the level of lumbar spine 
5 and sacral spine 1; 
vaginal application of a radioact ive source to the cervix (brachytherapy). There are 
different brachytherapy techniques that apply t he radioact ive source for short per iods of 
time or for several days; 
chemoradiation, which is defined as concomitant radiotherapy and cytotoxic 
chemotherapy. 
Any comparison of a surgical intervention with a radiotherapy intervention was considered. 
Types of outcome measures 
Primary outcomes 
The primary outcomes were OS and disease-free survival (DFS). 
Secondary outcomes 
Secondary outcomes of interest were adverse effects of treatment as intestinal, urogenital and 
premature menopausal complications and quality of life (QoL). 
Search methods for identification of studies 
Electronic searches 
The literature search was carried out according to the criteria set by the Cochrane Gynaecological 
Cancer Review Group. There were no language restrictions. Searches of Cochrane Central 
Register of Control led Tria ls (CENTRAL Issue 3, 2009), MEDLINE (1950 to July week S 2009) and 
EMBASE (1980 to week 32 2009). Searches of the Group's Special ised Register and Non-Trials 
Database was devised using the groups coding system, was carried out on 6 July 2009. 
Subsequent searches were run in June 2012 (MEDLINE 2009 to June week 2, 2012, EMBASE 
2009 to 2012 week 24, CENTRAL Issue 6, 2012, Special ised Register June 2012). 
For the search strategy we used a combinat ion of free text and indexed terms and included 
an extended RCT filter to include cohort and case cont rol st udies (which also picked up 
follow-up, retrospective and prospective studies). See Appendix 2; Appendix 3; Appendix 4; 
Appendix 5. 
The Web of Science and the reg ister of ongoing controlled trials were checked (www. 
controlled-tria ls.com). The reference lists of t he selected publications were searched. All 
relevant articles found, were identified on PubMed, and using the 'related artic les' feature, a 
further search was carried out for newly published articles. 
Searching other resources 
A handsearch of publications on the treatment of cervical cancer in the fo llowing journals 
was carried out: CME Journal of Gynecologic Oncology (from 1995), International Journal of 
Gynecologic Cancer (from 1993). Abstracts from conferences on gynaecological cancer (IGCS, 
SGO) and the British Library's Inside Conferences were checked . 
Data collection and analysis 
Selection of studies 
All t itles and abstracts retrieved by electronic searching were downloaded to a reference 
management database (Reference Manager 11), dupl icates were removed and the remain ing 
references were examined by two review authors (AB, YV) independently. Those studies 
that clearly did not meet t he inclusion criteria were excluded and copies of t he full text of 
potentially relevant references were obtained. The elig ibility of ret rieved papers was assessed 
independently by two review authors (AB, YV). Reasons for exclusion were documented. The 
number of references excluded is reported in a QUO ROM flow chart (Figure 1 and Figure 2). 
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1. QUOROM statement flow diagram 
I 
Potentially relevant studies identified and I 
screened for retrieval (n=43) 
Studies excluded, with reasons (n= 30) 
• Type of intervention did not match (about 
adjuvant therapy) 
• Purpose of study did not match 
• Only sec 
• No FIGO stage described 
• Advanced stage 
• Type of intervention did not match 
• results not described by intervention 
(survival not separately described for 
different therapy} 
Attanoos 1995;Chargui 2006, Charkviani 1990; Covens 
1999; Eifel 1990; Erzen 2002; Farley 2003; Grigsby 1988; 
Hansen 1981 ; Hopkins 1991 ; Ireland 1985; Kjorstad 1977; 
Leminen 1990; Marte12000; Miller 1993; Milsom 1983; Morley 
1976; New1on 1975; Papanikolaou 2006; Perez 1995; Piver 
1988; Rabin 1984; Roddick 1971 ; Rutledge 1975; Shingleton 
1981 ; Sundfor 1996; Townsend 1980; Waldenstrom 1999; 
Wei 2005; Yamashira 2005 
I 
Potentially appropriate studies to I 
be included in the meta-analysis 
Studies excluded from meta-analysis, with reasons 
(n= 12) 
• Potential bias in selecting mode of therapy 
and lack of proper patient radndomisation in 
pooled area 
Angel 1992; Baalbergen 2004; Berek 1981; Chen 1998; Eifel 
1991 ; Hopkins 1988; Hurt 1977; Kilgore 1988; Kleine 1989; 
Nola 2005; Saigo 1986; Weiss 1986 
I 
Studies with usuable information I 
by outcome (n= 1) (Landoni 1997) 
Figure 1. Quorum statement flow diagram 
2. QUOROM statement flow diagram review-update 
I 
Potentially relevant studies identified I 
and screened for retrieval (n=3) 
Studies excluded, with reasons (n= 3) 
• Onl y abstract avai lable (n=l ) 
• results not described by intervention (survival not 
separately described for different therapy) (n=2) 
Maneo 201 I, Bansal 2009, Galic 2012 
I 
Potentially appropriate studies to be I 
included in the meta-analysis (n=O) 
Figure 2. QUORUM st atement flow diagram for review· update 
Data extraction and management 
For included studies, data on characteristics of patients and interventions (surgery, radiot herapy, 
chemotherapy), study quality and end points were abstracted independently by two review 
authors (AB and YV) onto data abstraction forms (Table 1; Table 2; Table 3; Table 4) that were 
developed for the review. Differences between review authors were resolved by discussion or 
by appeal to a third review author (AA) if necessary. No effort was made to blind the review 
authors of names of investigators, institutions, journals, etc. The data abstraction forms were 
designed a priori and were filled out independently. 
Participants 
For each t r ial, data on the number of patients assigned to each t reatment, analysed and 
excluded from the investigators' analyses was extracted independently. The distribution of 
patients by age, stage, histology, grade and performance status was abstracted where available. 
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Interventions 
Data on the type of surgery was being collected. Details of dose and fractionation of external 
beam radiotherapy and detai ls of t he brachytherapy dose, insertions and dose rate were 
collected. Details of any chemotherapy given concomitantly with radiotherapy were recorded. 
Details on duration or follow- up and ascertainment of long-term toxicity were also recorded. 
Outcomes 
For time to event (OS and recurrence-f ree survival) data, we extracted the log of the hazard 
ratio [log(HR)] and its standard error from trial reports; if these were not reported, we 
attempted to estimate them from other reported statistics using the methods of Parmar 1998. 
For dichotomous outcomes (e.g. adverse events or deaths) if it was not possible to use an HR, 
we extracted the number of patients in each treatment arm who experienced the outcome of 
interest and t he number of patients assessed at end point, in order to estimate a r isk rat io (RR). 
For contin uous outcomes (e.g . QoL), we ext racted the final value and standard deviation (SD) 
of t he outcome of interest and the number of pat ients assessed at end point in each treatment 
arm at the end of follow-up, in order to estimate the mean difference (MD) (if t rials measured 
outcomes on t he same scale) or standardized mean differences (SMD) (if trials measured 
outcomes on different scales) between treatment arms and its standard error. If reported, 
both unadjusted and adjusted statistics were extracted. Where possible, all data extracted were 
those relevant to an intention-to-treat (ITT) analysis, in which participants were analysed in 
groups to which they were assigned. 
The time points at which outcomes were collected and reported were noted. 
Assessment of risk of bias in included studies 
An assessment of the risk of bias of included RCTs was assessed using the following criteria. 
Blinding 
We coded separately the blinding of patients, treatment providers and outcome assessors as: 
yes; 
no; 
unclear. 
Randomisation 
We coded the randomisat ion of participants to intervention groups as: 
adequate, for example a computer-generated random sequence or a table of random 
numbers; 
inadequate, for example date of bi rt h, cl inic identification number or surname; 
unclear, for example not reported. 
Allocation concealment 
We coded the concealment of allocation sequence f rom treatment providers and participants as: 
adequate, for example where the allocation sequence could not be foretold (A); 
unclear, for example not reported (B); 
inadequate, for example t he computer -generated random sequence was displayed so 
treatment providers cou ld see which arm of the t rial the next part icipant was assigned to, 
or kept in a sealed opaque envelope (C). 
Loss to follow-up 
We recorded the number of participants in each intervention arm whose outcomes were not 
reported at the end of the study; we noted if loss to follow-up was not reported. 
Risk of bias were assessed as above with the exception of randomisation and additiona lly 
assessed on the basis of: 
Comparability of treatment groups at basel ine: 
yes; 
no; 
unclear. 
Adjustment for potential confounders: 
yes; 
no; 
unclear. 
Assessment of heterogeneity 
Heterogeneity between stud ies was assessed by visual inspection of forest plots, by 
estimation of t he percentage heterogeneity between t rials t hat could not be ascribed to 
sampling variat ion (Higgins 2003) and by a Chi2 test of the sig nificance of the heterogeneity 
(Deeks 2001), irrespective of whether HRs or odds ratios (ORs) were calcu lated. If there 
was evidence of substantial heterogeneity, t he possible reasons for t his were investigated 
and reported. 
Data synthesis 
For meta-analysis of the time-to-event o utcomes (OS and PFS), the most appropriate statistic 
is the HR. If provided in a trial report, the HR and associated varia nce were used directly in the 
meta-analysis. Alternatively, using the methods described in Parmar 1998, t hey were estimated 
indirectly f rom other summary statistics (95% confidence in tervals (CI), P va lues, total number 
of events) or from data extracted from publ ished Kaplan-Meier curves (Parmar 1998). Where 
feasible, a number of methods were used to estimate the t r ia l HR indirectly, to check its 
reliability. The estimated HRs were t hen combined across al l trials using the generic inverse 
variance facility in RevMan 5 software to give a pooled HR (RevMan 2011). This represents the 
overal l risk of an event with surgery versus radiotherapy. 
In some papers only overall rates of local and distant recurrence were presented rather 
than a time-to -event analysis of these events. Therefore, only an OR of the rates of recurrence 
could be calculated, with no account being taken of the t ime to recurrence or any censoring. 
Data for recurrence were ext racted f rom the text and the OR calculated from t he total number 
of pat ients and the observed number of recurrences in each arm. The ORs for individual 
trials were t hen combined across all tria ls. These ORs indicate t he odds of a local or distant 
recurrence in the surgery arm versus t he radiotherapy arm. 
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Chi2 tests were also used to assess the consistency of effect across different subsets of trials 
and were referred to as Chi2 test for interaction. Pooling of data was only done if there was no 
clinical heterogeneity and if there were outcomes that cou ld be combined. In the absence of 
statistical heterogeneity, a fixed-effect model was used; if there was statistical heterogeneity 
a random-effects model was used. Where poolingwas not appropriate, the results of el igible 
trials was discussed in a narrative form. Ideally the analysis was on an ITT basis. In all tests of 
significance a two-sided P va lue is given. 
Sensitivity analysis 
If there was a major variation in the quality of studies, it was examined in a sensitivity analysis. 
RESULTS 
Description of studies 
See: Characteristics of included studies; Characteristics of excluded studies. 
Results of the search 
A MEDLINE search (Appendix 3) identified 4S3 hits. A similar EMBASE search was carried out 
(Appendix 4), which identified 174 studies and a CENTRAL search (Appendix 2) revealed 153 
hits. Search of Group's Specialised Register and Non-Trials Database revealed 81 and 40 studies, 
respectively. Searches of the Web of Science did not add any studies. The reference lists were 
checked and the handsearching of journals and congress abstracts did not add any studies. 
As it was known to us that only a small number, if any, of RCTs had been published, we also 
incorporated other types of studies in this review, that is prospective observat ional studies, 
case-contro l studies and studies with historic controls. 
Forty-three possible eligible studies were retrieved for more detai led information. We 
found five RCTs (Landoni 1997; Mor ley 1976; Newton 1975; Piver 1988; Roddick 1971). Reasons 
for excluding were descript ion of histology was not provided, short follow-up t ime (Roddick 
1971), survival of patients with AC was not described separately (Morley 1976;Newton 1975), the 
studies were identified as not being RCTs (Morley 1976; Piver 1988). One RCT was found to meet 
the inclusion criteria (Landoni 1997). 
Ofthe remaining 38 abstracts obtained, 25 studies were excluded fo r the fo llowing reasons: 
not AC, wrong FIGO stage, du plicate report about same study, only abstract available (Rabin 
1984;Wei 2005), FIGO stage not described, different type of intervention, no detai led result 
information. This left a total of 12 non-RCTs that were considered for inclusion (Angel 1992; 
Baalbergen 2004; Berek 1981; Chen 1998; Eifel 1991; Hopkins 1988; Hurt 1977; Kilgore 1988; 
Kleine 1989; Nola 2005; Saigo 1986;Weiss 1986). Two studies reported data from the same 
department, but from different t ime periods. Eifel et al reported from 1965 to 1985 and Rutledge 
et al from 1947 to 1971, which overlapped by five years (Eifel1991; Rutledge 1975). The five-year 
survival after surgery in stage IB in the Rutledge study was 33.3%, which is not in accordance 
to literature. Therefore we excluded the Rutledge study. After primary surgery, patients 
were irradiated in case of positive lymph nodes, compromised surg ical margins, extension 
to parametrium. The indication for adj uvant therapy was not well described in some studies 
(Berek 1981;Hurt 1977;Nola 2005; Saigo 1986) as well as t he percentage of patients who received 
adjuvant radiotherapy in Angel 1992 (12%), Baalbergen 2004 (21%),Chen 1998 (13%), Eifel 1991 
(14%), Hopkins 1988 (14%), Hurt 1977 (0%), Kilgore 1988 (18%), Landoni 1997 (64%), Nola 2005 
(not reported), Saigo 1986 (11%) and Weiss 1986 (55%). All studies apart f rom the RCT (Landoni 
1997) were retrospective and with a long t ime span of between nine (Weiss 1986) and 32 (Saigo 
1986) years. The studies of Baal bergen 2004 and Saigo 1986 were multicentric but therapy was 
uniform. All t he other studies were single cent re. 
Except for the RCT study (Landoni 1997), all other studies were retrospective cohort studies 
with var iable methodological qualit y and limitat ions of a ret rospective study. Compari ng the 
results from t hese retrospective studies was not possible due to diverging treatment strategies. 
See QUO ROM statement f low diagram (Table 1). 
Subsequent searches (2012) identified in EM BASE 135 hits and in CENTRAL 172 hits. Search of 
Group's Specialised Register and Non-Trials Database revealed no new studies. Searches of the 
Web of Science did not add any studies. The reference lists were checked and t he handsearching 
of journals and congress abstracts did not add any studies. Three studies seemed potentia lly 
relevant; of one only the abstract was available (Maneo 2011) and in two the results were not 
described by intervent ion (Bansal2009; Galic 2012) (Figure 2). 
Included studies 
We found only one RCT (Landoni 1997), which is described in detail in Characteristics of included 
studies. This study was a prospect ive RCT of radiot herapy versus surgery in stage I B-IIA cervical 
cancer f rom 1986 to 1991, in pat ients referred to t he Depart ment of Obstetrics and Gynecology 
and Radiation Oncology at t he lst ituto di Scienze Biomediche S Gerardo, University of Milan. 
Of t he 468 eligible patients, a high percentage, 27% (N=125) were excluded because of age 
(N=43), medical illness (N=54), former or concur rent malignancy (N=21), or doctors or patients 
preference for a primary therapy (N = 7). Women under 30 years of age were excluded, the 
mean age in the study was SO years. 
This study included 46 patients with AC. Twenty-six patients had primary surgery and 20 
had primary radiotherapy. A relatively high percentage of the primary surgery patients had 
adjuvant radiotherapy (64%) . 
Primary surgery was uniform. Surgery consisted of a class Ill radica l hysterectomy as 
described by Piver 1974. Adjuvant radiotherapy was given as a precaution for the fo llowing 
pathological risk factors: stage was greater than FIGO stage I lA, less than 3 mm of uninvolved 
cervical stroma, cut through or lymph node metastases. Adjuvant radiotherapy consisted of 
external pelvic irradiation, with a total dose of 50.4 Gy over five to six weeks. Sixty-four per cent 
(108 out of 170) of the surgery group received adjuvant radiotherapy, which is high compared 
to the percentages of 9% to 38%cited in literature (Morris 1994). For the 26 AC patients who had 
primary surgery and received adjuvant radiotherapy similar details were not provided. 
Primary radiotherapy included external pelvic irradiation with 18 MV photon beam by a 
multi-portal technique. The median total dose was 47 Gy (range 40 to 53). After two weeks 
one caesium-137 LDR insertion was given . The median total dose at point A (external beam plus 
brachytherapy) was 76 Gy (range70 to 90). When lymphangiography showed common iliac or 
para aort ic metastases, para aortic lymph nodes were treated wit h a radiotherapy dose of 45 Gy 
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over five weeks. A boost of 5 to 10 Gy was given to t he positive lymph nodes. In the surgery 
group, lymphangiography revea led positive nodes in 24 patients (14%). Six of these 24 patients 
showed no lymph-node metastases in the surgical specimen. Whereas 27 of the 145 patients 
in the lymphangiography negative surgery group also had nodal metastases. If nodal tumour 
metastases were discovered at the time of an attempted radica l hysterectomy, some surgeons 
completed the radical hysterectomy while other surgeons abandoned it and patients were 
treated by radiotherapy. It was not described in this study how these patients were allocated, 
to t he primary su rgery or t he primary radiotherapy group. 
Median fo llow-up was 87 months (range 57 to 120). No pat ient was lost to fo llow-up. 
The outcomes assessed were the five-year survival, rate and pattern of complications, and 
recurrences associated with each primary therapy. 
Excluded studies 
We had planned to incorporate observational studies, case-control studies, non-randomised 
studies with concurrent controls and studies with historical controls in t his review. We found 
42 possible el igible studies but all these studies were of insufficient methodological quality, 
therefore we excluded all these 42 non-RCTs. See Characteristics of excluded studies. 
Risk of bias in included studies 
Allocation 
In the Landoni study patients were randomly assigned radical surgery or radical radiotherapy 
(Landoni 1997). Patients were also stratified by cervical diameter. There was adequate sequence 
generation and allocation concealment (b lock randomisat ion from a computer-generated 
table in clusters of 10 cases of each stratum of cervical diameter). 
Blinding 
There was no blinding during treatment or follow-up surveillance. 
Incomplete outcome data 
After randomisation there were six protocol violat ions: two in the surgery group and four in 
the radiotherapy group. In 10 pat ients a treatment cross-over occurred. A total of 327patients 
received the scheduled t reatment, 169 primary surgery and 158 primary radiotherapy. The 
median follow-up was 87 (range 57 to 120) months. No patient was lost to follow-up. 
Selective reporting 
To describe survival all patients with ITT were analysed. For the analysis of complications, 
10 patients who had a treatment crossover were excluded. A high percentage of patients (27%, 
N = 125) were excluded before randomisation due to age or medical illness. 
Other potential sources of bias 
The current staging procedure for cervica l cancer (FIGO clinical staging system including 
imaging) is under discussion as it is a clinical pre-treatment staging . However, at t he t ime of 
performing this study, it was, and still is, the standard tool of staging cervical cancer. 
Effects of interventions 
There was no survival benefit for either arm for all cervical cancer patients, but the multivariate 
(subgroup) analysis showed a marginally significant advantage in OS in the 46 AC patients 
after primary surgery compared to primary radiotherapy (OR 0.67; 95% Cl 0.2 to 2.26; P = 0.05) 
(Analysis 1.1). OS was only just significantly better after primary surgery (70%) versus primary 
radiotherapy (59%). It is not clear if this minor difference could be explained by t he average 
higher age of the radiotherapy group. The DFS was 66% after primary surgery and 47% after 
primary radiotherapy (OR 0.43; 95% Cl 0.13 to 1.43; P = 0.02) (Analysis 2.1). 
Most compl ications were described after combinat ion therapy. In the surgery group 
(surgery only and surgery plus radiotherapy), 48 (28%) patients showed severe (grade 2 to 3) 
morbidity t hat required medical or surgical treatment, compared with 19 (12%) patients in the 
radiotherapy group (OR 3.32; 95% Cl 0.61 to 18.12) (Analysis 1.2). After surgery only 16% of the 
patients had short-term morbidity and 24% had long-term morbidity. After surgery and adjuvant 
radiotherapy these percentages were 20% and 29%, respectively, and after radiotherapy alone 
were 7% and 16%, respectively. Owing to the high percentage of adjuvant radiotherapy after 
surgery, and as a resu lt of combining treatment, the morbidity was relatively high in t he surgery 
arm. The study gave the complication data for the whole group but not for AC separately. 
DISCUSSION 
Summary of main results 
For ear ly-stage AC surgery was better than radiotherapy. The majo rity of operated patients 
requi red adjuvant radiotherapy. Combined t herapy (surgery and adjuvant radiotherapy) gave 
the highest complications and morbidity. The rad iot herapy used in this study was not optimal. 
Overall completeness and applicability of evidence 
We have found only one RCT for t his review. It included 46 patients with AC. The mean age 
of pat ients in the study was high (50 years) compared to that in other studies (43 to 47 years) 
(Chen 1998; Eifel1991; Kilgore 1988; Nola 2005; Saigo 1986). Because of the high percentage of 
patients excluded before randomisation due to age or medical illness, the results for t his study 
apply only for relatively healthy pat ients in the age range 30 to 70 years. 
The patients received a relatively low radiation dose (median dose: 76 Gy; range 70 to 90). 
Accord ing to t he recommendation of the American Brachytherapy Society, the total dose to 
'point A' in stage IB-IIA diseases should be in the range of 80 to 85 Gy (Nag 2002). 
The study was performed f rom 1986 to 1991. At that t ime, it was not standard practice to 
combine chemotherapy with radiotherapy in the treatment cervica l cancer patients. Since 
then, concurrent chemoradiation in either definitive or postoperative setting has been shown 
to be superior to radiotherapy alone (Green 2001; Green 2005; Peters 2000). 
Quality of the evidence 
The quantity and quality of the evidence was scarce and only one RCTwas found (Landoni 1997), 
which included only 46 patients with AC from 337 cervical cancer patients. 
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AUTHORS' CONCLUSIONS 
Implications for practice 
Analysis of a subgroup of the single RCT showed that surgery for early-stage AC was better 
than radiot herapy. However, the majority of the surgery group patients required adjuvant 
radiotherapy, which was associated with greater morbidity. Furt hermore, radiotherapy was not 
optimised and surgery was not compared to chemoradiation, which is currently recommended 
inmost cent res. Finally, modern imaging techniques (MRI, PET-CT), allow for better patient 
select ion enabling node-negative patients to be more easily identified fo r surgery, thereby 
reducing the risk of morbidity associated with surgery and adjuvant radiot herapy. 
In conc lusion, we recommend surgery for early-stage AC of t he uterine cervix in carefully 
staged patients. Whereas primary chemoradiation remains a second best alternative for 
patients unfit for surgery and chemoradiation probably is first choice in patients with (MRI or 
PET-CT-suspected) positive lymph nodes. 
Since the last version of this review no new studies were found . 
Implications for research 
There is a need for well-designed RCTs comparing primary surgery versus primary radiotherapy 
plus concurrent chemotherapy for early AC. This can only be car ried out in women who do not 
need fertility-sparing treatment. 
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CHARACTERISTICS OF STUDIES 
Characteristics of included studies [ordered b y study 10] 
Landoni 1997 
Methods 
Participants 
Intervent ions 
Outcomes 
Notes 
Risk of bias 
Randomised controlled t rial 1986 to 1991; Milan, Italy 
337 patients with stage IB or I lA cervical cancer: 46 with AC 
Surgery consisted of a Class Ill radical abdominal 
hysterectomy. Adjuvant radiotherapy was g iven if at least 
1 pathological risk factor (stage> pT2a, less than 3 mm 
uninvolved stroma, cut through, lymph-node metastases) 
Radiotherapy included ext ernal beam pelvic irradiation plus 
brachytherapy. Total dose at point A ranged 70 to 90 Gy 
(median 76 Gy) 
5-year overall survival: 70% after primary surgery (N = 26) 
versus 59% after primary radiotherapy (N = 20). No evidence 
of disease at 5 years: 66% after surgery versus 47% after 
radiotherapy 
Complications surgery-related 28%, radiation -related 12% 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Low risk 
Allocation concealment (selection bias) Low risk 
Blinding (performance bias and detection bias) High risk 
5 yr survival 
Blinding (performance bias and detection bias) High risk 
complicat ions 
Incomplete outcome data (attri t ion bias) Low risk 
All outcomes 
Selective reporting (report ing bias) Low risk 
Other bias Low risk 
In the follow-up primary 
therapy was obvious 
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Characteristics of excluded studies [ordered by study 10) 
Study 
Angell992 
Attanoos 1995 
Baalbergen 2004 
Bansal2009 
Berek 1981 
Chargui 2006 
Charkviani 1990 
Chen 1998 
Covens 1999 
Eifell990 
Ei fell991 
Erzen 2002 
Farley2003 
Galic 2012 
Grigsby 1988 
Hansen 1981 
Hopkins 1988 
Hopkins 1991 
Hurt 1977 
Reason for exclusion 
Retrospective study, 1966 to 1990, New York USA. 89 patients with stage I. Treatment 
prior to 1980 consisted mainly of radiotherapy and pre-operative radiotherapy, aft er 
1980 the primary therapeut ic approach was radical surgery 
Retrospective study, 1971 to 1990, Cardiff UK.SS patients. Survival was not described 
separately for stage and therapy 
Retrospective study, 1989 to 1999, Rotterdam, Netherlands. 200 stage I and I lA patient s. 
Pat ients had primary radiotherapy when their clinical condition was poor or because of 
o ld age 
Retrospective study, 1988 to 2005, SEER database USA. Survival for different therapies 
for adenocarcinoma alone was not given separately 
Retrospective study, 1953 to 1978, UCLA USA. 48 st age 18 pat ient s. Reason for choice of 
primary therapy not given 
Retrospective study, 1990 to 1999 Tunis. Pat ients with stage I and I lA had pre-
operative radiotherapy 45 Gy followed by radical surgery (51 patient s) or surgery and 
radiotherapy (1 patient ) 
Retrospective study, 1964 to 1989, USSR. 98 patients. Survival not separately mentioned 
for AC 
Retrospective study, 1977 to 1994, Taipei Taiwan. 240 patients. Patients were 
encouraged to undergo surgical treatment instead of radiotherapy 
Retrospective study, 1984 to 1995, Toronto Canada. Study was only about surgery in 
early stage I AC 
Retrospective study, 1965 to 1985, MD Anderson, USA. Different treatment for ear ly 
stage was precisely described but survival was not given separately for pr imary su rgery 
versus primary radiotherapy 
Retrospective study, 1965 to 1985, MD Anderseon USA. 160 patients with an abnormal 
lymphography were treated with radiotherapy. Patients determined to have positive 
nodes at explorative surgery did not undergo planned hysterectomy but were given 
radiotherapy 
Retrospective study, 1995 to 1999, Slovenia . Therapy (surgery versus radiotherapy) and 
outcome were not described separately 
Retrospective study, 1988 to 1999, Military Health Care System USA. Survival for 
different therapies was not given separately 
Retrospective study, 1988 to 2005, SEER database. Survival for different t herapies was 
not given separately 
Retrospective study, 1959 to 1982, Washington USA, only about radiation 
Prospective non-randomised study, 1974 to 1977, Odense, Denmark . Histology was not 
mentioned. Standard therapy was pre-operat ive radiotherapy followed by surgery. 
When a contraindication to operation was found patients had radiotherapy only 
Retrospective study, 1970 t o 1985, M ichigan USA. 125 st age I AC pat ient s. Allocation for 
primary therapy not given 
Retrospective study, 1970 to 198S, M ichigan USA. Only description of P value in a Cox 
Model Multiple Proportion Hazard Analysis for patients with stage IB AC according to 
treatment 
Retrospective study, 1954 to 1974, Virginia USA. 20 stage I AC patients. Choice for 
primary therapy not described, only 3 had pr imary surgery 
Characteristics of excluded studies [ordered by study 10) (Continued) 
Study 
Ireland 1985 
Kilgore 1988 
Kjorstad 1977 
Kleine 1989 
Leminen 1990 
Martel2000 
Miller1993 
Milsom1983 
Morley 1976 
Newton 1975 
Nola 2005 
Papanikolaou 2006 
Perez 1995 
Piver 1988 
Rabin 1984 
Roddick 1971 
Rutledge 1975 
Saigo 1986 
Shingleton 1981 
Sundfo r 1996 
Townsend 1980 
Reason for exclusion 
Retrospective study, 1969 to 1983, Gateshead, UK. Survival was not given separately for 
different treatment 
Retrospective study, 1963 to 1985, Alabama USA. 130 stage I AC patients. Selection of 
treatment was not described 
Retrospective study, 1963 to 1968, Oslo Norway. All patients had intracavitary radium 
treatment fol lowed by surgery or radiotherapy 
Retrospective study, 1964 to 1985, Freiburg Germany. 64 stage I patients. Clinical stage 
differentiation inadequate 
Retrospective study, 1976 to 1980, Helsinki Finland. 63 patients. Surgery was pre-t reated 
with a single intracavitary irradiation 
Case-control study, 1978 to 1992, Toulouse, France. Small numbers, survival was not 
separately given for different therapy per stage 
Retrospective study, 1964 to 1989, Memphis USA. Survival was not described for 
different therapies 
Retrospective study, 1965 to 1974, Goteborg Sweden. Primary therapy consisted of 
intracavitary radiation followed by surgery or intracavitary plus external irradiation 
Retrospective study, 194S to 197S, Michigan USA. Survival of patient s with AC was not 
separately described 
Prospective study of surgery versus radiotherapy in cervica l cancer, 1956 to 1966, 
Chicago USA. Survival of? patients w ith AC was not described separately 
Retrospective study, 1978 to 1998, Zagreb Croatia. 36 AC stage I-IV patients. Survival 
after primary surgery versus primary radiation was not subdivided for st age 
Retrospective study, 1993 to 2000, Greece. Therapy and survival for AC (only 11 
patients) not separately described 
Retrospective study, 1966 to 1995, Missouri USA. Irradiation versus irradiat ion plus 
surgery in cervical cancer. Survival of AC patients is not separately described 
Retrospective study, 1974 to 1983, Buffalo USA. Treatment and survival of pat ients with 
AC was not separately described 
South-Afr ican article from 1984. Study about radiotherapy plus surgery versus surgery in 
cervical cancer. In abstract no description of AC histology. Article could not be obtained 
Randomised study, Kentucky USA, Surgery versus radiotherapy in cervical cancer. But 
no description of histology, no AC described, short follow-up 
Retrospective observational study, 1947 to 1971, MD Anderson USA. 61 stage I and IIA 
patients. 5-year survival after su rgery in stage IB was 33.3%; t his is not according to 
literature 
Retrospective study, 1949 to 1981, New York USA. 102 stage IB and I lA patients. 
Allocation for primary treatment not described. Wide variation in radiation treatment 
during the interval of this study 
Retrospective study, 1969 t o 1980, Alabama USA. Survival is not separately described for 
different therapies. Same clinic as Kilgore 1988 
Randomised study, 1968 to 1980, Oslo Norway. Radiotherapy versus radiotherapy plus 
surgery in sec 
Randomised study, Melbourne. lntracavity radon followed by radical hysterectomy and 
pelvic lymph nodes versus intracavitary radon plus external megavoltage irradiation 
followed by extended hysterectomy in cancer of the cervix. Histology AC not described 
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Characteristics of excluded studies [ordered by study 10) (Continued) 
Study 
Waldenstri:im 1999 
Wei2005 
Weiss 1986 
Yamashita 2005 
Reason for exclusion 
Retrospective study, 1987 to 1994, Gi:iteborg Sweden. Survival was not separately 
described after primary surgery versus primary radiotherapy 
Retrospective study, 1970 to 2002, China. 105 AC patients. 5 year-survival for stage I 
58%, which is not in accordance with literature. Only abstract available 
Retrospective study, 1970 to 1979, San Diego USA. 28 AC stage IB and I lA patients, 
< 4 em. Treatment was based on stage of the lesion and the general medical condition 
of the patient 
Retrospective study, 1991 t o 2004, Tokyo Japan. Surgery versus radiotherapy in cervical 
cancer. Survival of 24 patients with AC was not described separately 
DATA AND ANALYSES 
Comparison 1. Survival 
No. of No. of 
Outcome or Subgroup title Studies Participants Statistical Method Effect Estimate 
1 5-year survival 
2 Complications 
Comparison 2. Disease-f ree su rvival 
No. of 
46 
46 
No. of 
Odds Ratio (M· H, Fixed, 95% Cl) 0.67 [0.20, 2.26) 
Odds Ratio (M-H, Fixed, 95% Cl) 3.32 (0.61, 18.12) 
Outcome or Subgroup title Studies Participants Statistical Method Effect Estimate 
1 Disease-free survival 46 Odds Ratio (M·H, Fixed, 95% Cl) 0.43 [0.13, 1.43) 
Analysis 1.1. Comparison I survival, Outcome I 5-year survival 
Comparison: I Survival 
Outcome: I S-year surviva l 
Primary surgery 
Study or Subgroup Events Total 
Landoni 1997 8 26 
Tota l (95" Cl) 26 
Total events 
Heterogeneity: Not applicable 
Test for overall effect: Z = 0.65 (P = 0.52) 
primary rad iothe rapy Odds Ratio 
Events Total Weight M- H. Fixed, 95" Cl 
8 20 100.0" 0.67 [0.20, 2.26] 
20 l OO.Ol' 0.67 (0.20, 2.26] 
8 
Odds Ratio 
M· H, Fixed, 95" Cl 
0. I 0.1 10 I 0 
Favours experimental Favours control 
Analysis 1.2. Comparison I Survival, Outcome 2 Complications. 
Compar ison: I Survival 
Outcome: 2 Complications 
Prtmilry surgery 
Study or Subgroup Events Total 
Landoni 1997 26 
Total (9S" Cl) 26 
Total events 7 
Heterogeneity: Not applicable 
Primary radiotherapy Odds Ratio 
Events Total Weight M- H, Fixed, 9S" Cl 
20 100.0" 3.32 (0.61, 18.12) 
20 100.0" 3.32 (0.61, 18.12) 
Odds Ratio 
M- H, Fixed, 9S" Cl 
0. 5 0.2 20 
Test for overall effect Z • 1.38 (P • 0.17) Favours experimental Favours control 
Analysis 2.1. Comparison 2 Disease-free survival, Outcome I Disease free 
survival. 
Compar iso n: 2 disease-free survival 
Outcome: I Disease-free survival 
Study or Subgroup 
Landoni 1997 
Total (9S" Cl) 
Total events 
Primary surgery 
Events Total 
26 
26 
Heterogeneity: Not applicable 
Primary radiotherapy Odds Ratio 
Events Total Weight M- H, Fixed, 95" Cl 
II 20 100.0" 0.43 (0 .13, 1.43) 
20 100.0% 0.43 (0.13, 1.43) 
II 
.002 
Odds Ratio 
M- H, Fixed, 9S" Cl 
0 .1 10 50 Test for overall effect: Z • 1.37 (P • 0.17) Favours experimental Favours control 
ADDITIONAL TABLES 
Table 1. Data collection form 
Intervention A 
Study identification: Form filled in by: 
Reference checked by: 
Date completing form: 
Name study: 
1st author, journal, year: 
Study properties 
RCT, non· randomised controlled study, CCT, observational 
study prospect ive/retrospective 
Time of inclusion: 
Purpose of the study, as stated by authors: 
Selection bias 
Performance bias 
Attribution bias 
Detection bias 
Analysis (statist ics) 
Intervention B 
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Table 1. Data collection form (Continued) 
Intervention A 
St udy elig ible for review: yes I no 
If not, why not: 
Types of participants : Intervention A Intervention 8 
Number of patients: 
Age: 
Mean: 
Median: 
SD: 
Ranges: 
Primary tumours: 
FIGOstage lA 
IB· IIA 
118Histological 
type 
Adenocarcinoma 
Adenosquamous 
Other (specify) 
Grade: I 
Il l 
unknown 
Performance Status: WHO 
Types of int ervention: 
Surgery planned 
Conservative surgery 
Radical surgery 
Protocol violations 
Radiationtherapy planned 
- External & brachytherapy: 
total Gy: fract ions: frequency: field: 
-Chemoradiation 
t otal Gy: fractions: frequency: field: 
CT agent(s) doses: frequency 
Protocol violations 
Surgery & Radiation therapy 
-reason: 
Outcom e A 8 
Total patients entering the study 
Declared ineligible 
Removed from study for other reasons 
Intervention B 
Table 1. Data collect ion form (Continued) 
Intervention A 
Included in analysis 
Completed prescribed treatment plan 
(and available for response) 
Follow up: A B 
Known of .. patients. 
Time of f.u. median: 
SD: 
Range: 
Alive (5-yr survival) 
Without evidence of disease 
With disease 
Death: 
DOD 
Treatment complications 
Not related death 
Unknown 
Recurrence: yes I no 
If yes time-interval (month) 
If yes: local, distant, both 
Complications: 
-radiation-related 
-surgery-related 
-death 
Table 2. Crit ical review fo rm; ra ndomized studies 
Yes- no 
Did study populat ion meet our criteria? 
or: is it possible to analyse patient s that meet our cri teria separately? 
Was assignment of patients to t reatment randomised? 
Were patients analysed in the groups to which they were randomised? 
Were the groups similar at the start of the trial? 
Aside from the experimental intervention, were the groups treated equally? 
Were all patients who entered the trial accounted for at its conclusion? 
How long was follow up? (Median and range) 
Were interventions defined adequately? 
Were all clinically important outcomes considered? 
-disease free su rvival 
-complications 
Intervention B 
" ~
$: 
)> 
~ 
V1 
c 
:0 
() 
m 
:0 
-< 
< 
m 
:0 
V1 
c 
V1 
" :0 
$: 
)> 
:0 
-< 
:0 
)> 
0 
6 
'"" I 
m 
:0 
)> 
" -< 
:'E 
=i 
I 
0 
:0 
:'E 
=i 
I 
0 
c 
'"" () 
I 
m 
$: 
0 
'"" I 
m 
:0 
)> 
" -< 
145 
""0 
~ 
s: 
):> 
~ 
Vl 
c 
;o 
() 
m 
;o 
-< 
< 
m 
;o 
Vl 
c 
Vl 
""0 
;o 
s: 
):> 
;o 
-< 
;o 
):> 
0 
6 
""" I 
m 
;o 
):> 
""0 
-< 
::!: 
=i 
I 
0 
;o 
::!: 
=i 
I 
0 
c 
""" n 
I 
m 
s: 
0 
""" I 
m 
;o 
):> 
""0 
-< 
146 
Table 3. Critical review form; studies with non- random ized controls 
Yes - no 
Did study populat ion meet our criteria? 
or: is it possible to analyse patient s that meet our cri teria separately? 
Is the study adjusted for confounders? 
Were patients analysed in the groups to which they were assigned? 
Were the groups similar before treatment? 
Aside from the experimental intervention, were the groups treated equally? 
Are controls concurrent or retrospective? 
Were all patients accounted for at t he end of follow up? 
How long was follow up? 
Were interventions defined adequately? 
How precise was the estimate of the treatment effect? 
-disease free survival 
-complications 
Were all clinically important outcomes considered? 
-disease free su rvival 
-complications 
Table 4. Crit ica l review form; observational studies 
Yes- no 
Did study population meet our criteria? 
or: is it possible to analyse patient s that meet our cri teria separately? 
Were all observed pat ients accounted for at the end of follow up? 
How long was follow up? 
Were interventions defined adequately? 
Is the study cohort defined temporally? 
Is the study cohort defined geographically? 
Percentage of defined patient population who are included in the study? 
Were all clinically important outcomes considered? 
-disease free survival 
-complications 
APPENDICES 
Appendix 1. FICO staging 
FICO Stage I 
Carcinoma is strictly confined to t he cervix (extension to the corpus should be disregarded). 
Invasive carcinoma that can be diagnosed only by microscopy. All macroscopical ly visible 
lesions, even wit h superficia l invasion, are allotted to Stage 18 carcinomas. The involvement of 
vascular spaces, venous or lymphatic, should not change the stage allotment. 
IA1 Measured stromal invasion of not more than 3.0 mm in depth and width of not more 
t han7.0 mm. 
IA2 Measured stromal invasion of more than 3.0 mm and not more than S.O mm wit h a 
width of not more than 7.0 mm. 
181 Clinically visible lesions not more t han 4.0 em, or pre-clinical lesions greater than IA2. 
182 Clinically visible lesions more t han 4.0 em. 
FICO Stage II 
Cervical carcinoma invades beyond the uterus, but not to t he pelvic sidewall or to the lower 
third ofthe vagina . 
IIA1 No obvious pa ra metrial involvement and tumour size of 4 em or less with involvement 
of less t han t he upper two-thirds of t he vagina. 
IIA2 No obvious parametrial involvement and tumour size of more than 4 em with 
involvement of less than the upper two-thi rds of the vag ina (Pecorelli 2009). 
li B Obvious parametrial involvement (Benedet 2001). 
Appendix 2. CENTRAL search strategy 
CENTRAL Issue 3 2009 
#1 MeSH descriptor Uterine Cervical Neoplasms explode all trees 
#2 MeSH descriptor Cervix Uteri explode all trees 
#3 cervi* 
#4 (#2 OR #3) 
#S cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom* or adenocarcinom* 
#6 MeSH descriptor Adenocarcinoma explode all trees 
#7 MeSH descriptor Carcinoma, Adenosquamous explode al l trees 
#8 (#S OR #6 OR #7) 
#9 (#4 AND #8) 
#10 (#1 OR #9) 
#11 MeSH descriptor Gynecologic Surgical Procedures explode al l t rees 
#12 surg* 
#13 Any MeSH descriptor with qualifi er : SU 
#14 MeSH descriptor Hysterectomy explode al l trees 
#1S hysterectomy 
#16 (#11 OR #12 OR #13 OR #1 4 OR #15) 
#17 MeSH descriptor Radiotherapy explode all trees 
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#18 Any MeSH descriptor with qual ifie r: RT 
#19 radiat ion 
#20 brachytherapy 
#21 chemoradi* 
#22 rad iochemo* 
#23 (#17 OR #18 OR #19 OR #20 OR #21 OR #22) 
#24 (#10 AND #16 AND #23) 
Appendix 3. MEDLINE search strategy 
MEDLINE Ovid 1950 to July week 5 2009 
1 exp Uterine Cervical Neoplasms/ 
2 exp Cervix Uteri/ or cervi* .mp. 
31 or 2 
4 exp Adenocarcinoma/ 
5 adenocarcinoma*.mp. 
6 exp Carcinoma, Adenosquamous/ 
7 adenosquamous carcinoma*.mp. 
8 4 or 5 or 6 or 7 
9 3 and 8 
10 exp Gynecologic Surgical Procedures/ 
11 surg*.mp. 
12 su rgery.fs. 
13 exp Hysterectomy/ 
14 hysterectomy.mp. 
1510 or 11 or 12 o r 13 or 14 
16 exp Radiotherapy/ 
17 radiothera p*.mp. 
18 radiotherapy.fs. 
19 radiation.mp. 
20 brachytherapy.mp. 
21 chemoradi*.mp. 
22 radiochemo*.mp. 
23 16 or 17 or 18 or 19 or 20 or 21 or 22 
24 9 and 15 and 23 
25 randomized controlled t ria l. pt. 
26 controlled cl inical t rial. pt. 
27 randomized.ab. 
28 clinical trials as topic.sh. 
29 randomly.ab. 
30 t rial.ti. 
31 exp Cohort Studies/ 
32 cohort* .mp. 
33 exp Case-Control Studies/ 
34 (case* and control*).mp. 
35 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 
36 24 and 35 
37 (animals not (humans and animals)).sh. 
38 36 not 37 
key: 
mp=title, original title, abstract, name of substance word, subject heading word 
fs=float ing subheading 
pt=publ ication type 
a b=a bstract 
sh=subject heading 
Appendix 4 . EMBASE search strategy 
EM BASE 1980 to 2009 week 32 
1 exp uterine cervix tumor/ 
2 exp uterine cervix/ or cervi*. mp. 
31 or 2 
4 exp adenocarcinoma/ 
5 adenocarcinoma*.mp. 
6 exp adenosquamous carcinoma/ 
7 adenosquamous carcinoma*.mp. 
8 4 or 5 or 6 or 7 
9 3 and 8 
10 exp gynecologic surgery/ 
11 surg*.mp. 
12 su.fs. 
13 exp hysterectomy/ 
14 hysterectomy.mp. 
1510 or 11 or 12 or 13 or 14 
16 exp radiotherapy/ 
17 radiotherap*.mp. 
18 rt.fs. 
19 radiation.mp. 
20 brachytherapy.mp. 
21 chemoradi*.mp. 
22 radiochemo*.mp. 
23 16 or 17 or 18 or 19 or 20 or 21 or 22 
24 9 and 15 and 23 
25 exp controlled clinica l trial/ 
26 randomized.ab. 
27 randomly.ab. 
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28 trial.ab. 
29 groups.ab. 
30 exp cohort analysis/ 
31 cohort*.mp. 
32 exp case control study/ 
33 (case• and cont rol*) .mp. 
34 exp retrospective study/ 
35 exp prospective st udy/ 
36 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 
37 24 and 36 
key: 
mp=t itle, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name 
fs=floating subheading 
ab=abst ract 
Appendix 5. Cochrane Gynaecological Cancer Group's Specialised Register 
and Non-Trials Database 
#8=CVX AND#11=SU AND#11=RT AND#12=TRT AND#4 <>ADVANCED AND#4 <>RECURRENT 
AND#4 <>REFRACTORY 
WHAT'S NEW 
Last assessed as up-to-date: 19 October 2009. 
Date Event 
14 November 2012 Amended 
7 November 2012 New citation required but 
conclusions have not changed 
7 November 2012 New search has been performed 
Description 
Contact details amended 
No new studies were identified for inclusion 
A new search has been performed. The literature 
searches as described in the search strategy section 
were updated in June 2012 
CONTRIBUTIONS OF AUTHORS 
AA and ABwrotethe protocol. AB and YV did the search strategy, with help from Anne Oestmann 
and Jane Hayes of the Cochrane Gynaecological Cancer Review Group. AB and YV assessed 
eligibi lity of ret rieved papers. AB prepared the initial text. AA advised on the methodology 
content and edited the text. LS searched for background material with special emphases on 
the radiotherapeutic subject and edited t he text. 
DECLERATIONS OF INTEREST 
None known . 
SOURCES OF SUPPORT 
Internal sources 
None, Not specifi ed. 
External sources 
None, Not specified. 
DIFFERENCES BETWEEN PROTOCOL AND REVIEW 
In t he Methods under the Types of studies we added "The methodological quality of non-RCTs 
was assessed on the basis of comparability of treatment groups at baseline, adjustment for 
potential confounders and allocation of treatment". We had not clearly stated t his in the 
protocol. When we encountered the non-RCTs we found them on methodologically grounds 
(mainly due to selection of primary t reatment) not qualified for our review, so that we excluded 
the non-RCTs. 
As only one RCT was found to be suitable for inclus ion the methods described in the 
Assessment of heterogeneity, Data synthesis and Sensitivity analysis were not used. 
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Astrid Baalbergen 
Frank Smedts 
Theo J.M. Helmerhorst 
International journal of gynecological cancer. 2077;21: 1640-1645 
·,r, 'A' 
ABSTRACT 
Introduction 
An evaluation of treatment and fo llow up in a large series of women with early cervical 
adenocarc inoma (AC), stages 1A1 and 1A2 and an extensive literature review, in an effort to 
ascertain weather conservative t herapy is justified. 
Methods 
Fifty-nine cases of microinvasive AC diagnosed between 1987 and 2006 in the Rotterdam 
district, The Netherlands were retrieved. Clinical and pathological data were reviewed and 
analysed. A mesh review of all relevant literature concern ing stage IA1 and IA2 was performed. 
Results 
Thirty-three pat ients had stage 1A1 and 26 stage 1A2 cervical AC. 42 patients were treated 
conservatively (i.e. conization or simple hysterectomy) and 17 patients were t reated radically 
(i.e. radical hysterectomy /trachelectomy with lymph node d issection). One recurrence (1.7%) 
in a pat ient with stage IA1disease (grade 1 adenocarcinoma, depth 1.4 mm and width 3.8 mm, 
with lymph vasculair space invasion (LVSI) treated by vagina l hysterectomy. The mean fo llow-up 
was 79.9 months. From the literature, pooling all data from patients with stage IA1 and IA2 AC, 
t he risk of recurrent disease after conservative therapy was 1.5%, and after radical t herapy 2.0%. 
Conclusions 
Extensive t reatment such as radical hysterectomy with pelvic lymph node dissection or 
trache lectomy does not prevent recurrent disease. Patients with microinvasive AC should 
be treated identically to patients w ith squamous cell carc inoma. In stage IA1 and IA2 AC 
we recommend conservative t herapy (by conization). In cases with LVSI, an additional 
lymphadenectomy is advised . For pat ients with stage IA2 AC with LVSI a trachelectomy I radical 
hysterectomy with lymph node dissect ion should be considered. 
INTRODUCTION 
Although the incidence of cervica l squamous cel l carcinoma (SCC) is decreasing in the 
Netherlands, the incidence of adenocarcinoma (AC) is increasing, especially in women of 
chi ldbearing age. There has been a 16% increase in women diagnosed with AC between 
15-29 years of age and a 2.5% increase in women between 30-44 years of age, in the period 
between 1989-1998 1• The mean age at birth of t he first child is 29.4 years in the Netherlands2, 
obviating the need for as conservative a therapeutic approach as possible in women with 
cervical carcinoma. 
The optimal t reatment for microinvasive cervical AC is controversial. Although curative 
therapy is pivotal, preservation of fertility is an important issue and therefore influences the 
choice of therapeutic strategy. The different strategies vary between radical hysterectomy 
(RH) with pelvic lymph node dissection (PLND) to conization of t he cervix. There are several 
reasons for the fact t hat there is no international consensus regarding treatment in early 
cervical carcinoma. Firstly, because the International Federation of Gynecology and Obstetrics 
(FIGO) and Society of Gynaecologic Oncologists (SGO) definitions of early cervical carcinoma 
are different, secondly the suggestion that cervical AC behaves more aggressively than SCC and 
thereforeAC should be treated in a different way3•4 • And thirdly because prospective randomized 
trials comparing conservative versus radical treatment in cervical adenocarcinoma are lacking, 
due to the rar ity of this carcinoma type, the optimal therapeutic strategy is not known. 
In the Netherlands, in patients with stage 1A1 AC a hysterectomy is performed. When fertility 
is an issue, treatment is conservative e.g. by conizat ion. If lymph vascular space involvement 
(LVSI) is present, a lymphadenectomy is advised. In patients with stage IA2 AC without LSVI and 
who desire to maintain fertility, a conization is sufficient however if LVSI has been demonstrated 
a lymphadenectomy is indicated {http:/ /www.oncoline.nl}. 
The purpose of this study is to evaluate the treatment and follow up in a large series of 
women with early cervica l AC, stages 1A1 and 1A2 in an effort to ascertain weather conservative 
treatment is justified. Furthermore to review relevant literature concern ing the outcome 
of therapy in early stage cervica l adenocarc inoma in an effort to come to a more unifying 
conclusion as to the most opt imal therapeutic approach in the treatment oft his carcinoma type. 
MATERIALS AND METHODS 
From the Rotterdam cancer registries: IKR regional cancer registration body, National 
pathology registration and oncology registry of the Daniel den Hoed Cancer Clinic Rotterdam, 
all recorded patients with stage IA1 and IA2 invasive cervical adenocarcinomas diagnosed during 
the period between 1987 and 2006 were requested. Cases were retrieved from the Erasmus MC 
University Hospital Rotterdam, t he Daniel den Hoed Cancer Clinic and the affil iated hospitals in 
the region. From each case, case fi les and all available slides were requested and revised. Slides 
were reevaluated according to FICO criteria i.e. : 1A1 lesions with a depth of invasion <3mm and 
width <7mm, and 1A2 lesions with a depth >3mm but <5mm and width <7mm. 
The following information was taken from the medical records: age, parity, type of 
treatment, recurrence, number of pregnancies after conization, pregnancy outcomes and 
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other fo llow-up data. All slides were reviewed by an experienced gynaecopathologist and 
classified according to WHO. Cases of usual/endocervica l type cervix AC were included, along 
with the variants of cervical adenocarcinoma. In cases of endometrioid type carcinoma the 
case was only included when the carcinoma was clearly located in the cervix. If a squamous 
component was present t he case was classified separately as adenosquamous . The following 
parameters were determined; histologic type, depth of stromal invasion, horizontal extent 
of the tumor, presence/absence of LVSI, presence/absence of metastasis to the pelvic lymph 
nodes and ovary, treatment, and recurrence. 
Pat ients were excluded f rom the study if tumor location was not obvious and/or clinical 
data were incomplete. 
The project was approved by the Medical Ethics Committee of t he ErasmusMC University 
Hospital Rotterdam (nr.211.651/2002/48). 
Furthermore a review of the English literature on microinvasive adenocarcinoma of the 
uterine cervix was performed using Pubmed (1952-2010) and EMBASE (OVID: 1950-2010) 
using combined disease-specific terms (uterine cervix neoplasms/ AND adenocarcinoma 
AND microinvasive) with t reatment-specific terms (conservative therapy, radica l t herapy, 
hysterectomy, conization). The reference lists were reviewed. Case reports were excluded and 
also studies reporting the same patient group more than once. Our search particu larly focused 
on conservat ive or radica l t herapy in relation to recurrent disease. We designated treatment 
consist ing of a conization or simple hysterectomy as conservative. Radical t reatment consisted 
of a radical hysterectomy or trachelectomy. 
RESULTS 
Fifty-nine patients were included in t he study; 33 women had FIGO stage 1A1 AC and 26 FIGO 
stage 1A2 AC. In all 59 patients formalin-fixed and paraffin-embedded tissue was retrieved. 
52 women had an adenocarcinoma of endocervical type. Six patients had an adenosquamous 
carcinoma and in one a clear cell carcinoma was diagnosed. The mean age at diagnosis in stage 
1A1 carcinoma was 37.8 (range 26-66) years and for stage 1A2 carcinoma it was 42.04 (range 
28-66) years. The clinicopathologic characteristics ofthe patients are summarized in Table 1. 
Initia l t reatment consisted of a radica l hysterectomy in 17 women, 22 women underwent 
conization, and in 20 a simple hysterectomy was performed. 
Of the 22 patients treated by conization, 15 had a stage 1A1 and 7 had stage 1A2 disease. 
Eleven of these women had eighteen pregnancies with thirteen live births and four spontaneous 
abortions. In two women fo llow-up data were not available, due to emigration. One of these 
women was three months pregnant on her last visit to the outpatient clinic. Two women had 
primary cerclage of the cervix and both delivered by a planned caesarean section. 
Only one recurrence (1.7%) was reported. This patient had a vag inal hysterectomy for 
prolaps uter i. During routine histopathology a grade 1 adenocarcinoma was diagnosed. Tumor 
depth was 1.4 mm and width 3.8 mm, there was LVSI. She developed lymph node metastasis 30 
months after initial therapy and was t reated by a course of chemo-radiation. Twelve months 
after therapy there is no evidence of d isease. 
Table 1. The clinicopatholo g ical characteristics of t he 59 pat ients with micro invasive adenocarcinom a of 
t he uterine cervix 
No of patients percentage No of patients percentage 
Stage IA1 IA2 
33 56 26 44 
Age (years) mean 37.8 42.0 
<35 13 39 8 31 
35-64 19 58 17 65 
>65 3 4 
Para 
0 11 33 10 39 
>=1 22 67 16 61 
Major presenting symptoms 
None 17 52 12 46 
Dysfunctional/postmenopausal 6 18 6 23 
Postcoit al 8 24 7 27 
Vaginal d ischarge 2 6 4 
Primary treatment 
conization 15 46 7 27 
radical surgery 4 12 13 so 
simple hysterectomy 14 42 6 23 
Histological Subtype 
Adenocarcinoma 29 88 23 89 n 
Adenosquamous 4 12 2 7 0 z 
Clear cell "' 4 m 
"' Tumor g rade <~ 
26 90 13 52 < 
m 
2 7 8 32 
.., 
I 
Ill 3 4 16 
m 
"' ~
unknown 4 ""0 
-< 
LVSI z 
yes 2 6 4 16 ~ n 
no 29 94 21 84 "' Q 
unknown 2 z < ~ 
LNM 
"' < 
no 4 13 m ~ 
not done 29 88 13 so Q m 
z 
recurrence 0 
n 
No 32 97 26 100 ~ 
"' yes 1 3 0 0 Q z 
pregnancy 0 s: 
yes 6 18 8 ~ 
no 7 21 2 19 
na 20 61 19 73 
LVSI Iymph vascular space involvement 
LNM lymph node metastases 
NA not applicable 
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The mean follow-up period after initial therapy in all patients is 79,9 months (range 
10-131 month). 
17 women were treated by RH with PLN D; 4 patients with stage 1A1 and 13 patients with stage 
1A2 disease. No lymph node metastases were found. In only 6 of the 59 women (10%) LVSI was 
reported. Four of these patients were treated by radical surgery. Positive lymph nodes were 
not found in t hese patients. Two had a simple hysterectomy, of which one developed lymph 
node metastasis 30 month after therapy and follow up in the ot her pat ient has been uneventful 
(5 years). 
DISCUSSION 
To determine the optimal therapy in women with microinvasive cervical AC, a number of 
aspects must be considered. In the past, a radical hysterectomy was recommended in all 
patients with any degree of invasive cervica l cancer. In an effort to reduce morbidity without 
sacrificing efficacy, the rad ical ity of surgery has decreased over the last decades. In 1973 the SGO 
accepted a new definition for microinvasive cervical cancer, the criteria for which were dept h of 
invasion less than 3 mm and the absence of LVSI. Conservative treatment was advised in cervical 
carcinomas complying with this criterium5. In 1985, FIGO introduced t he histo logic definition 
of stage lA cervical cancer, which was refined in 1994; the FIGO stage was based on invasion 
depth and horizontal extention•. Stage IA1 was defined as a tumor, which invades to a dept h 
of 3 mm or less with 7 mm or less horizontal spread. Stage IA2 was defined as stromal invasion 
of more than 3 mm and less than 5 mm with a horizontal spread of? mm or less. From 1994 the 
two different class ification systems were used to define and treat microinvasive carcinoma. In 
2009 the new FIGO staging system was published ;_ It states that a stage lA carcinoma can only 
by diagnosed microscopically. The involvement of vascular spaces-venous or lymphatic- does 
not change t he stage. Microinvasive AC of the uterine cervix should be staged using the same 
criteria as are used in microi nvasive SCC of the uterine cervix. In our study we applied the FIGO 
staging classification criteria, combined with WHO grading. 
During revision of the cases we were regularly confronted by difficulties in evaluat ing early 
invasion. These are well described in textbooks, never the less application can be difficult. The 
main problems noted were the delineation of an AIS-Iike gland structure, from adenocarcinoma. 
Also frank invasion was sometimes difficult to call because inflammation and a desmoplastic 
tissue response were not always present. Bulky outgrowth of tumor tissue was also noted in 
several cases and invasion in these cases was based on a deeply expansile growth pattern. 
According to available literat ure, in stage IA1 sec a conization is the treatment of choice if 
fertility is desired 8, otherwise a simple hysterectomy is sufficient. The risk fo r nodal met astases 
is <1%9• 
If a woman has a stage IA2 sec, the risk of lymph node metastases is estimated to be between 
2%9 and 7.4% 10• Treatment consists of radica l hysterectomy with pelvic lymph node dissection 
but if t here is desire to remain fertile, a large cone biopsy plus extra-peritoneal or laparoscopic 
pelvic lymphadenectomy, or radica l t rachelectomy and extra peritoneal or laparoscopic pelvic 
lymphadenectomy is considered adequate 11, although the necessity of a lymph node dissection 
is questionable 12 
Although one could argue that microinvasive AC should be staged and treated in the same 
way as microinvasive sec, in clinical practice, AC tends to be managed more aggressively than 
its squamous counterpart. There is a uniform consensus concern ing treatment in patients with 
stage IA1 AC, which are treated with conization or simple hysterectomy. In stage IA2 t his is not 
the case and there are different and diverse approaches. Many studies report stage IA1 and IA2 
carcinomas together as one group. 
Reviewing literature concerning the optimal treatment of microinvasive AC highlights 
this diverse approach, see table 2 and 3. This is attributable to t he fact t hat substantial trials 
comparing conservative versus radical t reatment are lacking, due to t he rarity of t his condition. 
Besides that, all retrospective reports lack a centra lized pathology review. And it is not always 
clear whether the guidelines for staging as reflected by FICO staging committee have been 
strictly followed by the investigators, e.g. some studies included tumors with horizontal spread 
of more than 7 mm (in a study of Kaku et al 1350% of the 30 patients had a width of more than 
7 mm) and other studies did not specifically note t his. 
The general consensus is that stage IA1 AC can be t rea ted conservatively. After reviewing 
literature and including our own data we found 19 studies on stage IA1 AC. 8 recurrences 
were reported in 733 cases of IA1 disease (1.1%). Pooling the percentages of recurrences for 
type of t herapy, we found 1.4% recurrence after conservative t herapy versus 1.0% after radica l 
surgery. See tab le 2. The review by Ostor et aP4 comprising 26 papers on microinvasive AC 
totalling 436 cases showed that when invasion is less t han 5 mm, LVSI is absent, and the 
conization margins are free, conservative surgery (including conization) may be acceptable 
and, even if radical surgery is performed, a cure is not guaranteed . In our study 4 of33 patients 
with stage IA1had rad ica l surgery, none had LNM and t here have been no recurrences. Smith 
et al '5 found an excellent survival in patients with stage IA1 and IA2 AC of the uterine cervix 
as defined by t he Surveillance, Epidemiology and End-Results Cancer Incidence Public-Use 
database (SEER). They included SEER and all other available data and found t hat the risk of 
positive lymph nodes, recurrence and death in stage IA1 versus IA2 were not stat istically 
different. 98 cases were managed conservatively (conization) and no recurrences were 
reported, but up to 10% of t hese patients received adjuvant rad iation t herapy or underwent 
lymph node dissection. In a study by Ceballos et al'6 it could not be concluded whether the 
favourable prognosis of the 29 patients with stage IA1 AC was the product of a favourable 
stage or t he aggressive surgica l treatment received . Most of t he patients (24/29) in this 
study had a radical hysterectomy with lymph node dissect ion. Bisseling et al", reviewed 
38 patients with early AC and reviewed literature observing that conization is an effective 
treatment in stage IA1 but when LVSI is present a lymphadenectomy should be performed . 
Recently more studies propose a conservative therapy in stage IA1. Yahata et al found 
no LVSI, no LNM and no recurrent disease in a serie of 27 patients with stage IA1 treated 
conservatively (44%) or radically18• Reynolds et al reported an identical outcome in their 
study of 52 patients with stage IA1 AC in which 44% of patients were treated conservatively 
(conization, simple hysterectomy). This contrasts with our study in which 1 recurrence was 
noted after conservative t herapy, which had LVSI. The explanation may be t hat we treated 
29 of our 33 patients (88%) with stage IA1 conservatively, which is a higher proport ion than 
described in most of the studies outlined above. 
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Table 2. Review of lit erature Stage IA1 adenocarcinoma 
Author Year Clinic 
1977-1990 NY, USA 
197S-1988 Texas, USA 
1972-1994 Fukuoka, Japan 
n 
9 
24 
21 
Jones199339 
Matthews 199340 
Kaku 1997" 
Ostor199741 
Covens 199941 
Nicklin 1999" 
Schorge 199944 
Elliott 200019 
Schorge 200045 
McHale 200146 
1971-1995 Melbourne, Australia 43 
1984-1995 Toronto-Ontario, Canada 46 
1986-1998 Queensland, Australia 
1982-1996 Boston, USA 
1953-1992 Sydney, Australia 
1998- Boston, USA 
1985-1996 California, USA 
Kasamatsu 200247 1969-1997 NCCH, Tokyo, Japan 
26 
21 
48 
6 
20 
24 
conservative therapy radical therapy 
cone SH 
2 
0 
12 
0 
5 
4 
21 
0 
10 
4 
rec RH RT rec 
7 
24 
10 
46 
15 
16 
Smith 200215 
Hirai 200341 
Balega 200412 
Poynor200649 
Ceballos 2006'6 
Bisseling 200711 
Reynolds 201024 
Yahata 201011 
1983-1997 new mexico, usa 200 31 
2 
3 
93 2 
14 
21 
76 
22 1977-1998 CIH, Tokyo, Japan 
1987-1998 Chicago, USA 
1992-1999 NY, USA 
1985-2002 Ontario, Canada 
1987-2004 Nijmegen, NL 
1993-2007 
1990-2004 
Baalbergen present 1987-2006 
study 
Rochester, USA 
Niigata, Japan 
Rotterdam, NL 
TOTAL 
Conservative therapy (conization, simple hysterectomy) 
SH simple hysterectomy 
RH radical hysterectomy 
RT radical trachelectomy 
Rec recurrence 
22 
32 
21 
29 
29 
52 
27 
33 
733 
0 
2 
16 
7 
10 
15 
107 
0 
4 
4 
9 
16 
14 
180 4 
32 0 
14 
22 2 
4 
29 
17 
4 0 
374 4 
In the literature we found 17 stud ies on stage IA2 adenocarcinoma. Pooling t he data, 
including our own data, we found 12 recurrences in 466 cases (2,5%). After conservative t herapy, 
the recurrence percentage was 1,5% and after radica l therapy it was 3.5%. The risk for nodal 
metastases in stage IA2AC is about1.7% •s and therefore a lymphadenectomy is recommended '9-21• 
But t here is ample evidence in the publ ished literature today to cast significant doubt o n the 
wholesale application of lymphadenectomy in true stage IA2 disease 22-24 
The question arises weather a conization is not sufficient, instead of parametrial 
resection as performed in a t rachelectomy or radical hysterectomy. In our study, 15 of t he 33 
(45%) patients with stage tAl and 7 of the 26 (27%) patients with st age IA2 were treated with 
conization only, no recurrence was noted. Dargent et al did not fi nd it logical to perform a 
pelvic lymphadenectomy without removi ng the paracervical t issues, because of the strong 
Table 3. Review of literature Stage IA2 adenocarcinoma 
Author year clinic 
Jones 199339 1977·1990 NY, USA 
Matthews 199340 1975-1988 Texas, USA 
Kaku1997" 1972-1994 Fukuoka, Japan 
Ostor199741 1971-1995 Melbourne, Australia 
Nicklin 199941 1986-1998 Queensland, Australia 
Elliott 200019 1953-1992 Sydney, Australia 
Kasamatsu 200247 1969-1997 NCCH, Tokyo, Japan 
Smith 200215 1983-1997 New Mexico, USA 
Hirai 200341 1977-1998 CIH, Tokyo, Japan 
Schlaerth 200350 1995-1999 Pasadena, USA 
Balega 200412 1987-1998 Chicago, USA 
Poynor200649 1992-1999 NY, USA 
Ceballos 200616 1985-2002 Ontario, Canada 
Bisseling 200717 1987-2004 Nijmegen, NL 
Meurs 2009" 1994-2006 AMC, NL 
Reynolds 201024 1983-2008 Rochester & LA, USA 
Park 2010" 1989-2006 Seoel, Korea 
Baalbergen present 1987-2006 Rotterdam, NL 
study 
TOTAL 
Conservative therapy (conization, simple hysterectomy) 
SH simple hysterectomy 
RH radical hysterectomy 
RT radical trachelectomy 
Rec recurrence 
conservative therapy radical therapy 
n 
3 
15 
9 
34 
4 
10 
4 
286 
6 
4 
16 
12 
3 
9 
3 
14 
8 
26 
cone SH 
0 
4 14 
29 123 
0 0 
0 
0 0 
2 3 
2 
7 6 
466 44 149 
rec RH RT rec 
1S 3 
2 
16 
4 
0 
4 
2 134 2 
6 
4 
16 0 
11 0 
0 
4 
2 
9 2 
8 
13 
3 248 6 9 
correlation between t he risk of pelvic lymph node involvement and t he risk o f paracervical 
involvem ent 25• In cont rast to Covens et aJ26, Stegeman et aF7, Fru movitz et aJ28, Smith et al 29 
and Reyno lds et all 24 all ad vocat ed a less radical surgery in selected patient s w ith early- stage 
cervical cancer, because of t he absence o f paracervica l/metrial involvement and because 
trache lectomy is associated with considerable morbidity and obstetrical o utcomes following 
this procedure are not always ideaJ3°. A prospective study eva luating the safety and feasibility 
of conservative surgery (conizat io n o r sim ple hysterectomy) pl us PLND in stag e IA2 and 181 is 
ongoing31 . Patients with LVSI are excluded. 
The question remains w hether LVSI is a pro g nost ic factor in m icroinvas ive A C. In the past t he 
SGO stag ing syst em excluded lesions w ith t hese characteristics based on t he hypo t hesis that 
SCC lesions with LVSI have a greater propensity to m etastasize, w h ich was recently confir med 
in a study by Milan et 32• Ho u et al 33 found in their recently pu b lished t h orou gh review o n 
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microinvasive adenocarcinoma in stage IA1 with LVSI no LNM, but LVSI was a significant risk 
factor for recurrence irrespective of lymph node metastases. None of the AC cases with 
LVSI reported in the literature had lymph node metastases17• In our group of 26 patients with 
stage IA216% had LVSI, but with no lymph nodes metastases or recurrent disease. We had one 
recurrence, in a stage IA1 with LVSI t reated with vaginal hysterectomy. Admittedly, with such 
low numbers, it remains difficult to definitively state the risk of lymphatic metastasis based on 
presence of LVSI in microinvasive adenocarcinoma of the cervix; however, t he combined data 
suggest it is quite low and radical hysterectomy with or without lymph node dissect ion does 
not always cure the pat ient 9• 
In our study of almost 60 patients with microinvasive adenocarcinoma with a long follow 
up we demonstrate that a conservative approach is safe in microinvasive AC. Although 
we had 1 recurrence after conservative therapy. This patient had a grade 1 endocervical 
adenocarcinoma, stage IA1 disease and was treated by simple hysterectomy. Therefore 
histologic tumor characteristics do not seem capable of explaining why the recurrence rate 
is higher than could be expected . The recurrence occurred more t han one year after primary 
t herapy. Case reports underline t hat recurrences occur not only in stage IA2 but also in IA1 
irrespective of therapeutic modality34 -38 Therefore we agree with other retrospect ive studies 
that a more conservative fert ility sparing approach is j ustified for stage IA1 and IA2 AC. Pooling 
all data f rom pat ients with stage IA1 and IA2, the risk of recurrent disease after conservative 
therapy was 1.5%, and after radical therapy 2.0%. No difference was found in recurrence after 
conservative or radical treatment, underlining the fact that conservative therapy is justified. 
However the question remains, is the excellent surviva l due to the low stage or due to the 
aggressive treatment? Even though all studies are retrospective, with relatively small numbers 
of patients seen over a long time span, we think there is enough evidence to advise not to t reat 
microinvasive AC radica lly. 
Patients with microinvasive AC should be treated in the same way as patients with SCC; in 
stage IA1 and IA2 AC we recommend conservative therapy (conization). The pat ient can choose 
for a hysterectomy. In cases with LVSI, an additional lymphadenectomy is advised. For patients 
with stage IA2 AC with LVSI a trachelectomy I radical hysterectomy with lymph node dissection 
could be considered. 
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INTRODUCTION 
Although the incidence of cervical cancer is decreasing, the relative and absolute incidence 
of adenocarcinoma of the uterine cervix (AC) en adenocarcinoma in situ (AIS) is increasing. 
As they are becoming more common, they are being recognized more f requently. A great 
deal is known about squamous cell carcinoma of t he uterine cervix (SCC) but there are still 
many questions pertaining to AC and AIS. AC is said to have a worse survival, AC and AIS are 
recognized with difficulty in screening, they are less often hrHPV positive, radical therapy for 
AIS and early stage AC is recommended at present, but this is open to debate as reliable figures 
are lacking. 
In chapter 1 the aim of the study is presented. Chapter 2 is an outline on premalignant 
adenocarc inoma of the uterine cervix with an overview of the literature including optimal 
therapy. In chapter 3 prognostic factors and markers in adenocarcinoma are described . 
In chapter 4 hrHPV and its prognostic value in adenocarcinoma and in clear cell carcinoma 
are discussed. Chapter S describes the optimal t herapy in early stage and microinvasive 
adenocarcinoma and proposes t he best approach. 
CHAPTER 2- ADENOCARCINOMA IN SITU (AIS) CAN 
BE TREATED CONSERVATIVELY 
AIS is a relatively rare, but increasingly more common precursor of invasive adenocarcinoma 
of t he uterine cervix. In t he nineties the incidence of squamous carc inoma in situ of the cervix 
in t he USA was 41.4 per 100.000, whereas the incidence of AIS was only 1.25 per 100.0001. 
Although the overal incidence of AIS remains low, t he incidence of AIS has been increasing; 
this is attributable to improved detection and also an absolute increase. The incidence of AIS 
increased from 0.2 in the seventies to 1.8/100.000 in the late nineties in the USAH. There are not 
many studies investigating the incidence of AIS in t he Netherlands. A national study showed a 
decrease in the incidence of AIS between 1989-20034 • We studied t he incidence of AIS and AC 
in the Netherlands by using data collected via PALGA, the nationwide Dutch database for histo-
and cytopathology and the national cancer registration IKNL5• 2093 cytologic and histologic 
cases of AIS/severe atypia were registered between 1 January 2003 and 31 December 2012 in 
the Netherlands. In total, 619 were excl uded: 445 cases that developed carcinoma and another 
174 cases the cytologic diagnosis of AIS was not confirmed histologically. 1474 cases of AIS 
remained. The population data for the Netherlands used to ca lcu late European standardized 
rates (ESRs) were obtained from the database of Statistics Netherlands (https:/ /www.cbs.nl). 
We found a decreasing incidence for cervical cancer, with its lowest point in 2001-2003. This 
extra decrease was compensated by a following increase in cadence, probably resulting from 
a reorganization of the Dutch screening programme for cervica l carc inoma6• This decrease is 
attributable to a decrease in the frequency of SCC, the incidence for AC has remained stable 
with a slight increase after 2009. The incidence for AIS decreased between 1992 and 2004. From 
2009 the incidence has been increasing (unpublished data). 
Most patients with AIS are asymptomatic and are found by cytologic screening. 42% of 
our cases were detected by diagnosing glandular abnormalities in cytology (AGC-FN, AIS, 
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Figure 1. Incidence rate (ESR) of cervical cancer (CC), Adenocarcinoma (AC) and Adenocarcinoma in situ (AIS) 
in the Netherlands, 1989-2012. 
AC). 76% of cases were diagnosed before cold knife con ization (CKC) or large loop excis ion 
transformation zone (LLETZ) I loop electrosurg ical excision procedure (LEEP). hrHPV is the 
et iologic agent in AIS and in CIN. In particular HPV type 16, 18 and 45 are important in AIS and 
AC8 . Type 18 is in general more commonly found2•9•10• This is confi rmed in our study in which 51% 
of cases harbored this type HPV. Cases with normal cytology taken 5 years before the diagnosis 
of AIS were hrHPV positive in 70% of cases and in 88% the same type of HPV was present as was 
found in the AIS, indicating a persistent HPV infection. 
In the last few years there has been a t rend to more conservative t reatment. The main 
reason to abject a conservative treatment is the high incidence of residual disease after various 
forms of con ization. Achieving negative margins is important in this respect because positive 
margins are associated with a 3-fold increase in risk of residua l disease and a 6-fold increase 
in risk of recurrence, 3% versus 17%. Previous studies11 have shown that pat ients who undergo 
an LEEP are more likely to have positive margins than those who undergo CKC. As achievi ng 
negative margins is so important, a LEEP should not consist of fragments of cervica l t issue 
(chips) but the entire transformation zone and the lesion should be removed in a single pass. 
Although after this uterine sparing approach there is a risk of relapse and residual disease 
with a chance of malignancy, this risk is so low that conservative t reatment by a CKC or LEEP 
with negative cutting edges is justified and j ust ifiable not only for women who wish to have 
chi ldren . These days patients should have the choice between conservative t herapy and strict 
follow up with the smal l chance of recurrence or defi nite t herapy with hysterectomy. 
Follow up after conservat ive t reatment should preferably consist of endocervical cytology 
and HPV-typing. If abnormalities are detected furt her colposcopic and histologic examination 
should be performed. 
CHAPTER 3 PROGNOSTIC FACTORS IN AC 
3.1 FIGO stage, grade and lymph node metastases are significant 
prognostic factors in adenocarcinoma of the uterine cervix 
Our study on cervical adenocarcinoma in southwest region of The Netherlands shows a similar 
pattern of survival to that found in previous reports. Survival rates were the highest in patients 
with early-stage disease, in younger patients and after primary surgery. In early stage disease, 
we found stage, grade and lymph node status to be of prognostic significance. The literature 
is consistent with regards to stage and lymph node status as prognost ic factors for survival 
in cervical adenocarcinoma, but inconsistent when it comes to factors such as of grade, 
histological type, LVSI and age. Al l studies investigat ing t hese characteristics are retrospect ive. 
They include different types of pat ients and some studies excluded adenosquamous carcinomas. 
Histology was not always reviewed and statistical analysis was not uniform. 
The significantly better survival noted in patients younger than 35 years as compared to 
those over 65 years is the resu lt of a different approach. Radica l surgery with or without adjuvant 
radiotherapy was carried out in 90% of the young patients, w hereas in the group >65 years, only 
41% underwent radical surgery. 
If preoperative factors were of prognostic value, they could be used when deciding on the 
most optimal t herapy. Lymph node status in early cervical adenocarcinoma is a poor prognostic 
factor. For example, we found LVSI to be predictive of lymph nodes metastases: if LVSI was 
present, 32% of pat ients had lymph node metastases and thus had an indication for adjuvant 
radiotherapy. Furthermore, when LVSI was not found, the chance of lymph node metastases 
was only 5%. 
We found a significantly decreased survival despite adjuvant radiotherapy. The 5-year 
survival decreased from 90% to 33% when there were positive lymph nodes. 
The standard therapy for cervical carcinoma stages I and IIA is radical surgery, but patients 
were irradiated when their clinical condition was poor due to old age (mean age 65 years in 
the radiation group vs. 41 years in the surgery group) or coexistent medical problems (obesity, 
cardiovascular disease). We found that survival was better after primary su rgery than after 
primary radiation therapy. In our study, patients with stage I lA (n = 26) had a 5-year disease-
specific su rviva l after primary surgery of77%, whereas after primary radiation therapy, this was 
approximately 15%. When comparing these groups, the mean age was sig nificant ly higher in the 
radiation group and the significant difference in survival disappeared after correcting for age. 
In stage I, we found no difference in survival after primary surgery or radiation therapy. 
We found a worse survival in 27 patients in which cervica l adenocarcinoma was diagnosed 
after surgery for other condit ions. Despite adjuvant radiation therapy, survival was worse 
compared to the group who received adeq uate treatment. This was not seen in patients 
with sec. 
Since our report in 2004, 9 other studies have been published on prognostic factors in 
cervical adenocarcinoma . All studies 12•20 confirmed the prognostic value of lymph node 
metastases on survival and 7 studies also showed prognostic significance of tumor stage, size, 
parametrial invasion. Tumor grade was only found to be of significant prognostic value in 
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1 study15. Our conclusion that FICO stage, grade and lymph node metastases are of significant 
importance for disease free survival in cervical adenocarcinoma, still stands. 
3.2 P53 is of significance for survival in cervical adenocarcinoma 
Unlike breast cancer and cancer of the uterine corpus where hormone receptor status is of 
prognostic significance and can determine response to endocrine therapy, the significance 
of hormone receptor status in adenocarcinoma of the uterine cervix st il l remains unclear. 
Our study suggests that it is not of cl inical significance to determine estrogen receptor, 
progesterone receptor, MIB-1 or bcl-2 in cervica l adenocarcinomas as an adjunct to determine 
survival. However, determination of p53 seems useful as p53 positivity appears to be linked to 
poorer survival in cervical adenocarcinoma, and adjuvant therapy may need to be adjusted. 
Since our study in 2007 no further studies about prognostic markers as estrogen receptor, 
progesterone receptor, p53, MIB-1or bcl-2 and AC were published. 
CHAPTER 4 HPV IN CERVICAL ADENOCARCINOMA 
4.1 HPV-type has no impact on survival of patients with adenocarcinoma 
of the uterine cervix 
This study confirms the hypothesis that almost all early stage AC of t he cervix are HPV positive 
and therefore HPV-testing seems to be a more powerful tool in detection of AC t han routine 
cytologic screening. The majority of AC in our study harboured HPV type 18 (n=SS; 54%); 37 
(37%) were type 16, 7 (7%) were type 45, and types 53 and 39 were found in 1 patient. This 
compares well with the literature. 
Although the prevalence of HPV in AC is age-dependent, we found a similar mean age in 
HPV-positive tumours (42.2 years) and HPV-negative tumours (42.8 years), suggesting that the 
patients in the latter group tested fa lse negat ive. In our group mean age of women harboring 
HPV-types 18 or HPV-16 was the same (42.1 and 43.2 years). However, a younger mean age of 
patients with HPV type-45 positive carcinomas (40.7 years) was noted in this study. We found a 
worse prognosis in women with AC harboring HPV-18 t han in women who's AC were associated 
with HPV-16. However, t his was not statistical ly significant . A worse survival was noted in cases 
with HPV type 45, 5-year survival 57%. 
Despite the limitations of analysing ret rospective data, the current la rge study shows that 
the great majority of AC of the cervix is hrHPV associated. Except for HPV-45, HPV type does 
not seem to have a prognostic impact on patient survival. However, this conclusion should be 
verified in a larger study. 
4 .2 High-risk human papillomavirus seems not involved in DES-related 
and of limited importance in non-DES-related clear-cell carcinoma of the 
cervix (CCAC) . 
In a relatively large group of CCAC we showed t hat hrHPV has a limited carc inogenic role. 
In summary, we limited our conclusions to the 21 of 28 fully analyzed CCAC. A causal role of 
hrHPV could not be ident ified in any of t he 10 DES-related tumors. Overa ll, three tumors were 
propably caused by a t ransforming hrHPV infection. Two were found in women not exposed to 
DES (2/8) and in one woman no information about DES-exposition was available (1/3). In the 
remaining 8 tumors (6 in DES-unexposed women and 2 in women with an unknown exposure) 
the etiology remains unclear, leaving room for other, unexplored factors in its carcinogenesis. 
CHAPTER 5 THERAPY IN AC 
5.1 Early stage adenocarcinoma (Figo stage I and II) should be treated 
by surgery 
We conducted a systematic review conform the Cochrane guidelines to evaluate if there was 
objective proof for the hypothesis that surgery was a better option than radiation therapy in 
the treatment of early stage AC. The quantity and quality of the evidence was scarce as only one 
RCT was found (Landoni 1997). 
Analysis of a subgroup of the single RCT showed that surgery for early-stage AC was better 
than radiot herapy. However, the majority of the surgery group patients required adjuvant 
radiotherapy, which was associated with greater morbidity. Furt hermore, radiotherapy was not 
optimized and surgery was not compared to chemoradiation, which is currently recommended 
in most centers. Finally, modern imaging techniques (MRI, PET-CT), allow for better patient 
selection enabling node-negative patients to be more easily ident ified fo r surgery, thereby 
reducing t he risk of morbidity associated with surgery and adjuvant radiotherapy. In 
conclusion, we recommend surgery for early-stage AC of the uterine cervix in carefully staged 
patients. Whereas primary chemoradiation remains the second best alternative for patients 
unfit for surgery, chemoradiation probably is the first choice in patients with (MRI or PET-CT-
suspected) positive lymph nodes. Since t he last version (2010) of this review no new studies 
were found (2013). 
There is a need for well-designed RCTs comparing primary surgery versus primary 
radiotherapy plus concurrent chemotherapy for early AC. This can only be carried out in 
women who do not need fertility-sparing treatment. 
5.2 Microinvasive adenocarcinoma (Figo stage IAl And IA2) should be 
treated conservatively 
In our study of almost 60 pat ients with microinvasive adenocarcinoma of the cervix a long follow 
up was available, we demonstrated that a conservat ive approach is safe. Although we found 1 
recurrence after conservative therapy. This patient had a grade 1 endocervical adenocarcinoma, 
stage IA1 disease and was treated by simple hysterectomy. Therefore histologic tumor 
characteristics do not seem capable of explaining why t he recurrence rate is higher than could 
be expected. The recurrence occurred more than one year after primary therapy. Case reports 
underline that recurrences occur not only in stage IA2 but also in IA1 disease irrespective of 
therapeutic modality2'·2>. Therefore our study is in line with other retrospective studies that 
demonstrate that a more conservative fe rt ility sparing approach is justified in stage IA1 and 
IA2 AC. Pool ing all data from patients with stage IA1 and IA2, the risk of recurrent disease after 
conservative therapy was 1.5%, and after radical therapy 2.0%. This means that no difference 
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was found in recurrence after conservative or radical treatment; underlining t he fact that 
conservative therapy is j ust ified. The remaining question is however; is t he excellent survival 
due to the low stage of t he carcinoma or due to the aggressive t reatment? Even though all 
studies are retrospective, with relatively small numbers of patients diagnosed over a long 
time span, we think that there is enough evidence to conclude that microinvasive AC should 
not be treated radically with radical hysterectomy with lymph node dissection. Patients with 
microinvasive AC should be t reated in the same way as patients with SCC; in st age IA1 and IA2 AC 
we recommend conservative therapy (by radical conization in a single pass). The patient should 
be given the choice between hysterectomy and conization. In cases with LVSI, an additional 
lymphadenectomy is advised. For patients with stage IA2 AC with LVSI a trachelectomy I radical 
hysterectomy with lymph node dissect ion could be considered. 
CONCLUSION 
As a general conclusion based on these studies we think that although they are relatively 
uncommon, but increasing in incidence, AIS and early stage adenocarcinoma of the uterine 
cervix harbour, when they are correct ly diagnosed, t he same prognosis as CI N and early sec 
and therefore should be treated in the sa me way. In AIS a radial cone by CKC or LEEP is obligato ry 
and sho uld really be radical wit h negat ive resection margins for conservat ive t reatment. 
Microinvasive AC sho uld be t reated as microinvasive SCC. For stage IA1 and IA2 t his means a 
radical conization (by CKC or LEEP), except in cases in which LVSI is present. Patients should be 
allowed to choose between radical therapy and conservat ive therapy with fol low up. Surgery is 
the treatment of choice in early stage AC. 
Stage, grade and LNM are the most important factors for survival in AC. AIS and AC are 
hrHPV related, especially type 18 and 16 and 45 are implicated. However in DES-related cervical 
clear-cell carcino mas HPV seems not involved. As more tha n 90% of AIS and AC are HPV-18 
and 16 related, it can be expected that prophylact ic HPV-vaccination may lead to an impressive 
reduction in the incidence of AIS and AC comparable to what can be expected in SCC. 
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SUMMARY 
The current study was designed to g ive more insight in adenocarcinoma of the uterine cervix. 
The more common cervix carcinoma, squamous ce ll carcinoma, has been thoroughly studied 
and published; etiology, diagnosis, therapy, prognosis etc. AC used to be a ra re cervical tumor, 
only 5% of all cervical cancers, lately its incidence has been increasing to 20%. AC was said to 
have a worse survival and therefor more radica l therapy was adjusted. The incidence of AC has 
not declined as the incidence ofSCC after starting the screeningsprogramms, which was due to 
the inability to detect abnormalities in glandular cells in cervical cytology. 
In chapter 2 we studied the precursor of AC, adenocarcinoma in situ. AIS is relatively rare but 
increasingly frequent. We evaluated the diagnostic and therapeutic strategies and follow-up 
in a large series of women with pre-invasive cervical adenocarcinoma, and we investigated 
whether HPV typing in previous cyto logy that has been classified as normal would have helped 
to detect AIS earlier. Beside, we conducted a review of literature if therapeut ic st rategies in 
AIS could lead to more conservative approach. We found t hat conservative treatment of AIS 
by cold knife conization (CKC) or Large Loop Excision Transformation Zone (LLETZ) or Loop 
Electrosurgical excision procedure (LEEP) with negative cutting edges is justified and justifiable 
not only for women to have children. Nowadays patients should chose whether they wa nt a 
strict follow up with the small change of recurrence or definite therapy with hysterectomy. 
Although AIS was in almost% of patients found by pap smear screening, HPV testing might be 
superior to cytology in screening for AIS. 
In chapter 3 we studied prognost ic factors for su rviva l in cervical adenocarci noma. Our report 
about cervica l adenocarcinoma in South-West region of The Netherlands showed a similar 
pattern of survival to that found in previous international reports. The best surviva l rate was for 
patients with early-stage disease, younger pat ients and after primary surgery. We found FIGO-
stage, grade and lymph node metastases to be of significant prognostic value for survival in 
cervical adenocarcinoma. In some tumors, like mammacarcinoma it has been shown useful to 
determine immunohistochemical markers in the tumor for survival. Our study suggests that it 
is not of clinical significance to determine estrogen receptor, progesterone receptor, MIB-1 or 
bcl-2 in cervical adenocarcinomas as an adjunct to determine survival. However, determination 
of p53 seems useful since p53 staining is a marker fo r surviva l. p53 positivity appears to be linked 
to poorer survival in cervical adenocarcinoma, and adjuvant therapy may need to be adjusted. 
Chapter 4 we described HPV in AC. We found t hat AC is hrHPV related in most cases (89%). 
Subtyping showed HPV-18 as the most frequent type (54%), 37% were HPV-16, 7% HPV-45 and 
1% were type 53 and 39. With the exception of HPV-45, HPV-positivity or type in endocervical AC 
has no significant influence on survival. Clear cell carcinoma (CCAC) is a relatively rare cervical 
tumor. Approximately 60% of all CCAC are associated with intra-uterine diethylstilbestrol (DES) 
exposure. Previous studies demonstrated that the association between hrHPV positivity and 
cervical clear-cel l adenocarcinoma (CCAC) varies between 0% and 100%. We determined in a 
cohort of both DES-exposed and DES-unexposed women with CCAC the prevalence of hrHPV 
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infections, and t he potentia l et iological role of hrHPV by additional analysis of pl61NK4a and 
p53 expression. Although the prevalence of hrHPV was high, only two DES-unrelated CCAC 
(25%) and one tumor in a woman with unknown exposure could be attributed to hrHPV.In none 
of the 10 DES-related tumors a causal role of hrHPV could be identified. 
Chapter 5 therapy in AC 
For early squamous ce ll carcinoma of the uterine cervix, the outcome is simi lar after either 
primary surgery or primary radiotherapy. There are reports that this is not t he case for early 
adenocarcinoma (AC) of t he uterine cervix. We conducted a systematic review conform the 
Cochrane guidelines. We found one randomized contro lled study where they compared the 
effectiveness and safety of primary surgery for early stage AC of the uterine cervix with primary 
radiotherapy or chemoradiation. We concluded that for early stage cervical cancer of the 
glandular cell type (adenocarcinoma) surgery is recommended. Second best alternative for 
patients unfit for surgery is chemoradiation. For patients with suspected posit ive lymph nodes, 
chemoradiation is probably the fi rst choice. 
Microinvasive adenocarcinoma is divided in stage IAl, which is defined as a tumor, 
who invades to a depth of 3 mm or less with 7 mm or less horizonta l spread and stage IA2, 
defined as stromal invasion of more t han 3 mm and less than 5 mm with a horizontal spread 
of 7 mm or less. We evaluated t he treatment and follow-up in a large series of women with 
MIC. Extensive treatment such as radica l hysterectomy with pelvic lymph node dissection or 
trachelectomy does not prevent recurrent disease. Patients with microinvasive AC should be 
treated identically to patients with sec. In stage IAl and IA2 AC, we recommend conservative 
therapy (by conization). In cases with LVSI, an additional lymphadenectomy is advised. For 
patients with stage IA2 AC with LVSI, a trachelectomy/radical hysterectomy with lymph node 
dissection should be considered . 
Final ly, we concluded that AIS and early stage AC, rare but increasingly existing, especia lly 
in young women, harbour the same prognosis as CIN and early SCC and t herefore should be 
treated as such. 
SAMENVATTING 
De huidige stud ie werd ontworpen om meer inzicht te krijgen in baarmoederhalskanker 
van het cilinderceltype (adenocarcinoom, AC). Het meest voorkomende carcinoom van de 
baarmoedermond, het plaveiselcelcarcinoom (SCC), is grondig bestudeerd en gepubliceerd; 
et iologie, diagnose, therapie, prognoseetc. Het AC iseen zeldzametumor, halverwegedevorige 
eeuwwas slechtsS %van aile gevallen van baarmoederhalskanker een A C. Er werd altijd beweerd 
dat het AC een slechtere overleving zou hebben dan het plaveiselcelcarcinoom en daarom 
werd er meer radicale t herapie toegepast. Sedert het invoeren van het bevolkingsonderzoek 
naar baarmoederhalskanker is de incidentie van het AC is niet afgenomen, zoals bij het SCC. Dit 
komt doordat afwijkingen van ci lindercellen niet goed worden vastgesteld in het uitstrijkje. De 
laatste tijd is de incident ie van het AC toegenomen tot 20 %. 
In hoofdstuk 2 beschrijven we de voorloper van het adenocarcinoma, het adenocarcinoom 
in situ (AIS). AIS is relatief zeldzaam, maar komt steeds vaker voor. We evalueerden de 
diagnostische en therapeutische strategieen en follow-up in een grote reeks van vrouwen met 
een AIS en onderzochten we of HPV-typen gevonden in voorgaandejaren afgenomen uitstrijkje 
dat werd geclassificeerd als normaal, zou hebben geholpen om AIS eerder detecteren. Tevens 
werd een systemat isch literatuuronderzoek uitgevoerd om te beoordelen of therapeutische 
strategieen in AIS zouden kunnen leiden tot een meer conservatieve aanpak. Wij vonden 
dat de conservatieve behandeling van AIS door conisatie of LEEP met negatieve snijranden 
gerechtvaardigd is. Niet aileen voorvrouwen met kinderwens. Tegenwoordig moeten patienten 
kunnen kiezen of ze een baarmoedersparende behandeling met strikte follow-up en met een 
kleine kans van recid ief willen of kiezen voor een definitieve behandeling met hysterectomie. 
Hoewel AIS in bijna driekwart va n de patienten wordt gevonden door mid del van een uitstrijkje, 
zou HPV-testen superieur zijn aan screening door middel van uitst rijkjes voor AIS. 
In hoofdstuk3onderzochten we prognostischefactoren voor overleving in hetadenocarcinoom. 
Ons verslag over adenocarcinoom in Zuidwest Nederland toonde een vergelijkbaar patroon van 
de overleving met die in eerdere internationale studies. De beste kans op overlevi ng was ervoor 
patienten met een vroeg stadium van de ziekte, bij jongere pat ienten en na prima ire chirurgie. 
We vonden FIGO-stadium, graad en lymfekliermetastasen de belangrijke prognostische 
factoren voor de overleving bij het adenocarcinoom. Bij de behandeling va n sommige 
t umoren, zoals het mammacarcinoom is het nuttig om immunohistochemische markers te 
bepalen, die invloed hebben op de over leving. Onze studie suggereert dat het niet zinvol is 
om oestrogeenreceptor, progesteronreceptor, MIB - 1 of bel - 2 in het adenocarcinomen te 
bepalen omdat zij geen significante invloed op de overleving hebben. Echter de bepal ing van 
p53lijkt wei nuttig omdat p53-positiviteit verband lijkt te houden met een slechtere overleving 
in het adenocarcinoom, zodat de aanvu llende behandeling zou moeten worden aangepast. 
In hoofdstuk 4 beschrijven we de bijdrage van hrHPV in het adenocarcinoom. We vonden dat 
AC meestal hrHPV gerelateerd was (89%). Subtypering toonde HPV-18 als het meest f requent 
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(54%), 37% was HPV-16, 7% HPV-45 en 1% type 53 en 39. Met uitzondering van HPV-45, heeft 
HPV-positiviteit in AC heeft geen significante invloed op de overleving . 
Het heldercellige adenocarcinoomvan de baarmoedermond (CCAC) iseen relatiefzeldzame 
tumor. Ongeveer 60 %van aile CCAC zijn geassocieerd met in t ra - uteriene diethylstilbestrol 
(DES) blootstelling. DES is een synthetisch vervaardigd oestrogeen dat vroeger (onterecht) 
werd gebruikt om miskramen te voorkomen. Eerdere studies toonden aan dat de associatie 
tussen hrHPV-positiviteit en baarmoederhalskanker van het clear cell adenocarcinoom type 
(CCAC) varieert tussen 0% en 100%. We bepaalden in een cohort van zowel DES-gerelateerde 
en niet-DES gerelateerde vrouwen met CCAC de prevalentie van hrHPV infecties en de 
mogelijke et iologische rol van hrHPV door aanvullende analyse van pl6'NK•• en p53 expressie. 
Hoewel de prevalentie van hrHPV hoog (46,4%) was, toonde onze studie een zeer bescheiden 
rol van hrHPV in de carcinogenese van CCAC. Geen van de hrHPV geassocieerde tumoren 
werd aangetroffen in vrouwen die intra-uterien waren blootgesteld aan DES en in de overige 
vrouwen bleek slechts een minderheid (20-25%) door hrHPV veroorzaakt. 
Hoofdstuk 5 beschrijft de therapie van het adenocarcinoom. 
Voor het vroegstadium plaveiselcelcarcinoom van de baarmoedermond is het succes van 
een primaire behandel ing (operatie of radiotherapie) gelijk. Er zijn studies dat dit niet het geval 
is voor het vroegstadium adenocarcinoom (AC) . We verrichtten een systemat ische review 
conform de Cochrane richtlijnen. We vonden een gerandomiseerde gecontroleerde studie 
waarin men de effectiviteit en vei ligheid van primaire chirurgie met primaire radiotherapie 
of chemoradiatie van het AC vergeleek. We concludeerden dat voor een vroegstadium 
baarmoederhalskanker van het ci linderceltype (adenocarcinoom) chirurgie wordt aanbevolen. 
Het beste alternatief voor patienten die niet geopereerd kunnen worden, is bestraling 
gecombineerd met chemotherapie. Voor patienten met verden king op positieve lymfeklieren 
is chemoradiat ie waarschijnlijk de eerste keus . 
Het microinvasive adenocarcinoom (MIC) is onderverdeeld in stadium IA1 en IA2. Stadium 
IA1 is gedefinieerd als een tumor met infiltratiediepte van 3 mm of minder en een hor izontale 
diameter van 7 mm of minder. Stadium IA2 is gedefinieerd als een tumor met infi ltratiediepte 
tussen de 3 mm en 5 mm en met een horizontale diameter van 7 mm of minder. We evalueerden 
de behandeling en fo llow - up in een groot aantal van de vrouwen met MIC . Uitgebreide 
behandeling zoals radicale hysterectomie met verwijdering van de lymfeklieren in het bekken 
of t rachelectomie (verwijdering van de baarmoedermond en - hals) verhindert niet de 
terugkeer van de ziekte . Patienten met MIC moeten net zo behandeld worden als patienten met 
microinvasiefSCC. In stadium IA1 en IA2 AC adviseren wij conservatieve therapie (door middel 
van conisat ie). In gevallen met een uitzaaiing in de lymfkl ieren (LVSI) is een lymfadenectomie 
geadviseerd. Voor patienten met stadium IA2 AC met LVSI, moet een trachelectomie of een 
radica le hysterectomie met lymfeklierdissect ie overwogen worden. 
Tot slot conc luderen we dat AIS en het vroeg stadium AC, hoewel zeldzaam doch in toenemende 
mate voorkomend voora l bij jonge vrouwen, dezelfde prognose als het voorstadium (CIN) en 
het vroegstadium sec hebben. Eenzelfde behandeling ligt dan ook voor de hand. 
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